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Human Umbilical Cord Blood Cells Migration To Stroke CNS Tissue Extracts
And The Potential Cytokines And Chemokines Involved
Mary B. Newman
ABSTRACT
Human umbilical cord blood (HUCB) cells consist of a heterogeneous
population of cells, rich in hematopoietic stem and progenitor cells. These cells have
been used in the treatment of various nonmalignant and malignant hematopoietic
diseases. With in the last few years HUCB cells have been used in pre-clinical animal
models of brain and spinal cord injuries, in which functional recovery has been shown.
The properties of cord blood cells that could be important in cell transplantation (repair or
replacement) of CNS injury or disease are currently being evaluated. The major focus of
this study was to determine whether HUCB cells would migrate to ischemic tissue
extracts. In addition, factors that may be inducing the cells to migrate were examined by
identifying the cytokines or chemokines present in the ischemic tissue extracts. The
secondary focus was to establish whether cultured HUCB cells are releasing cytokines
and chemokines (in vitro) in response to their environment. The results of these studies
showed that HUCB cells migrate to ischemic tissue in a time dependent manner. In
which there is a 48 to 72 hour window of opportunity for the delivery of HUCB cells to
the ischemic brain. In addition, the cord blood cells were shown to release cytokines and
chemokines that may be aiding in the behavioral recovery seen in the transplantation

vii

studies. The results from this study are promising in that the current 3-hour therapeutic
window for the treatment of stroke victims, using approved anticoagulant treatment, may
be extended with the use of cord blood cell therapy with the peak at 48 hours.

viii

Chapter 1

1.0

Umbilical Cord Blood (HUCB) Cells in the Repair of Damage in the CNS

1.1

Introduction
Numerous CNS diseases are characterized by the deterioration of cognitive and

motor functions, frequently leading to prolonged periods of increasing incapacity.
Among the most problematic and prevalent neurological disorders are those associated
with the loss of CNS cells populations, such as Alzheimer’s (AD), Parkinson’s (PD),
Huntington’s disease (HD), amyotropic lateral scelerosis (ALS), and stroke. While
advances in molecular biology, genetic engineering, proteomics, and genomics will
hopefully produce compounds with enormous treatment potential in the future, currently
there are no available means of altering the pattern, rate of cell loss, or function in
diseased or injured CNS once damage has occurred.
For several decades, researchers and clinicians have been exploring the potential
of cellular treatment for diseases, disorders, and injuries of the CNS. Fetal neural tissue
was initially grafted into the brain in order to study its development and regenerative
capacity. These studies quickly revealed the therapeutic potential of tissue grafting in
animal models of neurological disorders, which eventually led to pre-clinical and then
clinical trials. The outcomes of clinical transplantation studies were generally positive
enough to warrant further investigation. However, the lack of significant improvement
1

reported in the older population or late stage of disease in patients with Parkinson’s
disease has brought some doubt and uncertainty to the future direction of the neural
transplantation field (Newman et al 2003, Sanberg et al 2002)
In addition, societal, legal, and ethical issues, along with the limited availability
of tissue, complicate the use of fetal tissue. These factors have not only pushed
investigators to look for alternative sources of cells, but also alternative ways in which
cells may be utilized in cellular therapies. This is supported by the growing consensus
that stem cells are obtainable from several sources and can be epigenetically expanded or
genetically perpetuated to develop, if needed, into specific cellular phenotypes or to
deliver needed substrates/factors from genetically engineered cells. One of the most
promising sources for human stem cells is those cells from hematopoietic origin, which
include HUCB, adult peripheral blood, and bone marrow. Each has their own sets of
distinct advantages and disadvantages and a comprehensive review of each source is
beyond the scope of this dissertation. This chapter will focus on the utilization of HUCB
cells as a potential source for cellular therapies, the clinical and pre-clinical studies that
have been preformed, and a general description of research undertaken for this
dissertation.
Stem cells derived from hematopoietic sources, such as HUCB, are an emerging
and relatively young area of research that may provide the opportunity to further our
understanding of the extent and limitations in the use of stem cells in cellular therapy
field.

2

1.2

Brief History of Stem Cells
Most stem cell biologists would agree that Artur Pappenheim (1870 – 1916) was

the first to propose the concept of a common ancestral stem cell (Lajtha 1980), 1980).
Till and McCulloch (1961) were the first to demonstrate the ability of transplanted bone
marrow cells to form colony-forming units (CFU) on the spleen of lethally irradiated
mice in vitro. Their initial studies, measured the proliferation potential of bone marrow
cell colonies, and led to the developing hypothesis of hematopoietic stem cells (Potten
1983, Till & McCulloch 1961). Since then much confusion has occurred in the meaning
and usage of the words “stem, progenitor, and precursor cells.”
In an attempt to unify terminology in this field, a workshop in 1978 comprised
mostly of hematologists (Lajtha 1979a, Lajtha 1979b, Schofield & Lajtha 1983), defined
stem cells as “cells with extensive self-maintaining (self-renewal capacity), extending
throughout the whole (or most) of the life-span of the organism. Differentiation potential
is a property of some types of stem cells but is not an essential feature of stem-ness.”
Differentiation has been defined as “cells becoming specialized for particular functions”
(Lackie & Dow, 1999) and as “the change in genetic expression patterns” (Lajtha 1979a).
Therefore, any cell that replicates its own numbers throughout most of the organism’s life
is considered a stem cell, regardless of whether the cell differentiates further. As Lajtha
(Lajtha 1979b) has pointed out, “every cell in the body except for the zygote is already
differentiated,” the question is whether a cell is capable of further differentiation (Lajtha
1979b). More recently, however, other scientists, mostly in the neuroscience and
transplantation field, have defined a stem cell as – an undifferentiated cell that is capable
of self-renewal, proliferation, and can asymmetrically divide to generate differentiated
3

cells or multipotent cells (Rao & Mattson, 2001; Shihabuddin, et al. 1999; Gage, 2000).
At this time there seems to be a consensus regarding the terminology stem cells, although
there has been no formal establishment of a nomenclature. Table 1.1 presents a
hierarchical listing along with defined terminology of stem cells, which has been
incorporated from several scientific publications. Please refer to the following papers for
their discussion of this topic: (Blau et al 2001, Marshak et al 2001, National Research
Council (U.S.). Committee on the Biological and Biomedical Applications of Stem Cell
Research., Rao 2001a, Rao & Mattson 2001, Rao 2001b).
Totipotent stem cells are of interest due to their ability to generate any cell type
from both ectodermal and extraectodermal tissue. Pluripotent stem cells can give rise to
cells derived from the three embryonic germ layers, however, they are more restricted,
produce committed progenitor and precursor stem cells of more than one lineage or cell
type, and can self-renew. Cell lineage can be described as the embryonic origins of
specific cells, which can be recorded through fate maps that trace the cell(s) embryonic
origin through developmental stages. Accordingly, a stem cell that is more ancestral or
primitive (higher in the hierarchy) is of greater interest due to the cell’s ability to generate
progenitors of more than one lineage. The progenitor and precursor cells are more
limited (more restricted) than stem cells in their ability to give rise to cells of a different
lineage.

4

Table 1.1: Description of Stem Cells
Primitive Stem Cells
Totipotent – early blastula stage cells, giving rise to both ectodermal
and extraectodermal tissue.
Stem Cells
A cell that is capable of proliferation, self-renewal, self-maintaining
during the life of the organism is a stem cell. The cell may or may
not produce cells that are further differentiated.
Ancestral Cell – stem cells that yield further differentiated
descendants.
Pluripotent Stem Cells – These cells originate from the inner cell
mass after development of the blastula, they give rise to cells from
the three embryonic germ layers (mesoderm, endoderm and
ectoderm). However, they cannot give rise to the tissue of the
placenta (this is restricted to cells from the trophectoderm). They
can differentiate into germinal and somatic tissues.
Multipotent, Bipotent and Unipotent – these are used to describe
stem cells that are further differentiated daughter cells of
pluripotent or totipotent stem cells. They may produce daughter
cells that are further differentiated. However, they are restricted in
the ability to give rise to other cells of different lineages.
Progenitor/Precursor Cells
These are the progeny of stem cells, and have a much more
restricted differentiation potential with limited self-renewal
capacity, and a limited lifespan. These cells cycle more than stem
cells and provide the necessary cells for self-maintenance of the
organism, thus conserving the stem cell.
Table 1.1 Presents an interpretation of the hierarchy and increased
complex terminology of stem cells. The definitions are a compilation
from several sources as referenced in the paper.
Both the progenitor and precursor cells (also referred to as transit amplifying
cells) are the progeny of more ancestral stem cells and seem to be responsible for the
ongoing regeneration of the given tissue in which they reside; allowing the more
5

primitive stem cells to proliferate only as necessary (Marshak et al 2001). This concept is
in agreement with the slow cycling observed in more primitive stem cells, which has
been proposed as a way to protect the integrity of the genome (Cairns 1975, Potten 1983).
Thus, the fewer cell cycles, the less chance there is of disrupting or damaging the
genome.
The endogenous factors that trigger proliferation and differentiation of stem cells
and their progeny are just beginning to be resolved. The proliferation, expansion, and
differentiation of stem cells are regulated through intrinsic cellular factors, extrinsic
cellular factors (cytokines/growth factors, cell adhesion molecules), and cell-to-cell
interaction (Rao & Mattson 2001). For example, embryonic stem cells can be maintained
in vitro in the presence of Leukemia Inhibitory Factor (LIF) and these cells will produce
neural stem cells when supplemented with fibroblast growth factor (FGF) in culture
(Tropepe et al 2001). Both epidermal growth factor (EGF) and basic fibroblast growth
factors (FGF2) will keep neural stem cells in a proliferative state (Gritti et al 1999), while
brain derived neurotrophic factor (BDNF) will direct neuronal progenitors to
differentiation (Eaton & Whittemore 1996). Some stem cells have been reported to
transdifferentiate; that is to give rise or transit to a cell with properties distinct from the
germinal layer in which they originated. Kondo and Raff (2000) have shown that
oligodendrocyte progenitor cells may transdifferentiate to pluripotent stem cells and give
rise to neurons(Kondo & Raff 2000). However, caution should be employed when
determining the ability of a cell to transdifferentiate. Progenitor cells that were obtained
from muscle and thought to be of muscle origin were reported to transdifferentiate into
hematopoietic stem cells. Upon further investigation, these stem cells were, in fact,
6

determined to be hematopoietic stem cells residing within the muscle (Ogawa et al 2002).
While it is possible to direct the differentiation of pluripotent stem cells and lineage
restricted progenitor cells in vitro, we are only at the initial stages of learning how to
direct stem cells to phenotypes that might be useful in vivo.

1.3

Advantages of HUCB Cells
Many fundamental observations have already been made in the use of cord blood

cells as transplantable cells for treating CNS diseases. Those observations are discussed
here.
1.3.1

Easily Obtainable Source of Cells

HUCB is a well-established, reliable source of a heterogeneous population of
cells, which is known to be rich in hematopoietic stem and progenitor cells (Broxmeyer
1996, Mayani & Lansdorp 1998). Additionally, millions of healthy babies are born each
year leading to virtually an unlimited supply of HUCB cells that can be easily preserved
and available for transplantation at any time. Cord blood is easily obtained and routinely
collected without jeopardizing the mother or infant (National Center For Farmworkers
2002). Cord blood can be collected either in utero or ex utero. Typically, cord blood is
collected after the placenta has been delivered (ex utero - which does not endanger
mother or infant) in a closed system to prevent contamination, which utilizes either
placental collection bags or blood collection bags that contain the anticoagulants. The
placenta is suspended in a specially designed scaffold enabling the cord to hang down
and causing enlargement of the cord. This permits easier access in which to cannulate
the cord vein and allow the blood to drain. Standard procedures are used to process and
7

test the isolated cord blood to ensure the absence of infectious agents such as HIV and
hepatitis prior to cryopreservation. In addition, cord blood cells are available from every
ethnic group for human leukocyte antigen (HLA) matching. The cells that are isolated
from the cord blood have the advantage of being immunologically immature (discussed
below) and thus are less likely to rejected by the host.. Obviously, the ethical issues
associated with using cells or tissues from embryos or aborted fetuses are obviated,
removing the arguments that a potential life is being sacrificed for the advancement of
science or that the use of aborted fetuses influences or justifies the decision to have an
abortion.
1.3.2

Abundant Source of Cryopreservable Cells

The yield of hematopoietic stem cells is relatively high with a greater potential
for proliferation and expansion when compared to those of adult bone marrow (Cardoso
et al 1993a, Cardoso et al 1993b, Hows et al 1992). For example, a higher percentage of
cluster differentiation (CD)34+ CD38- cells are present in HUCB; 4% fraction when
compared 1% bone marrow (Broxmeyer et al 1992b, Cardoso et al 1993b, Metcalf 1984).
In addition, cord blood contains CD133 positive cells, which are a subpopulation of
CD34 cells and are believed to be more primitive stem cells (Miraglia et al 1997, Potgens
et al 2001, Yin et al 1997) (see section – on phenotypes for further discussion). The
advantages of a high yield of stem and progenitor cells dovetails nicely with the ability to
cryopreserve cord blood cells for indefinite period, which is an essential prerequisite for
any cell-based therapy. With proper handling and processing cryopreservation does not
materially affect the viability of the stem or progenitor cells obtained from HUCB. Cells
8

from cord blood frozen maintain their viability and proliferation capacities for as long as
15 years and are no different than HUCB cells stored for shorter periods (Broxmeyer &
Cooper 1997, Broxmeyer et al 2003). For example, cells that were magnetically
separated with CD34 antibody and cryopreserved for 15 years were infused into
irradiated NOD/SCID mice. After 11-13 weeks in vivo the cells expressed multi-lineage
phenotypes that were comparable to those obtained using freshly harvested cord blood
(Broxmeyer et al 2003). More importantly, cryopreserved cord blood stored up to 4
years has been transplanted successfully in allogeneic sibling that had malignant or nonmalignant diseases (Broxmeyer 1998b, Wagner et al 1992).
Cryopreservation may actually confer certain advantages, in gene therapy,
relative to fresh, non-cryopreserved cord blood. Cord blood cells that have been
cryopreserved transduce retroviral vectors more easily than fresh cells, and this has been
suggested to be the result of higher expression of amphotropic retrovirus receptor mRNA
in the cryopreserved cord blood cells (Orlic et al 1999a, Orlic et al 1999b). The easy
transduction of retroviral vectors and the high expression of amphotropic retrovirus
receptor on HUCB cells may suggest a role for these cells in gene therapy, especially
since, amphotropic retrovirus receptors are the most widely used receptors for the
transduction of gene vectors currently. This area is further discussed in section “HUCB
Stem Cells for Gene Therapy.”

9

1.3.3 Low Incidence of GvHD Following Transplantation of Cord Blood Cells
and Their Immune Immaturity
In children that were transplanted with HUCB cells from related or unrelated
donor with one HLA-mismatch there was a low incidence of graft-vs-host disease
(GvHD) (Gluckman 2001, Rocha et al 2001, Rocha et al 2000; Wagner et al 1995). This
suggests that the host antigen-presenting cells did not recognize these transplanted cells
as foreign. The immaturity of cord blood cells has been postulated as the reason for this
low rejection rate. Several converging lines of evidence support this notion. One way to
study this area of immune immaturity is to compare the phenotypes and functionality of
T-lymphocytes in cord blood to that of mature T-cells such as those from adult blood (for
review on this subject see – Fallen & Cohen 2000). Most T cells from cord blood
express CD45RA (naïve isoform) with a few expressing CD45RO (mature - memory
isoform), whereas in adult blood the opposite of this is true with few CD45RA and more
CD45RO cells (Beck & Lam-Po-Tang 1994, Han et al 1995). Also in cord blood there
are fewer T cells that express CD29 compared to adult blood T cells (Rabian-Herzog et
al 1993). In the adult, CD29 recognizes T cells (CD4 positive memory cells) that have
been stimulated by specific antigen, therefore the lack of CD29 expression in cord blood
T cells is further evidence of their naïve state. In addition, the expression of the receptor
α subunit for IL –2 (CD25), a potent cytokine that acts as a major T cell growth factor, is
markedly lower in cord blood cells than in adult blood cells (Cohen et al 1999).
Moreover, in cord blood the functional response of T cells is less than those cells in the
adult blood. For instance, approximately 30% of CD45RA T cells from neonates
produce CD40 ligand (CD40L) whereas over 80% of T cells in adult blood have been
10

shown to produce this ligand (Fallen & Cohen 2000, Nonoyama et al 1995). CD40L
plays a role in the maturation of B cells and it has been proposed that the lack of CD40L
production in T cells contributes to the immaturity of B cells in cord blood. This
coincides with B cell production of IgG or IgA, which is less in the blood of newborns
compared to adult blood (Miyawaki et al 1981, Nagaoki et al 1981). Furthermore, the
production of certain cytokines, such as IL-2, IL-3, and IFN, is less in T cells from cord
blood than adult blood (for review see – Fallen, 2000).
A second line of evidence is based on telomeric analysis of HUCB cells. Cellular
division is associated with a sequential loss of telomeric DNA leading to cellular
senescence. Adult bone marrow cells have inherently shorter telomeres than cord blood
cells, providing circumstantial evidence that HUCB cells are immature(Vaziri et al
1994).
Together this evidence strongly supports the proposition that HUCB cells are
immune-immature and further suggests the immune cells within cord blood are
functionally and phenotypically at an early stage of development. If additional studies
confirm that HUCB cells are indeed in an immature state at the time of delivery and
shortly thereafter, this raises the clinically important possibility that immunosuppressive
therapy may not be necessary at the time of transplantation. The ability to avoid
immunosuppression is especially important for children who are victims of stunted
growth, when have increased risk of malignancy resulting from systemic
immunosuppressant therapy.
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1.3.4 HUCB Cells Have Been Safely Transplanted Clinically for Over 15
Years
Systemic administration of HUCB cells has a long standing and successful
history in the hematopoietic field and is commonly used to treat various nonmalignant
and malignant hematopoietic diseases (for review see - Broxmeyer 2000, Lu et al 1996).
The first documented HUCB transplant with an HLA-matched sibling was performed in
1988 on a child with Fanconi’s anemia. The procedure was well tolerated and, at last
report, the patient had survived for more than nine years without disease reoccurrence
(Broxmeyer 2000, Gluckman et al 1989). Concurrent pre-clinical studies demonstrated
that the bone marrow of lethally irradiated adult mice could be fully
rescued/reconstituted by injections of cord blood from pre-term and term deliveries
(Broxmeyer 1998a, Broxmeyer et al 1991). Since these initial reports, over 850 cord
blood transplants have been performed in children (NMDP, 2003) using either complete
or partial HLA-antigen matches for the treatment of nonmalignant and malignant
hematopoietic diseases (for reviews see – Broxmeyer 1998a, Lu et al 1996).
HUCB has also been successfully transplanted into adult recipients although the
number of transplants are fewer than those performed on children (Gluckman et al 1997,
Laughlin et al 2001). Fewer adult transplants have been performed because of the open
question concerning the appropriate “dosage” of HUCB cells. It is unknown whether a
single collection or sample of cord blood contains enough stem cells to repopulate the
adult hematopoietic system. Despite the need for continued clinical evaluation to
address this issue, HUCB cells from a single donor have been successfully used.
Interestingly, the number of cord blood cells infused in these studies has often been less
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than the number of bone marrow cells typically used (Gluckman et al 1999a, Gluckman
et al 1999b) further supporting the supposition that the number of hematopoietic stem
cells residing in cord blood is sufficient for improved clinical outcome. These
suppositions from the clinical data are supported by quantitative in vitro evidence in
which the number of myeloid progenitor cells supplemented with steel factor (SLF) and
hematopoietic colony-stimulating factors (CSFs) were analyzed. The result suggested
that a single collection of cord blood contains a sufficient number of cells for
engraftment and repopulation of the adult hematopoietic system (for review see Broxmeyer et al 1992a).

1.4

Phenotyping of HUCB Cells
Careful and accurate phenotyping of cells within a heterogeneous substrate such

as cord blood is essential for full realization of the clinical potential. Clonogenic assay,
flow cytometry, and the expression of CD antigens coupled with self-renewal
proliferation assays have historically been used to delineate hematopoietic stem and
progenitor cells from the other cellular components of cord blood. Clonogenic assays
have identified several colony-forming units, such as, erythroid burst forming units
(BFUe), granulocyte-macrophage colony-forming cells (CFU-GM), and granulocyteerythroid-macrophage-megakaryocyte colony forming units (CFU-GEMM) (Broxmeyer
& Carow 1993, Broxmeyer et al 1989).

Phenotypic markers that recognize cell

surface components, such as CD34 (a type I transmembrane glycophosphoprotein), are
routinely used to identify and sort cells. CD34 is believed to identify hematopoietic stem
cells, but the expression of this protein alone does not reliably distinguish hematopoietic
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stem cells from progenitor cells. For example, the heterogeneous population of cells in
cord blood consist of several lineage committed cells that express CD34: myeloid lineage
cells that consist of mononuclear phagocytes and granulocytes co-express CD34 and
CD33 (marker for myeloid progenitor cell); erythroid lineage cells co-express CD34 and
CD71 ( a proliferating cell marker); lymphoid lineage cells can co-express CD34 with
either CD19 (B cells) or CD7 (T cells); and megakaryocyte lineage cells co-express
CD34 and CD61 (platelets, megakaryocytes) (for review see –Kinniburgh & Russell
1993).
A more reliable discriminatory technique to isolate and identify hematopoietic
stem cells uses combinations of cell surface markers, CD antigens. For example, cells
that are CD34+, CD38-, CD90low, CD117low, CD135+ or HLA-DR- are younger cells and
are higher in the hierarchy of hematopoietic stem and progenitor cells (Broxmeyer 1995,
Cardoso et al 1993b, Mayani & Lansdorp 1998, Rappold et al 1997, Traycoff et al 1994).
The converse of this is also true - CD38+ cells that also co-express CD34 are more
committed progenitor cells (erythroid and granulocyte)(Mitsui et al 1993), and CD34 and
HLA-DR are shown to be expressed on mature dendritic cells, B-cells, and erythroid
progenitors (Kempuraj et al 1999). In addition, cells that are CD34+ and Thy-1+ (CD90 –
progenitor cell subset) express low levels of CD117 (c-Kit tyrosine kinase receptor). The
ligand for c-Kit is steel factor, also known as stem cell factor, which is believed to play a
vital role in the proliferation and viability of hematopoietic cells. CD34+ cells that are
negative for c-Kit have been shown to give rise to long-term culture-initiating cells
(LTC-IC), while in those high in c-Kit expression, LTC-IC were almost absent. This
pattern correlates with telomerase activity; in cells that are CD34+ CD38- or CD34+
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CD117- have less mitotic activity, thus conserving telomeres, compared to CD38+ or
CD117 high and low expressing cells (Sakabe et al 1998a, Sakabe et al 1998b). The
authors in this study, suggested cells that are CD34+ and CD38- or c-kit negative are
more quiescent and therefore probably more primitive. Although CD34 has been
extensively used to identify hematopoietic stem and progenitor cells, studies have
suggested there may be subset of stem and progenitor cells within cord blood that are
CD34- and lineage negative (Goodell et al 1997, Osawa et al 1996). However, the
importance of this cell type in relation to cell transplantation requires further
investigation.
Within the hematopoietic stem cell population there is a subset of CD133+
(originally called AC133) cells that strongly co-express with CD34 bright cells. There
are two forms of the antigen that have been identified; CD133/1 is a cell surface
glycoprotein and CD133/2 an intracellular protein (perinuclear label) (for review see
Miraglia et al 1997, Yin et al 1997, for CD133/1 and Potgens et al 2001, for CD133/2).
These antigens appear to be present on more primitive stem cells, in that, CD133/1 is not
recognized in cultured human umbilical vein endothelial cells (HUVECs) or peripheral
blood cells, but is expressed in human cord blood, fetal and adult bone marrow, and fetal
liver cells (Yin et al 1997). CD133/2 also shows no reaction with cultured HUVECs, but
is expressed in placental tissue, specifically trophoblast cells(Potgens et al 2001). This
provides circumstantial evidence that CD133+ cells may be more a primitive stem cell
than the CD34+ lineage- cells of HUCB. However, further investigation into their
proliferation and expansion capacity is needed before their clinical relevance is
understood.
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CD markers have also been used to assist in identifying neural stem cells. CD133
is consistently found in 90-95% of neurosphere cells whereas cells of the neurosphere
express neither CD34 nor CD45. Nor can CD34 and CD45 (common leukocytes
antigen) positive cells form neurospheres (Uchida et al 2000). Cells that are CD133+,
CD34-, CD45- and CD24-/lo (B cell marker) that were isolated from human fetal brain and
spinal cord (week 12) differentiated into neurons and glia, generated neurospheres, and
had self-renewal properties (Tamaki et al 2002, Uchida et al 2000). Additional markers
are available to aid in identifying neural stem cells (for review see – Newman et al
2003). Using these tools, in vitro studies have clearly demonstrated the expression of
neural phenotypes in a subset of mononuclear cells within HUCB.

1.5

In Vitro Studies of HUCB Cells
Sanchez-Ramos and colleagues (2001) initially cultured HUCB cells for 7 days in

a proliferation media supplemented with N2 (neural proliferating component), epidermal
growth factor (EGF) and basic fibroblast growth factor (bFGF). Additional cells were
cultured in differentiation medium consisting of the proliferation medium with the
addition of all-trans-retinoic acid (Yamaguchi et al) and nerve growth factor (NGF).
Immunocytochemical analysis revealed an increased expression of Musashi-1 (an early
marker of neural precursors), β-tubulin III (a specialized tubulin found in neurons –
TuJ1) and glial fibrillary acidic protein (GFAP - a marker for astrocytes) in HUCB cells
that were cultured in retinoic acid (RA) and NGF. RT-PCR analysis confirmed the
presence of Musashi-1, the mRNA for neuronal markers, nestin and necdin, GFAP in RA
and NGF treated cord blood cells (Sanchez-Ramos 2002, Sanchez-Ramos et al 2001).
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Since then, studies have confirmed and extended these results. β-mercaptoethanol
has been shown to differentiate cultured HUCB cells towards a neural phenotype, which
was confirmed by immunocytochemical expression of NeuN, neurofilament, and GFAP
and by RT-PCR mRNA for nestin, neurofilament and MAP2 (Ha et al 2001). A
multipotent HUCB cell subset that does not express CD14, CD34, or CD45 was
identified by Bicknese et al., (2002). These cord blood cells when plated in a low
glucose and more acidic media and supplemented with bFGF and hEGF differentiated
and expressed both GFAP and TuJ1 after 7 day in culture. Interestingly, both
hematopoietic progenitors and osteoclast-like cells were eliminated in this media
condition (Bicknese et al 2002). Finally, some of the most elegant work elucidating the
differentiation of HUCB cells into neural cells has been conducted by Buzanska et al.,
(2002). Using a magnetic cell sorter, isolated CD34+ and CD45+ cells were used to
provide a clonogenic cell subfraction of the mononuclear heterogeneous fraction of cord
blood cells. Following culturing in DMEM with selected growth factors the remaining
cells showed a very high commitment (30-40%) to neuronal, astrocyte fates, and a
modest proportion of oligodendrocytes (11%). These clone-forming cells expressed
nestin, but did not produce hematopoietic colonies. Cells were immuno-positive for
TuJ1 (a low level was present in untreated cells), MAP2, GFAP, and GalC
(oligodendrocyte marker) after exposure to RA and brain-derived neurotrophic factor
(BDNF). While BDNF seemed to increase the number of astrocytes, RA treated cells
alone had more neuronal expression. In addition, when HUCB selected cells were cocultured with rat cortical cells for 4 days all three types of neural progeny were present
(Buzanska et al 2002).
17

These same investigators recently reported that after 2 years in culture, HUBCderived stem cells continue to display normal chromosomal patterns, proliferation, and
self-renewal properties (Buzanska et al 2003a). EGF and FGF receptor profiles appeared
normal and both early and late passage cultures expressed internexin, Glutamate
Receptor-2 (GluR2), Glutamic acid decarboxylase (GAD 65), GAD 67, and tyrosine
hydroxylase (TH). HPLC analysis confirmed that the HUCB stem cells produced and
secreted serotonin (5-HT) and dopamine (DA) metabolites. Differentiated HUCB stem
cells also exhibit electrophysiological properties indicative of neurons including
hyperpolarization-activated inward and outward currents (Buzanska et al 2003b).
Missing from this area of research is the long-term potential and expansion capabilities
of these cells. More than likely the establishment of a “neural” stem cell line derived
from HUCB cells that is both homogenous and reliable will be the next research step. At
this time, it remains unknown whether it is necessary to establish such a cell line in order
to repair CNS diseases or disorders. However, such a cell line would allow researchers
to test the hypothesis of cell replacement to treat certain neurodegenerative and
neurological disorders more easily.

1.6

Transplantation Studies Utilizing HUCB Cells
To date, there are comparatively few published papers demonstrating that HUCB

cells express neural phenotypes after transplantation (Table 1.2). Nonetheless, the
accumulating in vivo data is quite consistent with the available in vitro data and points to
the possibility that HUCB transplants may provide a means of ameliorating the deficits
associated with a wide range of CNS diseases. In addition, the in vivo evidence suggest
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that there are alternative mechanisms, besides cell replacement, in which transplanted
HUCB cells are delivering therapeutic benefits in animal models of injury and disease.
These mechanisms include but are not limited to the release of trophic and neurotrophic
factors by HUCB cells and the attraction of endogenous factors or stem cells by cord
blood cells to the site of injury/damage. These alternative possibilities are discussed
below with the appropriate study(s).
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Table 1.2 Significant Published CNS Transplantation Studies Using the
Mononuclear Fractions of HUCB Cells

Work Cited

Animal Model &
Cell Treatment

Route & Time of
Delivery/
Concentration of Cells
for
Transplant

Behavioral Effects Immunocytochemistry Results

Zigova et al., 2002
Cell
Transplantation,
Vol. 11, pp 265274

Developing rat brain
Sprague-Dawley rats
Cells treated with:
1. DMEM, FBS + RA
& NGF
2. DMEM, FBS only

*SVZ injection of cells
in 1 day old neonates
6 X 104

No behavioral measures were taken.
No detrimental or adverse effects noted.
One month PT*:
Both treatment cell groups:
~2% positive for GFAP, with less than 0. 2% of positive
for TuJ1

Chen et al., 2001
Stroke, Vol. 32,
pp 2682-2688

Transient MCAO
Adult male Wistar rats
HUCB cells used
immediately after
thawing

Intravenous tail vein
injection
24 hrs or 7 days after
MCAO
3 X 106

Motor neurological severity scores improved:
24 hr & 7 day groups.
Rotarod improvements:
24 hr group only
14 and 35 day PT
More cells located in injured tissues in 24hr group. Both
groups had some positive cells
for NeuN, MAP-2, GFAP, & FVIII*

Willing, et al.,
2003a
J of Neuroscience
Research, Vol. 37,
pp 296-307

Permanent MCAO
Adult male SpragueDawley rats
HUCB cells used
immediately after
thawing

1. Intravenous femoral
vein
2. Intrastriatal injection
In both groups cells
delivered 24hrs after
MCAO at
concentrations of
1 X106 or 2.5 X 105

Both groups had functional improvements on a number
of measures.
1mo PT both groups improved on elevated body swing
test.
2mos PT femoral group showed improved motor
asymmetry on step test.
2mos PT more cellular debris in area of infarct of
striatal group compared to femoral delivery where no
cellular infiltration was noted. Human nuclear staining
did not clearly demonstrate survival of HUCB cells in
injured area.

Willing, et al.,
2003b
Cell
Transplantation
Vol. 12, pp 449454

Permanent MCAO
Adult male SpragueDawley rats
HUCB and PBPC*
cells were used
immediately after
thawing.

Intravenous femoral
vein
Cells were injected
24hrs after MCAO
1 X106

From 2 to 4 weeks PT HUCB treated rats increased in
spontaneous activity and motor
asymmetry was prevented in both groups measured on
elevated body swing test.
No immunocytochemistry or cell analysis performed.

Vendrame et al.,
2004
Stroke, Vol 35 (10)
pp
2390-2395

Permanent MCAO
Adult male SpragueDawley rats. HUCB
cells were used
immediately after
thawing.

HUCB cells
intravenous infused.
From 104 to 5 X 107
cells injected.

106 or more cells used significant behavioral
improvement in step test and elevated body swing. A
reduce infarct size was also reported.

Lu, et al., 2002
Cell
Transplantation
Vol. 11, pp 275281

TBI*
Wistar rats
HUCB cells were used
immediately after
thawing.

Intravenous tail vein
injection
Cells were injected
24hrs after TBI
2 X 106

At days 14 and 28 PT HUCB treated rats had
improvements on rotarod test and on neurological
severity scores.
28 days PT Large number of human nuclei cells found
in the brain and some double labeled for NeuN, MAP-2,
and GFAP. Most found in boundary zone of injured
area.

Table 1.2 (Continued)

20

Table 1.2 (Continued)
Animal Model &
Cell Treatment

Work Cited

Route & Time of Delivery/
Concentration of Cells for
Transplant

Saporta, et al., 2003
J of Hematotherapy &
Stem Cell Research
Vol. 12, pp 271-278

SCI* Hemicompression
Adult male Sprague-Dawley
rats
HUCB cells were used
immediately after thawing.

Intravenous
tail
injection
1. 1 day after injury
2. 5 days after injury
1 X 106

Garbuzova-Davis et al.,
2003 J of Hematotherapy
& Stem Cell Research
Vol. 12, pp 255-270

ALS
Transgenic male mice
B6SJL-TgN (SOD-G93A)
1GUR ~9.5 weeks of age.
HUCB cells were used
immediately after thawing.

Intravenous jugular vein
injection
Cells were delivered to presymptomatic G93A mice at
66.2 + 0.75 days of age.
1 X 106

vein

Behavioral Effects
Immunocytochemistry Results
Open field locomotor activity (Basso,
Beattie, Bresnehan -BBB) after
3weeks:
5 day group had improved score
compared to 1 day group.
4 weeks PT HUCB cells were found
only within the area of SCI.
More cells were found in 5 day group
than 1 day group.
(Identification was difficult due to
endogenous fluorescence.)
Delayed progression of ALS for 2-3
weeks and increased lifespan of
treatment group.
At 17 weeks of age PT HUCB treated
mice finished footprint test faster
compared to controls.
10 to 12 weeks PT cells were found in
the brain, spinal cord, and other
organs.
HUCB cell in CNS were identified
with HuNu and double labeled for
CD45, Nestin, TuJ1, and GFAP.

* PT = post transplantation, PBPC = peripheral blood progenitor cells,
FVIII = coagulation factor VIII, TBI = traumatic brain injury, and SCI =
spinal cord injury, SVZ = Subventricular Zones.
1.6.1

Normal Developing Brain

Prior to initiating studies in animal models of CNS disease, mononuclear HUCB
cells were transplanted into the subventricular zone of neonatal rat pups (1 day old)
(Zigova et al 2002). Given that the subventricular zone is an area known to promote stem
cell survival and provide instructive signals for stem and progenitor cells, it offers a
logical starting point to examine the engraftment and differentiation potential of HUCB
cells into neural cells. The mononuclear fraction of HUCB cells were cultured in either
DMEM with fetal bovine serum or Neurobasal medium with RA and NGF. Rat pups
were transplanted with the cultured cells (60,000) and 30 days afterwards were sacrificed
for immunohistochemical analysis of transplanted cells that survived and the
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corresponding phenotype. Under both culture conditions, cells were found proximal to
the transplantation site and in the overlying cortex and corpus callosum. There was a
greater distribution and survival rate of cells cultured with DMEM and FBS than with RA
and NGF. Double-labeling experiments confirmed the neural nature of at least some of
the human transplanted cells that were labeled with either GFAP or TuJ1. Qualitative
analysis suggested that the majority of cells possessed an astrocytic-like phenotype and
morphology.
The study described above suggests that HUCB cells are capable of surviving and
migrating within the developing, normal brain. Future studies will certainly need to
continue to explore the developmental biology and neural stem cell properties of these
cells when grafted into the developing and aging brain. However, the potential use of
HUCB cells to treat the damaged brain is among the most exciting contemporary research
areas. Despite being a completely new field there are initial results demonstrating the
functional effects of HUCB cells transplants in several different animal models of acute
and chronic disease.
1.6.2

Stroke

Stroke is the third leading cause of death in the majority of developed countries
and is a leading health care burden in all developed countries(American Heart
Association, 2005). Even though the incidence of stroke has declined over the past
decades, progress in treating stroke has been disappointing. Despite our continued
understanding of the pathological underpinnings of cell death in stroke, there are no
effective treatments for mitigating the loss of neurons in patients once that pathological
cascade has been initiated. Cell transplantation has been proposed as one means of
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repairing the stroke ravaged brain and recent studies suggest that systemic infusion of
HUCB cells produces potent behavioral effects in animal models. Indeed, recent data
indicate that intravenously administered HUCB cells can survive, migrate to the site of
injury, and provide functional recovery in a rat model of cerebral ischemia. In a
pioneering study, Wistar rats received a transient (2 hour) middle cerebral artery
occlusion (MCAO) followed by a tail vein injection of HUCB cells (3 x 106 as a bolus
injection) either 24 hours or 7 days after stroke (Chen et al 2001). Animals were
sacrificed at 14 and 35 days after MCAO and all animals showed significant lesions.
However, no reduction in lesion volume was observed at either transplant time. Detailed
histological analysis revealed grafted HUCB cells within the ipsilateral cortex, subcortex,
and striatum. In addition, neuronal markers NeuN, astrocytic marker GFAP, and the
endothelical cell marker, FVIII, were shown in animals transplanted at 24 hours after
MCAO. Associated with the survival of HUBC cells were improvements in behavioral
indices. A battery of tests including the rotarod motor test and the modified neurological
severity score test (MNSS) was conducted at 1, 7, 14, 21, 28, and 35 days after MCAO.
Rats that received HUCB cells 24hrs post stroke showed significant performance
improvements on both tests, whereas treatment at 7 days produced less robust recovery
with improved function seen only on the MNSS. Therefore, this data suggest that a time
dependent mechanism may be involved in delivery of the cells. We examine this issue in
more detail in Chapter 4.
Subsequent studies have begun to examine whether the route of administering
HUBC cells following MCAO, impacts behavioral recovery. Sprague-Dawley rats
received permanent MCAO and 24 hours later HUCB cells were injected either into the
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femoral vein (1 x 106 cells) or directly into the striatum (250,000 cells) (Willing et al
2003a). Behavioral tests conducted 1-2 months later included measures of locomotor
activity, elevated body swing test, step test, and passive avoidance. The pattern of
behavioral recovery was dependent to some degree on the route of cell delivery. Motor
activity and passive avoidance testing improved in both treatment groups while
performance on the step task (a measure of forelimb dexterity) improved in only those
animals receiving HUBC cells via the femoral artery. While it is tempting to speculate
that the femoral route of administration was more effective than direct striatal injection,
several outstanding issues remain including: the lack of definitive identification of HUCB
cells in the brain (Figure 1.1), the differences in cell numbers transplanted in the two
treatment groups, and the potential role of the immune/inflammatory response produced
by the MCAO. This last possibility is especially intriguing and the authors raise the
possibility that the immune cells of the transplanted cord blood are attracted to the site of
injury, which could help induce endogenous signals for the recruitment of stem cells
within the animal or possibly the release of trophic factors from the HUCB cells
themselves. This could aid in the repair and the eventual behavioral improvements seen
in these stroke animals. In a second study, Willing, et al. (2003b), observed similar
behavioral results in MCAO induced rats as in their first study. This study also showed
that human granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood
progenitor cells delivered by femoral vein (1 x 106 cells) improved behavioral deficits
seen in MCAO rats(Willing et al 2003b). If a non-specific immunological effect does
contribute to the behavioral recovery, it is of interest because in both studies cyclosporine
was co-administered (to minimize graft rejection), and yet it did not alter the behavioral
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effects of HUCB cell transplants in rats following MCAO. These results provide
compelling support for the potential use of HUCB cells in treating stroke. However,
because the survival of HUCB cells at the site of damage appears to be relatively low
(Figure 1.1) and the behavioral recovery, although present, is only partial, strategies are
being developed for further improvement in the beneficial effects of HUCB transplants.
Figure 1.1: HUCB Cells Transplanted into Stroke Rat Brain

Figure 1.1 Fluorescence photomicrograph of striatum. Converted into black and white (A) Cellular
debris in lateral striatum associated with permanent MCAO (MCAO-only group). DAPI was used
to label cell nuclei within the striatum. With this method, a cellular infiltrate in the region of the
infarct can be seen. These are small cells characteristic of either microglia or neutrophils in the
same section as shown in A. (C,D) Higher magnification views from selected areas of the image in
A. (E) Cellular debris in striatum in an animal from the femoral group. (F) Striatal group. (G)
Normal contralateral striatum from the same animal as shown in E. Scale bar in B = 300 µm; for
A,B; bar in D = 100 µm for C,D; bar in G = 50 µm for E–G. With permission from J Neurosci Res
73(3), 296-307, (2003) Willing, et al.
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Not only have functional improvements in behavioral deficits of MCAO been
seen, but reduction in the volume of the infarct have been reported(Vendrame et al 2004).
In this study, MCAO rats were intravenously infused with 104 to 5 X 107 HUCB cells 24
hours after surgery. At 4 weeks after delivery of HUCB cells at the 106 or higher dose,
the rats with MCAO showed significant improvements in behavioral measures. More
importantly, MCAO rats that were treated with 107 cells showed a reduced infarct
volume, and cells were localized either to the infarct brain or in the spleen.
Several important points are clear from theses stroke studies. First, the behavioral
improvements are consistent and contribute to a growing literature suggestive of the
functional benefits of HUCB cell transplants. Secondly, the study by Vendrame et al.,
provides the first clear evidence that transplanted HUCB cells can minimize the structural
consequences of ischemic damage. Third, the dose range of cells required for behavioral
improvements and reduced infarct volume have been determined. Fourth and last, “proof
of principle” for both the behavioral improvement seen in the use of HUCB cells in the
treatment of ischemic stroke and the intravenous delivery method has been established.

1.6.3

Traumatic Brain Injury

No class of CNS injuries is more steeped in history and frustration than traumatic
brain injuries (TBIs). Neurosurgery began with the treatment of head injuries as
evidenced by what we know of medical practice in ancient civilizations. Despite this
long history, TBIs are much like stroke, in that, we have an enhanced understanding of
the pathology associated with injury and have continually refined our principles of patient
management. In addition, TBI, similar to stroke, has no effective treatment. While cell
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therapy offers theoretical promise for a wide range of CNS diseases, its promise is
especially true for trauma if a non-invasive means of cell delivery could be developed.
The exact nature of the localized trauma often times prohibits additional surgical
intervention at the site until some time after the initial damage has occurred.
Unfortunately, much of the potential benefit of an intervening cell therapy may be lost
during this time. In contrast, delivery of cells via the circulatory system would bypass
these obstacles perhaps permitting sufficient cell delivery to the injured region resulting
in anatomical and/or functional repair processes.
To evaluate the potential of HUCB transplants in traumatic brain injury, Lu et al.,
(2002) examined the neurological benefits afforded by intravenous administration of
HUCB cells in rats with contusive brain injury. HUCB cells were injected into the tail
vein 24 hours after injury and the rats were sacrificed 28 hours later for histological
analysis of the migration of cells to the site of trauma. The injected cells were distributed
in the brain, heart, lung, kidney, liver, spleen, bone marrow, and muscle as demonstrated
by immunohistochemical staining and laser confocal microscopy. It would seem that
there was preferential entry and migration of HUCB cells into the parenchyma of the
injured brain. The transplanted cells expressed the neural markers, NeuN and MAP-2,
and the astrocytic marker, GFAP. Some HUCB cells integrated into the vascular walls
within the boundary zone of the injured area. Significant functional improvements were
also produced as assessed by both the Rotarod test and the NSS (Lu et al 2002).
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1.6.4

Spinal Cord Injury

Similar behavioral benefits of cord blood cells were observed in animals with
spinal cord injury (SCI) (Saporta, et al., 2003). SCI was induced by unilateral
hemicompression with an aneurysm clip for 1 minute and HUCB cells (pre-labeled with
FITC-conjugated cholera toxin) were intravenously injected either 1 or 5 days later.
Behavioral recovery was determined using open field behavior at 1, 2, and 3 weeks after
treatment. Rats receiving HUCB cells at 5 days, but not 1 day after surgery, had gradual
and significant improvements on the locomotor tests that were seen over the course of the
study. Histological analysis of these animals confirmed the presence of HUCB cells at
and around the site of injury, but not in areas of necrosis or in the areas of intact spinal
cord (Figure 1.2). Consistent with the pattern of behavioral recovery, nearly twice the
number of viable HUCB cells were present within the damaged spinal cord when
transplanted at 5 days versus 1 day after surgery (Saporta et al 2003). This is the first
study to report that HUCB cells migrate specifically to the site of injury in the spinal cord
and not to the contralateral side and the first to show that HUCB cells can improve motor
behavior deficits in rat SCI model.
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Figure 1.2: HUCB Cells Transplanted into Spinal Cord Injury in Rats

Figure 1.2 HUCB cells in the injured spinal cord 4 weeks after intravenous injection. Endogenous
fluorescence was quenched with Pontamine Sky Blue (A) Fluorescent photomicrograph through the area of
compression from a SCI only animal. No fluorescent HUCB-like cells were visible in these sections.
Fluorescent photomicrograph of a section of spinal cord from a laminectomy-only animal that also received
an intravenous injection of HUCB cells. No FITC-prelabeled HUCB cells are visible in these sections. (C)
FITC-labeled HUCB cells (arrows) in a section from the spinal cord of a rat that received HUCB 5 days
after compression injury within the area of compression. (D) Fluorescent photomicrograph through the area
of compression of an animal that received HUCB 1 day after compression injury. FITC + HUCB cells
similar to those seen in C were seen in these sections (arrows). Calibration bar: A, B, and D, 50 µm; C, 100
µm. With permission from J Hematother Stem Cell Res, 12(3), 271-278, Saporta et al., (2003).

1.6.5

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is
caused by a progressive degeneration of motor neurons. In the United States, 1 to 2
people per 100,000 develop ALS each year with men affected slightly more often than
women(NINDS & NIH 2003). Although ALS may occur at any age, it is most
commonly diagnosed in middle-aged and older adults. Over a period of months or years,
ALS causes increasing muscle weakness, inability to control movement, and problems
with speaking, swallowing, and breathing. In general, weakness progresses steadily with
no periods of improvement or stability leading to death, usually within 3 to 6 years.
There is no cure for ALS at this time. Current treatment for ALS focuses on helping the
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person cope with symptoms and avoiding complications for as long as possible. Cell
therapy has been proposed as a possible replacement/repair strategy for the lost motor
neurons. However, the diffuse nature of the disease, a significant number of cells are
required for transplantation, although in theory, cell replacement via stem cells injected
into the circulatory system could be beneficial if the cells could migrate into the region
proximal to the motor neurons.
The mouse SOD-1 model of ALS provides a useful means of evaluating cellbased neurorepair and neuroprotective strategies. In a recent study 1 x 106 mononuclear
cells from HUCB were administered intravenously (via the jugular) into G93A
transgenice male mice at 9.5 weeks of age (prior to the onset of significant behavioral
impairments)(Garbuzova-Davis et al 2003). Significant benefits were observed in
hindlimb extension and gait. Grafted animals lost less weight over the course of the
study and, most impressively, lived a significantly longer (2-3 weeks) than controls. A
detailed analysis of the survival and distribution of the injected HUCB cells revealed
cells in the parenchyma of the brain, spinal cord, spleen kidneys, liver, lungs and heart.
Some HUCB cells were immuno-positive for neural and astrocytic markers (TuJ1 and
GFAP) within the parenchyma of the brain. This study was the first to report that HUCB
cells are capable of migrating to a progressive brain and spinal cord disease without
occurrence of an acute traumatic injury. Future studies should examine this approach in
other progressive degenerating diseases such as PD, HD, and AD. Although there have
been studies demonstrating longer life span expectancy in animal models of degenerative
disorders treated with cord blood cells (Ende, Weinstein, Chen, & 2000; Ende, Chen, &
Ende-Harris, 2001; Ende & Chen, 2002), they did not examine the size of lesion, grafted
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cell survival, location of the cells, immuno-markers, or optimal time periods in which to
administer the cells.

1.7

HUCB Stem Cells for Gene Therapy
Gene therapy, or the manipulation of human genetic material to produce a

therapeutic effect, is a maturing scientific field and hematopoietic stem cells are
promising targets for gene therapy. Like other areas of gene therapy, the use of modified
hematopoietic cells suffers from low and variable transfection efficiency, uncontrolled
production of foreign gene products, and poor safety profiles. Nonetheless, significant
progress has been made in transfecting hematopoietic stem cells using both viral (sendai
virus, simian foamy virus, human foamy virus, lentivirus, and adenovirus) and non-viral
(centrifugal enhancement and particle-mediated gene delivery) methods (Buchet et al
2002, Falk et al 2002, Hughes et al 2002, Mitta et al 2002, Rosenqvist et al 2002, Watson
et al 2003). In addition, cryopreserved HUCB cells may offer a certain advantage in the
field of gene therapy research (as discussed early) in that they express a high level of
amphotropic retrovirus receptors and amphotropic retrovirus receptors are widely used
for transduction of gene vectors (Orlic et al 1996). Figure 1.3 represents one of the viral
methods using green fluorescent protein (GFP).
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Figure 1.3: HUCB Cell that are Labeled with Green Fluorescent Protein

Figure 1.3 Green fluorescent protein labeling of HUCB.
Using the lentiviral vector approach (provided by Dr. Didier
Trono), HUCB cells (A, phase contrast) exhibit the green
fluorescent protein (GFP) in vitro (B, FITC fluorochrome). In
addition, following transplantation into the striatum, HUCB
cells retain GFP epifluorescence at least up to 6 months of
graft maturation (C, magnified in D). Figure kindly provided
by Dr. Didlier Trono and with permission from Newman et
al., (2004) Expert Opin Biol Ther, 4(2), 121-130.

The results obtained, using Sendai viral mediated transfection, are particularly
promising. Very high transfection of GFP has been achieved by using CD34+ HUCB or
BM cells (>80%) and other HUCB progenitor cells (Woods et al 2001, Woods et al
2003). Efficient gene transfer was independent of cell cycle and in vitro cell
differentiation studies confirmed that gene transfer occurred in progenitor cells of
multiple lineages (Luther-Wyrsch et al 2001) indicating that this system provides very
high gene transfer rates while maintaining the cells’ ability to reconstitute the normal
compliment of hematopoietic lines.
In theory, stem/progenitor cells within the mononuclear fraction of HUCB offer
yet another unexplored means of enabling gene therapy for the CNS. Cell-based gene
therapy is hampered by the lack of an abundant, safe, and immunologically acceptable
source of tissue. Conceivably, HUCB stem cells could overcome this limitation because
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of their ability to evade detection by the host immune system and continue to secrete a
therapeutic compound. As described above, several of in vivo studies have confirmed
that HUCB cells survive following engraftment into the brains of xenogeneic hosts (i.e.
human to rat). The continued survival of HUCB cells in these studies cannot be solely
attributed to the adjunctive pharmacological regimen, such as cyclosporine, but rather it
reflects some inherent aspect of the transplanted cells. A recent study by Weiss and
colleagues (2003), clearly shows that a subset of umbilical cord matrix cells from pigs
differentiate into glia or neurons and survive following transplantation in rat brain for
more than six weeks without triggering any recognition by the immune system (Weiss et
al 2003). The authors suggest that the in vivo differentiation of cord blood cells into
neurons might provide a unique approach to treating CNS diseases. This may be the
case; however, this also provides a new opportunity to engineer and transplant stem cells
from HUCB that could produce a desired therapeutic protein such as dopamine or GDNF
for the treatment of PD. If longer-term studies confirm the stable transfection and
longer-term survival of HUCB cells following transplantation this may create a new arm
of xenotransplantation research that could potentially obviate many of the issues
associated with tissue rejection.
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1.8

Clinical Studies using HUCB Cells
1.8.1

Transplantation of HUCB cells into Patients with Inborn Errors in
Metabolism

As mentioned HUCB cells, along with bone marrow cells have been used to treat
various nonmalignant and malignant hematopoietic diseases, such as juvenile chronic
myelogenous leukemia, Fanconi's anemia, and in patients with neuroblastoma that have
varying clinical outcomes depending on the stage of the disease at time of transplantation
and the disease itself. In addition, HUCB cells have been used to treat
lysosomal/enzymatic disorders, such as Krabbe disorder and Maroteaux-Lamy
syndrome. Krabbe disease is caused by a deficiency in galactocerebrosidase (GALC),
which results in insufficient myelin formation in the peripheral and CNS. The majority
of infants diagnosed with this disorder die before reaching 2 years of age, while the
prognoses in adults is quite variable. Hematopoietic stem cells have been used to treat
patients with Krabbe disease (Wenger et al 2000), and although this treatment decreases
the symptoms, it does not eliminate or cure it. Infants with this disorder have been
shown to have a longer lifespan if they receive hematopoietic stem cells within the first
two weeks of life.
Snyder and colleagues recently presented their findings, at the America Society
of Neural Transplantation and Repair annual conference (2003), on a 21-month-old
female infant suffering from Krabbe leukodystrophy, who received HUCB cells of male
origin, and survived for a year after transplantation (Kosaras et al 2003). This study
showed that upon postmortem examination of the brain, by FISH and
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immunocytochemistry analyzes, the transplanted HUCB cells were located in both white
and gray matter, the ventricular ependyma, and within blood vessels throughout the host
brain. Furthermore, HUCB cells were determined to differentiate into microglia, but not
neural cells and the authors proposed that these cells could be producing GALC. This
finding directly supports the pre-clinical studies discussed here that suggest that
transplanted HUCB cells are acting through other mechanisms besides the differentiation
of these cells into neural phenotypes to produce the improved behavioral results observed
in animal models of injury.
The FDA has already approved clinical trials using HUCB cells for hematologic
malignancies, aplastic anemia, immunodeficiency diseases, and metabolic disorders
(Thomson et al 2000, Wagner et al 1995). While these clinical trials are not for
neurological disorders, the level of comfort that regulatory agencies already have with
this general approach together with the data collected from ongoing trials (related to
dosage, GVHD, cell survival, safety of the HUCB cells, and their efficacy) will facilitate
entry into clinical trials for cellular transplantation therapies. With over 1500 cord blood
transplants performed worldwide, a strong safety and efficacy database is being compiled
(Gluckman et al 2001, Laughlin et al 2001). Although no official clinical trials for
neurological disorders are in progress, various media sources have reported that HUCB
cell transplants for ALS, stroke, and Sanfilippo Syndrome have been performed.
However, without corroborating scientific data to review: these reports are insufficient to
determine the effects of the HUCB cells on the treated patients.
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1.9

Conclusions Thus Far
Cell transplantation for CNS diseases has always held tremendous medical

potential. Nevertheless, despite the generally promising clinical results of numerous
strategies, widespread clinical evaluation has been difficult. The most obvious example
of this is the use of fetal neural tissue. Even though fetal grafts, survived and produced
functional benefits in pre-clinical models, and have been suggested to be beneficial in
small clinical trials, the limited tissue availability and ethical concerns have seriously
hampered development of this approach. Described here is an alternative approach to the
traditional problems of cell therapy that focuses on the use of HUCB as a rich and
transplantable source of non-embryonic or adult stem cells that appear to be capable of
exerting pronounced effects even when administered systemically.

1.10

Explanation of Study and Overall Purpose

The studies within this manuscript were preformed to answer questions that will
advance the potential of HUCB cells in the field of cell therapy and repair. In the
research that was presented, in this chapter, three areas clearly required further
exploration; the ability of HUCB cells to migrate to the injured tissue, the
chemoattractants (if any) within the damaged tissue and the factors responsible for the
improvement in behavior. We examined basic characteristics that were needed to
proceed with the planned studies, such as, the average diameter of the cells, their
phenotypes in culture, the ability of these cells to proliferate in culture, their ability to
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migrate to known chemoattractants along with the optimal time, testing of several assays
in which to measure migrating cells, protein assay to standardized protein amount in
migration studies, and migration to the young rat brain, which we believed at the time
could be use as a positive control. These findings are presented in Chapter 3.
The ability of HUCB cells to migrate to injured tissue, which is especially
important when using systemic administration, and the optimal time after injury to
deliver these cells was examined. Initially experiments were designed to address the
cells’ ability to migrate in a variety of animals models of disease or injury of the CNS.
After the initial migration experiments with several animal models of injury (Chapter 3)
one in particular (ischemic rat) showed significant clinical and basic science relevance,
and this study is present in Chapter 4. The ischemic rat migration study was expanded to
determine some of the cytokines or chemokines present in the ischemic tissue (Chapter
4), and the ability of HUCB cells to produce cytokines/chemokines, these data are
presented in Chapter 5. Compared to the number of cells that were injected, in the
HUCB cells transplantation studies, few cells were found at the site of injury. This is
very interesting due to the significant improvements in behavior that were presented in
the animal models of injury therefore; we felt exploration in this area was essential.
These experiments and results are present in Chapter5. In addition, the relevance to
clinical and basic sciences from these studies is discussed in Chapter 6.

37

1.11

References

AHA - American Heart Association. 2005. Heart Disease and Stroke Statistics. Dallas,
Texas: American Heart Association
Beck R, Lam-Po-Tang PR. 1994. Comparison of cord blood and adult blood lymphocyte
normal ranges: a possible explanation for decreased severity of graft versus host
disease after cord blood transplantation. Immunol Cell Biol 72: 440-4
Bicknese AR, Goodwin HS, Quinn CO, Henderson VC, Chien SN, Wall DA. 2002.
Human umbilical cord blood cells can be induced to express markers for neurons
and glia. Cell Transplant 11: 261-4
Blau HM, Brazelton TR, Weimann JM. 2001. The evolving concept of a stem cell: entity
or function? Cell 105: 829-41
Broxmeyer HA, ed. 1998a. Cellular characteristics of cord blood and cord blood
transplantation. Bethesda: AABB Press
Broxmeyer HE. 1995. Cord blood as an alternative source for stem and progenitor cell
transplantation. Curr Opin Pediatr 7: 47-55
Broxmeyer HE. 1996. Primitive hematopoietic stem and progenitor cells in human
umbilical cord blood: an alternative source of transplantable cells. Cancer Treat
Res 84: 139-48
Broxmeyer HE. 1998b. Cord Blood Transplantation Study Standard Operating
Procedures: an evolving document will improve cord blood unit quality. J
Hematother 7: 479-80
Broxmeyer HE. 2000. Introduction: Cord blood transplantation - looking back and to the
future. In Cord Blood Characteristics: Role in Stem Cell Transplantation., ed. SB
Cohen, E Gluckman, P Rubinstein, JA Madrigal. London: Martin Dunitz
Broxmeyer HE, Carow CE. 1993. Characterization of cord blood stem/progenitor cells. J
Hematother 2: 197-9
Broxmeyer HE, Cooper S. 1997. High-efficiency recovery of immature haematopoietic
progenitor cells with extensive proliferative capacity from human cord blood
cryopreserved for 10 years. Clin Exp Immunol 107 Suppl 1: 45-53
Broxmeyer HE, Cooper S, Yoder M, Hangoc G. 1992a. Human umbilical cord blood as a
source of transplantable hematopoietic stem and progenitor cells. Curr Top
Microbiol Immunol 177: 195-204
38

Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, et al. 1989. Human umbilical
cord blood as a potential source of transplantable hematopoietic stem/progenitor
cells. Proc Natl Acad Sci U S A 86: 3828-32
Broxmeyer HE, Hangoc G, Cooper S, Ribeiro RC, Graves V, et al. 1992b. Growth
characteristics and expansion of human umbilical cord blood and estimation of its
potential for transplantation in adults. Proc Natl Acad Sci U S A 89: 4109-13
Broxmeyer HE, Kurtzberg J, Gluckman E, Auerbach AD, Douglas G, et al. 1991.
Umbilical cord blood hematopoietic stem and repopulating cells in human clinical
transplantation. Blood Cells 17: 313-29
Broxmeyer HE, Srour EF, Hangoc G, Cooper S, Anderson SA, Bodine DM. 2003. Highefficiency recovery of functional hematopoietic progenitor and stem cells from
human cord blood cryopreserved for 15 years. Proc Natl Acad Sci U S A 100:
645-50
Buchet D, Serguera C, Zennou V, Charneau P, Mallet J. 2002. Long-term expression of
beta-glucuronidase by genetically modified human neural progenitor cells grafted
into the mouse central nervous system. Mol Cell Neurosci 19: 389-401
Buzanska L, Machaj EK, Zablocka B, Pojda Z, Domanska-Janik K. 2002. Human cord
blood-derived cells attain neuronal and glial features in vitro. J Cell Sci 115:
2131-8
Buzanska L, Stachowiak E, Stachowiak M, Domanska-Janik K. 2003a. Neural stem cell
line derived from human umbilical cord blood - morphological and functional
properties. Journal of Neurochemistry 85: 33
Buzanska L, Sun W, Salvi RJ, Domanska-Janik K, Stachowiak MK. 2003b. Changing
electrophysiological properties in differenitating human cord blood-derived
neural stem cells. Journal of Neurochemistry 85: 33
Cairns J. 1975. Mutation selection and the natural history of cancer. Nature 255: 197-200
Cardoso AA, Li ML, Batard P, Hatzfeld A, Brown EL, et al. 1993a. Release from
quiescence of CD34+ CD38- human umbilical cord blood cells reveals their
potentiality to engraft adults. Proc Natl Acad Sci U S A 90: 8707-11
Cardoso AA, Li ML, Batard P, Sansilvestri P, Hatzfeld A, et al. 1993b. Human umbilical
cord blood CD34+ cell purification with high yield of early progenitors. J
Hematother 2: 275-9

39

Chen J, Sanberg PR, Li Y, Wang L, Lu M, et al. 2001. Intravenous administration of
human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke
32: 2682-8
Cohen SB, Perez-Cruz I, Fallen P, Gluckman E, Madrigal JA. 1999. Analysis of the
cytokine production by cord and adult blood. Hum Immunol 60: 331-6
Eaton MJ, Whittemore SR. 1996. Autocrine BDNF secretion enhances the survival and
serotonergic differentiation of raphe neuronal precursor cells grafted into the
adult rat CNS. Exp Neurol 140: 105-14
Falk A, Holmstrom N, Carlen M, Cassidy R, Lundberg C, Frisen J. 2002. Gene delivery
to adult neural stem cells. Exp Cell Res 279: 34-9
Fallen P, Cohen SBA. 2000. Cord blood T-cell immunobiology. In Cord Blood
Characteristics: Role in Stem Cell Transplantation., ed. SB Cohen, E Gluckman,
P Rubinstein, JA Madrigal, pp. 39-60. London: Martin Dunitz Ltd
Garbuzova-Davis S, Willing AE, Zigova T, Saporta S, Justen EB, et al. 2003. Intravenous
administration of human umbilical cord blood cells in a mouse model of
amyotrophic lateral sclerosis: distribution, migration, and differentiation. J
Hematother Stem Cell Res 12: 255-70
Gluckman E. 2001. Hematopoietic stem-cell transplants using umbilical-cord blood. The
New England Journal of Medicine 344: 1860-1
Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, et al. 1989.
Hematopoietic reconstitution in a patient with Fanconi's anemia by means of
umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321: 1174-8
Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, et al. 1997. Outcome
of cord-blood transplantation from related and unrelated donors. Eurocord
Transplant Group and the European Blood and Marrow Transplantation Group. N
Engl J Med 337: 373-81
Gluckman E, Rocha V, Chastang C. 1999a. Peripheral stem cells in bone marrow
transplantation. Cord blood stem cell transplantation. Baillieres Best Pract Res
Clin Haematol 12: 279-92
Gluckman E, Rocha V, Chastang CL. 1999b. Umbilical cord blood hematopoietic stem
cell transplantation. Eurocord-Cord Blood Transplant Group. Cancer Treat Res
101: 79-96
Gluckman E, Rocha V, Chevret S. 2001. Results of unrelated umbilical cord blood
hematopoietic stem cell transplant. Transfus Clin Biol 8: 146-54
40

Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, et al. 1997. Dye efflux
studies suggest that hematopoietic stem cells expressing low or undetectable
levels of CD34 antigen exist in multiple species. Nat Med 3: 1337-45.
Gritti A, Frolichsthal-Schoeller P, Galli R, Parati EA, Cova L, et al. 1999. Epidermal and
fibroblast growth factors behave as mitogenic regulators for a single multipotent
stem cell-like population from the subventricular region of the adult mouse
forebrain. J Neurosci 19: 3287-97
Ha Y, Choi JU, Yoon DH, Yeon DS, Lee JJ, et al. 2001. Neural phenotype expression of
cultured human cord blood cells in vitro. Neuroreport 12: 3523-7
Han P, Hodge G, Story C, Xu X. 1995. Phenotypic analysis of functional T-lymphocyte
subtypes and natural killer cells in human cord blood: relevance to umbilical cord
blood transplantation. Br J Haematol 89: 733-40
Hows JM, Marsh JC, Bradley BA, Luft T, Coutinho L, et al. 1992. Human cord blood: a
source of transplantable stem cells? Bone Marrow Transplant 9 Suppl 1: 105-8
Hughes SM, Moussavi-Harami F, Sauter SL, Davidson BL. 2002. Viral-mediated gene
transfer to mouse primary neural progenitor cells. Mol Ther 5: 16-24
Kempuraj D, Saito H, Kaneko A, Fukagawa K, Nakayama M, et al. 1999.
Characterization of mast cell-committed progenitors present in human umbilical
cord blood. Blood 93: 3338-46
Kinniburgh D, Russell NH. 1993. Comparative study of CD34-positive cells and
subpopulations in human umbilical cord blood and bone marrow. Bone Marrow
Transplant 12: 489-94
Kondo T, Raff M. 2000. Oligodendrocyte precursor cells reprogrammed to become
multipotential CNS stem cells. Science 289: 1754-7
Kosaras B, Kurtzberg J, Sidman RL, Wenger D, Bianchi D, Snyder EY. 2003. Human
umbilical cord cells (UCCS) distribute themselves throughout the degenerating
huma brain but do not transdifferentiate into neural cells. Exp Neurol 181: 96
Lajtha LG. 1979a. Haemopoietic stem cells: concept and definitions. Blood Cells 5: 44755
Lajtha LG. 1979b. Stem cell concepts. Nouv Rev Fr Hematol 21: 59-65
Lajtha LG. 1980. Bone marrow: The seedbed of blood, in Wintrobe MM (ed): Blood,
Pure and Eloquent. New York: McGraw Hill. p 57.
41

Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, et al. 2001. Hematopoietic
engraftment and survival in adult recipients of umbilical-cord blood from
unrelated donors. The New England Journal of Medicine 344: 1815-22
Lu D, Sanberg PR, Mahmood A, Li Y, Wang L, et al. 2002. Intravenous administration
of human umbilical cord blood reduces neurological deficit in the rat after
traumatic brain injury. Cell Transplant 11: 275-81
Lu L, Shen RN, Broxmeyer HE. 1996. Stem cells from bone marrow, umbilical cord
blood and peripheral blood for clinical application: current status and future
application. Crit Rev Oncol Hematol 22: 61-78
Luther-Wyrsch A, Costello E, Thali M, Buetti E, Nissen C, et al. 2001. Stable
transduction with lentiviral vectors and amplification of immature hematopoietic
progenitors from cord blood of preterm human fetuses. Hum Gene Ther 12: 37789
Marshak DR, Gardner RL, Gottlieb D, eds. 2001. Stem cell biology., Vols. Monograph
40. Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Mayani H, Lansdorp PM. 1998. Biology of human umbilical cord blood-derived
hematopoietic stem/progenitor cells. Stem Cells 16: 153-65
Metcalf D. 1984. Clonal culture of hemopoietic cells: techniques and applications. The
Netherlands: Elsevier Science Publishers B.V. 3 pp.
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, et al. 1997. A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization, and
molecular cloning. Blood 90: 5013-21
Mitsui H, Furitsu T, Dvorak AM, Irani AM, Schwartz LB, et al. 1993. Development of
human mast cells from umbilical cord blood cells by recombinant human and
murine c-kit ligand. Proc Natl Acad Sci U S A 90: 735-9
Mitta B, Rimann M, Ehrengruber MU, Ehrbar M, Djonov V, et al. 2002. Advanced
modular self-inactivating lentiviral expression vectors for multigene interventions
in mammalian cells and in vivo transduction. Nucleic Acids Res 30: e113

Miyawaki T, Moriya N, Nagaoki T, Taniguchi N. 1981. Maturation of B-cell
differentiation ability and T-cell regulatory function in infancy and childhood.
Immunol Rev 57: 61-87
42

Nagaoki T, Miyawaki T, Ciorbaru R, Yachie A, Uwadana N, et al. 1981. Maturation of B
cell differentiation ability and T cell regulatory function during child growth
assessed in a Nocardia water soluble mitogen-driven system. J Immunol 126:
2015-9
National Center For Farmworkers INCFH. 2002. National Vital Statistics Reports
Centers for Disease Control and Prevention.
National Research Council (U.S.). Committee on the Biological and Biomedical
Applications of Stem Cell Research. 2002. Stem cells and the future of
regenerative medicine. Washington, D.C.: National Academy Press. xv, 94 pp.
Newman MB, Freeman TB, Davis Sanberg C, Sanberg PR. 2003. Neural Stem Cells for
Cellular Therapy in Humans. In Neural stem cells : development and
transplantation, ed. JE Bottenstein, pp. 379-13 p. Boston: Kluwer Academic
Publishers
NINDS NIoNDaS, (NIH) NIoH. 2003. Amyotrophic Lateral Sclerosis Fact Sheet.
Nonoyama S, Penix LA, Edwards CP, Lewis DB, Ito S, et al. 1995. Diminished
expression of CD40 ligand by activated neonatal T cells. J Clin Invest 95: 66-75
Ogawa Y, Sawamoto K, Miyata T, Miyao S, Watanabe M, et al. 2002. Transplantation of
in vitro-expanded fetal neural progenitor cells results in neurogenesis and
functional recovery after spinal cord contusion injury in adult rats. J Neurosci Res
69: 925-33
Orlic D, Bock TA, Kanz L, New York Academy of Sciences. 1999a. Hematopoietic stem
cells : biology and transplantation. New York, N.Y.: New York Academy of
Sciences. x, 405 pp.
Orlic D, Girard LJ, Anderson SM, Barrette S, Broxmeyer HE, Bodine DM. 1999b.
Amphotropic retrovirus transduction of hematopoietic stem cells. Ann N Y Acad
Sci 872: 115-23; discussion 23-4
Orlic D, Girard LJ, Jordan CT, Anderson SM, Cline AP, Bodine DM. 1996. The level of
mRNA encoding the amphotropic retrovirus receptor in mouse and human
hematopoietic stem cells is low and correlates with the efficiency of retrovirus
transduction. Proc Natl Acad Sci U S A 93: 11097-102

Osawa M, Hanada K, Hamada H, Nakauchi H. 1996. Long-term lymphohematopoietic
reconstitution by a single CD34-low/negative hematopoietic stem cell. Science
273: 242-5
43

Potgens AJ, Bolte M, Huppertz B, Kaufmann P, Frank HG. 2001. Human trophoblast
contains an intracellular protein reactive with an antibody against CD133--a novel
marker for trophoblast. Placenta 22: 639-45
Potten CS, ed. 1983. Stem Cells: Their identification and characterisation. New York:
Churchill Livigstone. 1 pp.
Rabian-Herzog C, Lesage S, Gluckman E, Charron D. 1993. Characterization of
lymphocyte subpopulations in cord blood. J Hematother 2: 255-7
Rao MS. 2001a. Stem cells and CNS development. Totowa, N.J.: Humana Press. x, 370
pp.
Rao MS, Mattson MP. 2001. Stem cells and aging: expanding the possibilities. Mech
Ageing Dev 122: 713-34
Rao SG. 2001b. Stem cells and their therapeutic potential. Indian J Exp Biol 39: 1205-6
Rappold I, Ziegler BL, Kohler I, Marchetto S, Rosnet O, et al. 1997. Functional and
phenotypic characterization of cord blood and bone marrow subsets expressing
FLT3 (CD135) receptor tyrosine kinase. Blood 90: 111-25
Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, et al. 2001. Comparison of
outcomes of unrelated bone marrow and umbilical cord blood transplants in
children with acute leukemia. Blood 97: 2962-71
Rocha V, Wagner JE, Jr., Sobocinski KA, Klein JP, Zhang MJ, et al. 2000. Graft-versushost disease in children who have received a cord-blood or bone marrow
transplant from an HLA-identical sibling. Eurocord and International Bone
Marrow Transplant Registry Working Committee on Alternative Donor and Stem
Cell Sources. N Engl J Med 342: 1846-54
Rosenqvist N, Hard Af Segerstad C, Samuelsson C, Johansen J, Lundberg C. 2002.
Activation of silenced transgene expression in neural precursor cell lines by
inhibitors of histone deacetylation. J Gene Med 4: 248-57

Sakabe H, Kimura T, Zeng Z, Minamiguchi H, Tsuda S, et al. 1998a. Haematopoietic
action of flt3 ligand on cord blood-derived CD34-positive cells expressing
different levels of flt3 or c-kit tyrosine kinase receptor: comparison with stem cell
factor. Eur J Haematol 60: 297-306
Sakabe H, Yahata N, Kimura T, Zeng ZZ, Minamiguchi H, et al. 1998b. Human cord
blood-derived primitive progenitors are enriched in CD34+c-kit- cells: correlation
44

between long-term culture-initiating cells and telomerase expression. Leukemia
12: 728-34
Sanberg PR, Willing AE, Cahill DW. 2002. Novel cellular approaches to repair of
neurodegenerative disease: from sertoli cells to umbilical cord blood stem cells.
Neurotoxicity Research 4: 95-101
Sanchez-Ramos JR. 2002. Neural cells derived from adult bone marrow and umbilical
cord blood. J Neurosci Res 69: 880-93
Sanchez-Ramos JR, Song S, Kamath SG, Zigova T, Willing A, et al. 2001. Expression of
neural markers in human umbilical cord blood. Experimental Neurology 171:
109-15
Saporta S, Kim JJ, Willing AE, Fu ES, Davis CD, Sanberg PR. 2003. Human umbilical
cord blood stem cells infusion in spinal cord injury: engraftment and beneficial
influence on behavior. J Hematother Stem Cell Res 12: 271-8
Schofield R, Lajtha LG. 1983. Determination of the probability of self-renewal in
haemopoietic stem cells: a puzzle. Blood Cells 9: 467-83
Tamaki S, Eckert K, He D, Sutton R, Doshe M, et al. 2002. Engraftment of
sorted/expanded human central nervous system stem cells from fetal brain. J
Neurosci Res 69: 976-86
Thomson BG, Robertson KA, Gowan D, Heilman D, Broxmeyer HE, et al. 2000.
Analysis of engraftment, graft-versus-host disease, and immune recovery
following unrelated donor cord blood transplantation. Blood 96: 2703-11
Till JE, McCulloch EA. 1961. A direct measurement of the radiation sensitivity of normal
mouse bone marrow cells. Radiation Research 14: 213
Traycoff CM, Abboud MR, Laver J, Clapp DW, Hoffman R, Srour EF. 1994. Ex vivo
expansion of CD34+ cells from purified adult human bone marrow and umbilical
cord blood hematopoietic progenitor cells. Prog Clin Biol Res 389: 385-91
Tropepe V, Hitoshi S, Sirard C, Mak TW, Rossant J, van der Kooy D. 2001. Direct
neural fate specification from embryonic stem cells: a primitive mammalian
neural stem cell stage acquired through a default mechanism. Neuron 30: 65-78
Uchida N, Buck DW, He D, Reitsma MJ, Masek M, et al. 2000. Direct isolation of
human central nervous system stem cells. Proc Natl Acad Sci U S A 97: 14720-5

45

Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. 1994.
Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric
DNA with age. Proc Natl Acad Sci U S A 91: 9857-60.
Vendrame M, Cassady CJ, Newcomb J, Bulter T, Pennypacker KR, et al. 2004. Infusion
of human unbilical cord blood cells in rat model of stroke dose-dependently
rescues behavioral deficits and reduces infarct volume. Stroke 35: 1-6
Wagner JE, Broxmeyer HE, Byrd RL, Zehnbauer B, Schmeckpeper B, et al. 1992.
Transplantation of umbilical cord blood after myeloablative therapy: analysis of
engraftment. Blood 79: 1874-81
Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. 1995. Allogeneic
sibling umbilical-cord-blood transplantation in children with malignant and nonmalignant disease. Lancet 346: 214-9
Watson DJ, Longhi L, Lee EB, Fulp CT, Fujimoto S, et al. 2003. Genetically modified
NT2N human neuronal cells mediate long-term gene expression as CNS grafts in
vivo and improve functional cognitive outcome following experimental traumatic
brain injury. J Neuropathol Exp Neurol 62: 368-80
Weiss ML, Mitchell KE, Hix JE, Medicetty S, El-Zarkouny SZ, et al. 2003.
Transplantation of porcine umbilical cord matrix cells into the rat brain. Exp
Neurol 182: 288-99
Wenger DA, Rafi MA, Luzi P, Datto J, Costantino-Ceccarini E. 2000. Krabbe disease:
genetic aspects and progress toward therapy. Mol Genet Metab 70: 1-9
Willing AE, Lixian J, Milliken M, Poulos S, Zigova T, et al. 2003a. Intravenous versus
intrastriatal cord blood administration in a rodent model of stroke. J Neurosci Res
73: 296-307
Willing AE, Vendrame M, Mallery J, Cassady CJ, Davis CD, et al. 2003b. Mobilized
peripheral blood cells administered intravenously produce functional recovery in
stroke. Cell Transplant 12: 449-54
Woods NB, Mikkola H, Nilsson E, Olsson K, Trono D, Karlsson S. 2001. Lentiviralmediated gene transfer into haematopoietic stem cells. J Intern Med 249: 339-43
Woods NB, Muessig A, Schmidt M, Flygare J, Olsson K, et al. 2003. Lentiviral vector
transduction of NOD/SCID repopulating cells results in multiple vector
integrations per transduced cell: risk of insertional mutagenesis. Blood 101: 12849
Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, et al. 1999. IgE enhances
Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid
46

mediators from human umbilical cord blood-derived mast cells: synergistic effect
of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator
release. J Immunol 162: 5455-65
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. 1997. AC133, a
novel marker for human hematopoietic stem and progenitor cells. Blood 90:
5002-12
Zigova T, Song S, Willing AE, Hudson JE, Newman MB, et al. 2002. Human umbilical
cord blood cells express neural antigens after transplantation into the developing
rat brain. Cell Transplant 11: 265-74

47

Chapter 2

2.0

Chemotactic Assay and Cell Migration

2.1

Introduction

Cell migration is an essential component of embryonic development, adult
maintenance (such as inflammatory response and wound healing), and tumor metastasis.
Additionally, cell migration is of critical importance in the field of cell transplantation.
Stem cell replacement therapy is one of the more promising treatments for certain
neurodegenerative disease and traumatic insults such as Parkinson’s disease and
ischemia. Scientific studies are rapidly being published regarding the capability of
transplanted stem cells to regenerate, integrate, and/or supply trophic factors to the target
tissue. However, a major dilemma within this field is the migratory behavior of cells
once transplanted, whether locally in the target tissue (e.g. intrastriatial) or distally (e.g.
intravenous injection). In addition, if cells migrate to areas beside the target tissue this
could cause problems, therefore it is essential that these cells are tracked and safety
studies performed.
There are real limitations in cell migration research. In vivo, it is a slow and
labor-intensive process to track cell migration and the migrated cells are only identified
after histological examination. There is the possibility of using magnetic resonance
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imaging (MRI) system to track labeled cells. However, MRI systems are rather costly
and not many researchers have access to these systems. In addition, without disturbing or
invading the brain, .there is no in vivo method to study the possible factors that induce the
migration of cells to the injured tissue in the brain. Endogenous microenvironment
factors at the site of injury or damage may serve as chemoattractants for the migration of
the transplanted cells or may inhibit the migration. Again, only by invading the brain or
after tissue processing are those factors possibly identified. Furthermore, both the
disruption of the brain and the tissue processing may interfere with obtaining reliable
results.
The homing or migration of stem cells to a chemoattractant(s) has been
determined in bone marrow transplantation. Hematopoietic stem cells once transplanted
will home to the bone marrow, leave the peripheral circulation, become stable and
proliferate in extravascular space of the bone marrow cavity, thus serving to reconstitute
the hematopoietic system (Whetton & Graham, 1999). Yet, even in this area of research,
the migration and trafficking of cells and the molecular mechanisms regulating these
interactions are poorly understood.
There are a number of studies that have reported the migration of stem cell and
neural stem cells to the sites of degenerative or injured tissue (reviews see - (Keirstead,
2001; Zigova, Snyder, & Sanberg, 2002). Moreover, when compared to our knowledge
of cellular migration during development, inflammatory response and wound healing,
which is limited, our understanding of cell migration from allografts or xenografts to
injured tissues is in infancy. A further understanding of the intrinsic and extrinsic
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mechanisms and signals involved in the migration of cells to injured or damaged tissue is
certainly warranted. However, the first step is to determine systematically whether a
given population of cells will migrate to the damaged tissue. The second step would be
to determine whether there is an optimal time at which to administer the cells. In
addition, the third step would be possible chemoattractant factors in the damaged tissue,
and to identify the cytokines or chemokines that may be released by the transplanted
cells.

2.2

Background on Chemotactic Assay and Cell Migration

The chemotactic assay Boyden Chamber – (Boyden, 1962) was originally
developed for and is now a standard method in the area of cancer and inflammatory
response research. This type of transmigration assay has been widely used to study
leukocyte, fibroblast, and endothelial cell migration to chemoattractants, chemotactic and
adhesion stimulants, and/or chemokines. Although the methodologies and types of
chambers have advanced, the basic function remains the same. In addition, these types of
chambers or apparatus allow control over the chemoattractants, stimulants, and type of
migration. There are three basic types of cell movement/migration. Chemotaxis, in
general, refers to the movement of leukocytes or cells induced by a chemotactic stimulus
and typically, the cells are attracted in a positive gradient (those moving towards the
agent) or negative gradient (those moving away from the agent). Chemokinesis is the
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migration of cells in a random direction by a chemoattractant (stimulant to move), and
random migration refers to undirected and spontaneous migration of cells.
The process of cell migration is closely coupled to the presence of chemokines
(chemoattractants), which belong to the super family of cytokines; these are also referred
to as chemotactic cytokines. Chemokines in the range of 8 to 17 kD molecular mass have
been shown to be a chemoattractant selective for leukocytes, the reason for this is still
unclear (Benveniste, 1998). Recently several studies have examined factors influencing
the migration of hematopoietic progenitor cells (HPC) in the bone marrow environment.
HPCs are known to migrate to bone marrow during transplantation and fetal
development. These cells also migrate from bone marrow to the peripheral blood in
response to cytokines (Imai et al., 1998; Kim, Pelus, White, & Broxmeyer, 1998). The
mobilization of stem cells within the stromal layer of bone marrow and peripheral blood
is a complex interaction of numerous cytokines (for review see – Horuk, 2001; Pelus,
Horowitz, Cooper, & King, 2002). Stromal cell-derived factor-1 (SDF-1) has been
shown to be a strong chemoattractant for HPCs and has induced migration of CD34+ cells
from HUCB (Kim & Broxmeyer, 1998) using chemotactic assays, and is believed to play
a vital role in the homing of HPC to bone marrow (Voermans, Anthony, Mul, van der
Schoot, & Hordijk, 2001). SDF-1 is classified as a CXC-chemokine and is a
chemoattractant for monocytes and lymphocytes. The receptor for SDF-1 is CXCR4
(also called Fusin and LESTR), which is a G-protein coupled receptor, typical for
chemokines. Another chemoattractant, somatostatin (SST), which is not a chemotactic
cytokine, but a regulatory peptide produce by neuroendocrine and immune cells, has been
reported to attract immature hematopoietic cells (CD34+ CD117+) in a transwell
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migration assay (Oomen, Hofland, van Hagen, Lamberts, & Touw, 2000). Interestingly,
the attractant and homing molecule for leukocytes, L-selectin, was reported not to attract
hematopoietic stem cells (CD34+) (de Boer et al., 2002). The use of the in vitro
migration assay is a well-established method for screening a select cell population to
chemoattractants, and the proven chemoattractant, SDF-1, for hematopoietic stem and
progenitor cells was used in this study as a positive control.

2.3

Migration Induced by Inflammation

The migration of white blood cells in inflammatory and wound response is well
documented. In brief, the inflammation response occurs by a number of separate and
simultaneous events. There is an acute vascular response, in which the blood vessels
widen to increase blood flow to the inflamed area, leading to an increase in vascular
permeability allowing diffusible substances to enter, and an acute cellular infiltration
occurs through chemotaxis or movement of the proinflammatory cells. The hallmark of
inflammation is the appearance of neutrophils in the tissue and they migrate directly
through the blood vessel walls to the site of injury. There is also a change in biosynthesis
profiles of many organs and the release of several substances including cytokines.
Lastly, there is the activation and migration of immune cells to the inflamed site. The
migration of cells to an injured area is regulated by a variety of signaling molecules that
are produced locally by mast cells, nerve endings, and platelets in which there is a
selective production of adhesion, chemokines, and inflammatory molecules (cytokines)
(Johnston & Butcher, 2002). Initially, leukocytes are adherent to endothelial cells by L52

selectin (CD62L), which is expressed by leukocytes. When cytokines are activated,
endothelial cells produce E-selectin (CD62E), and the receptors for this adhesion
molecule are expressed on neutrophils, monocytes, eosinophils, and subsets of
lymphocytes. Only after cytokine activation, is P-selectin (CD62P) released from
granules of platelets or Weibel-Palade bodies of endothelial cells and the target cells are
the same as E-selectin (Lorant et al., 1995; Shah et al., 2002; Smith, Kunjummen,
Kishimoto, & Anderson, 1992; Stanimirovic, Wong, Shapiro, & Durkin, 1997). The
integrins, which are expressed by leukocytes, monocytes, macrophages, granulocytes and
a variety of other cell types, allow stronger adherence of neutrophils to the endothelium,
where they crawl and migrate to the tissue in response to a chemoattractant gradient
(Johnston & Butcher, 2002). Other molecules also act as chemoattractants for specific
types of white blood cells, escaping into the blood and inducing the production of
leukocytes within the bone marrow (Alberts et al., 1994)
Little is known about the mechanisms involved in stem cell migration. We know
now that stem and progenitor cells migrate from “organ to organ” during embryogenesis
through adulthood (Broxmeyer, 1998), and we are just beginning to understand the
factors and circumstances that drive or direct these cells to their targets. The process of
cell migration itself is complex and varies in accordance with the conditions of migration.
For example, during embryonic development cellular migration is conceptualized within
the context of tissues and organ formation. The migrating cell and its resulting
phenotype are exclusively dependent upon the three germ layers formed at gastrulation.
Embryonic stem cells proliferate and their progeny undergo a process of progressive
lineage restriction finally generating differentiated cells that form mature tissue. For
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example, cells from the endoderm layer will migrate and give rise to the digestive tract
and its associated components and glands (e.g. the esophagus, stomach, salivary glands,
liver, lungs etc…), while the mesoderm layer cells give rise to the supporting muscular
and fibrous elements. The ectoderm layer cells, which form the epidermis, will give rise
to the entire nervous system through neurulation.
The involvement of the extracellular matrix (EMC) is vital for cellular migration,
along with the complex signaling of several cytokines, integrins, selectins, and other
adhesion molecules and receptors that create a cascade of intracellular and extracellular
events that participate in the directing of embryonic cell migration. For instance, cell
adhesion to the ECM is essential; however, there is a necessary loss of cell-cell contact
when cells move through the ECM during mesoderm and neural crest formation (Perris &
Perissinotto, 2000). In addition, cells acquire migratory properties when they split off
(delaminate) from the ectodermal layer and transit from the epithelial to the mesenchymal
layer (Locascio & Nieto, 2001; Perris & Perissinotto, 2000).
In the development of the CNS, stem cells reside, proliferate, and migrate from
two germinal matrices. The neuroepithelium (also called ventricular zone and ependymal
layer) is the primary source of neurons and is derived from the neuroectoderm of the
neural plate. The second germinal matrices consist of the subventricular zone, which is
close to the ventricle and the external germinal/granular layer, which is farther away
(Committee., 1969). Stem cells in this region give rise to mostly granular cells. The
neuroblast cells (precursors of neurons) migrate away from the matrices, stop
proliferating, and differentiate (Altman & Bayer, 1995). The stem cell proliferation,
differentiation, and migration are regulated by a strict timetable. Neurogenesis is known
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to continue in the postnatal period, mainly in the subventricular zone, the external
granular layer of the cerebellar cortex and perhaps in the dentate gyrus of the
hippocampus (Altman & Bayer, 1995; Peretto, Merighi, Fasolo, & Bonfanti, 1999).
Until recently, only embryonic stem cells were thought to be pluripotent since
they must form all tissue types. However, a certain degree of plasticity is now
recognized with adult stem cells, in that, some adult stem cells are capable of acting and
expanding outside where they reside and assist in regeneration of distal tissue (Blau,
Brazelton, & Weimann, 2001). Moreover, adult neural stem cells that reside within the
subventricular zone (subependymal layer) of the forebrain, migrate a great distance
within the rostral migratory stream to reach the olfactory bulb and regenerate this
population of cells (reviews see - Gritti, Vescovi, & Galli, 2002; Peretto et al., 1999).
The external granular proliferative layer in the dentate gyrus of the hippocampus is also
known to give rise to astrocytes and neurons (Kuhn, 1996; Okano, Pfaff, & Gibbs, 1993).
With global ischemia (Liu, Solway, Messing, & Sharp, 1998) and induced seizure, this
area showed an increase in neurogenesis. Additionally, in neuronal injury models,
transplanted adult neural stem cells have been shown to migrate to the site of damage
(Akiyama et al., 2001; Herrera, Garcia-Verdugo, & Alvarez-Buylla, 1999; Kurimoto et
al., 2001).
2.4

Summary
Very little is known about the properties involved in the migration of HUCB cells.

We do know HUCB cells will migrate towards ischemic brain tissue extract (Chen et al.,
2001). When administered intravenously to rats that have undergone traumatic brain
injured or ischemia, HUCB cells will survive and migrate to the damaged brain area
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(Chen et al., 2001; Lu et al., 2002). Together the results suggest that some signal may be
attracting and/or inducing these cells to migrate towards these tissue extracts. From what
has been presented so far it is plausible that HUCB cells, especially the stem and
progenitor cells, would migrate to the developing, degenerating, and/or injured brain.
Chapter 4 and 5 will present our findings on the probable cytokines and chemokines that
might induce the migration of HUCB cells to injured or damaged tissues and those the
could be produced by these cells once at the site of injury, which could aid in the
behavioral recovery that has been seen in the animal models of injury.
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Chapter 3

3.0

Progression of the Dissertation Studies, Disease Models,
and Preliminary Data

3.1

Progression of the Dissertation Studies
The use of HUCB cells as a possible treatment for certain CNS diseases or

injuries is becoming increasingly feasible. However, as discussed in Chapter 1 and 2
there are many issues to address for progress to continue in this area of research. The
study presented in this and the next two chapters addresses some of those issues: 1)
Whether HUCB cells have the ability to migrate to injured brain. 2) The optimal time or
“window of opportunity” at which to administer the cells based on the migration data. 3)
The identification of chemokines and chemoattractants in tissue extract from stroke brain
(that may have induced HUCB cells to migrate). 4) And the numerous cytokines
produced by HUCB cells in response to their microenvironment are identified. Figure
3.1 is a flow chart of the Dissertation Studies.
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Figure 3.1 Dissertation Studies
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Initially, the study was designed to investigate the migration of HUCB cells to
several models of injury or disease (Parkinson’s Disease, Stroke, Sanfilippo Syndrome
and aging brain). The cell migration experiments using tissue extracts from these animal
models were accomplished for all models except aging brain. The aging brain was not
studied, because of the long wait period and the expense in obtaining aged rats.
However, instead the migration of HUCB cells to the young rat brain was performed,
results of which are presented in preliminary data section of this chapter.
In addition, during the initial migration experiments, one of the animal models in
particular became of great interest - middle cerebral artery occlusion (MCAO) rat model
of stroke. The preliminary migration assay data from this model showed a time
dependent factor indicating there could be a “window of opportunity” for delivery of
these cells after ischemic stroke that could result in the most cells migrating to the site of
injury. Therefore, in order to tease apart this phenomenon, the migration of cord blood
cells to rat ischemic tissue extracts, at several time points after the induction of stroke (4
hours to 1 week), and for three areas of the brain (striatum, hippocampus, and the frontal
cortex surrounding the striatum) was performed (see - Chapter 4). The next logical step
was to identify the mechanism(s) that may be responsible for inducing migration of these
cells. Therefore, the chemokine(s) or chemoattractant(s) present in the striatal ischemic
rat tissue extracts were determined. This data is presented in Chapter 4. Also of
importance was to determine whether the cord blood cells were producing
cytokines/chemokines that may be aiding in the functional recovery that has previously
been reported when HUCB cells are transplanted into MCAO rats (reviewed in Chapter
1) (Chen et al., 2001; Vendrame et al., 2004; Willing, Lixian et al., 2003; Willing,
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Vendrame et al., 2003). The cells were cultured in various conditions to determine how
microenvironments might influence their cytokine/chemokine production and these
cytokine profiles are presented in Chapter 5. Further characterization, by performing
ELISAs on the most significant chemokines in condition media of cultured HUCB cells
(Chapter 5) and those from the striatal extracts were performed (Chapter 4). Lastly, to
characterize these cells further, migration assays of cord blood cells to monocyte
chemoattractant protein-1, (MCP-1), (which was present in both the tissue extracts and
condition media) and the stimuli IL-3 and thrombopoietin (TPO) (which were added to
the cells in culture), were completed. In concentrating on one model of injury (stroke),
the study developed further than the several migration assays alone, and the results
provide data that have true clinical relevance for the utilization of HUCB cells in the
treatment of human injuries and/or diseases.

3.2 Background and Preliminary Data
Several issues needed to be address before beginning the migration and cytokine
assays, such as the mean diameter of cord blood cells, basic culturing and proliferation
ability, general morphology and phenotypes of the cells, develop and optimize the
migration assay, and perform protein assays to standardize tissue extracts. These are
presented in the following sections of this chapter. The preliminary experiments that
were required in order for the main studies to occur and the experimental results from the
other animal models used are discussed. The methods for each are presented along with
the findings.
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3.2.1 Migration Apparatus
Until recently, the most common way of performing migration assays was to use
Transwell plate (Corning) or the traditional Boyden Chamber. However, these apparatus
proved to very expense due to the small number of samples the plates hold. Furthermore,
the Transwell did not allow for true gradient migration, because the top well sit within the
media or the chemoattractant. The decision was made, after extensive testing, to use the
96-Chemotx® Chamber plate (Neuro Probe, Inc.). This plate allows 96 samples to be run
simultaneously, and the cells must be attracted or stimulated to migrate due to the design
of the plate (Figure 3.2).
Figure 3.2

Depiction of Migration Chamber

A.

B.

Figure 3.2 Illustration of 96-Chemotx® Chamber from Neuro Probe, Inc.
(A.) This diagram shows a single top well with a porous membrane and a
hydrophobic coating surrounding it. (B.) A diagram of top well (side
profile) representing how cell suspension is kept in place. Cell
concentrations are placed on the top well and tissues extracts are placed in
the bottom well. (C.) Shows the 96-well chamber fully assembled.
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3.2.2

Cell Diameter of HUCB Cells

One study previously explored the migration of HUCB cells to ischemic brain
tissue extract (Chen et al., 2001). However, in their study a membrane with 8µm pore
size was used. The preliminary data present here shows that the average size of HUCB
cells at 1 day in vitro (DIV) and 3 DIV to be between 6 and 8µm, depending on the
sample (Figure 3.3). This finding suggests that the pore size used by Chen et al. (2001)
allowed cells to drop through the membrane instead of truly migrating to the extract.
Therefore, the all migration experiments in this study used a pore size of 5µm on the top
membrane. There were no significant differences between the diameters of the cells at 1
DIV compared to those at 3 DIV or between the samples. Typically, in our hands,
HUCB cells began to differentiate at day 4 in culture in which distinct morphologies are
apparent by 7 DIV.
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Figure 3.3

Average Cell Diameters of HUCB Cells
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Figure 3.3 The graph represents the average cell diameter of HUCB cells.Different lots
of HUCB cells, 5 lots total, were cultured in DMEM, with 5% FBS and Gentamicin (50
µg/mL) for either 1 or 3 DIV. Initial seeding density was 106/cm2 and 500 cells were
randomly measured per sample and day. The cells measured on day 1 were not from the
same plate as those on day 3. Live cells were measured for their diameter with an image
analysis program, ImagePro-Plus (Version 5.0, Media Cybernetics, San Diego, CA).
Data is presented as mean + SEM. There were no significant differences in the diameter
of the HUCB cells between lots or days in culture. (Student’s T-test, p<0.05)
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3.2.3

HUCB Cells in Culture

To establish the general characteristic of the cord blood cells and to ensure that
they would sustain and grow, in our hands, the cells were cultured for different periods
and proliferation and live/dead assays were performed.
3.2.3.1

Preparation of HUCB Cells

Cryopreserved mononuclear fractions of HUCB cells were obtained from Saneron
CCEL Therapeutics, Inc. Cells were thawed and pipetted into 9 mL of media [clear
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carlsbad) with 10% FBS and
1 µL/1mL of Gentamicin (Sigma, St. Louis)]. Cells were centrifuged at 400 g for 15
minutes, the supernatant was removed, cells were resuspended in 1 mL of media, and
viability assessed using the trypan blue dye exclusion method as described previously
(Zigova & Newman, 2002). Cord blood cells were then plated in either 8-well chamber
slides, 35 mm dishes (Nunc, Naperville), or low adherence 6-well culture dishes
(Corning, Corning) at a seeding density of 105/cm2 and placed in water jacket incubator
set at 370C and with 5% CO2...
3.2.3.2

Phenotype of HUCB Cells

To determine phenotype and morphology HUCB cells were cultured from 1 to 14
days in 8-well chamber slides, as described above. The media was changed very 3 days
until cells were fixed. Phenotyping of the cell used immunocytochemistry methods.
Media was removed and cell cultures were fixed in 4% paraformaldehyde (pH 7.4) and
then thoroughly washed (3 x 10 min each) in 0.1 M phosphate-buffered saline (PBS).
Then the cultured cells (slides) were incubated for 1 hr at room temperature in 10%
normal goat serum and 0.03% Triton X-100 in 0.1 M PBS for blocking. Slides were then
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incubated for 24 hrs at 4°C with the primary antibody directed against one of several
hematopoietic cell markers with PBS containing 0.03% Triton X-100 and 2% normal
goat serum. The control slides were handled in the same manner except that the primary
antibody was omitted. Primary antibodies used were CD45 leukocyte common antigen
(BD PharMingen; 1:500), CD133/1 (AC133) cell surface antigen present on
hematopoietic stem and progenitor cells (MACS; 1:50), and CD34 (TUK3)
transmembrane glycoprotein expressed on hematopoietic progenitor cells (Santa Cruz;
1:50). Rhodamine or fluorescein conjugated secondary antibody were used against
primary at 1:500– 800 (Molecular Probes, Inc.). Slides were then rinsed in 0.1 M PBS, 3
x 10 minutes, coverslipped with either 95% glycerol or Vectashield mounting medium
with DAPI (Vector Laboratories) to help visualize cells and quantify immunostaining,
and then examined by standard epi-illumination fluorescence microscopy. Results are
presented in Table 3.1 and were quantified by counting cells in 80 random fields for 8
slides per antibody by investigators blind to the conditions. Scores were then tabulated as
percentage of total cells.
In Table 3.1 the stem and progenitor cells showed a decrease in number that
corresponded to the length of time the cells were kept in culture. These results are in
agreement with the current literature, and because cells were allowed to differentiate and
not kept in a proliferation media the percentage of stem and progenitor cells should
decrease the longer the cells are kept in culture. Depending on the culturing conditions
(media, growth factors, etc...) the cells can be directed to keep proliferating or to
differentiate towards specific phenotypes.
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Table 3.1

Phenotype of HUCB Cells at 1 to 14 DIV

1 DIV
CD45
CD34
CD133

80 - 90%
4 – 5%
1 – 4%

2 – 4 DIV
90 - 95%
1 – 4%
<1 – 2%

5 – 10 DIV
90 - 95%
< 1%
0

11 – 14 DIV
95 – 99%
0
0

Table 3.1 HUCB cells immunostaining results for hematopoietic cell markers. Cord
blood cells from 5 different donors where used. The total number of cells and those
immuno-positive for specific markers were counted and averaged over 80 fields. Data
are expressed as the percentage range of phenotypes from donor cells.

3.2.3.3

Morphology of HUCB Cells

In order to evaluate morphology of the HUCB cells, slides were stained with
Giemsa (Sigma) counterstain to visualize the cell bodies and processes. After cell were
prepared and cultured as described above, the cells were in fixed 4% paraformaldehyde
(pH 7.4) and then thoroughly washed (3 x 10 min each) in 0.1 M phosphate-buffered
saline (PBS). Giemsa stain (100 µL) was applied to single wells in the 8-well chamber
slides for 5 minutes, then rinsed with tap water 3 times, and coverslipped 95% glycerol.
Figure 3.4 shows cells cultured until day 14 and the five distinct cell types are
represented. Cord blood cells started differentiating at 4 DIV and by 14 DIV most of the
small around cells from days 1-3 had either differentiated or died.
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Figure 3.4

HUCB Cells Morphology

Figure 3.4 Photomicrographs demonstrating morphology of HUCB cells. Cells were
stained with Giemsa after 14DIV. The morphology of the cord blood cells shows 5
distinct cell types which are numbered 1 – 5. (1) Depicts cells that have a small cell body
with single long process. (2) Show cells with large cytoplasm and nucleus. (3)
Represent cells with small cytoplasm and multiple processes. (4) These cells are similar
to 2, but appear to have a smaller cell body and nucleus. (5) These cells appear to be
forming bipolar cell morphology or they could not yet be fully differentiated. (20x
objective)
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3.2.3.4

Live/Dead Assay of HUCB Cells

Part of the procedure in characterizing the population of HUCB cells was to
determine their viability while in culture. The viability of HUCB cells in suspension was
determined by a double-labeling procedure using the fluorescein diacetate (FDA,
Molecular Probes) and propidium iodide (PI, Sigma) method (Zigova & Newman, 2002).
This method allows identifying the viable, FDA-labeled cells fluorescing bright green
while dead cells, stained by PI, are bright red. Cells were periodically assayed
throughout the 14 DIV.
FDA/PI solutions were prepared as follows: FDA was prepared from stock
solution of 5 mg of FDA in 1 mL of acetone from which a working dilution of 5 µL of
stock FDA in 1 mL of 0.1 M phosphate buffer was made prior to staining. PI stock
solution was 1 mg of PI in 50 mL of 0.1 M phosphate buffer (kept refrigerated). FDA/PI
solution was made be adding 100 µL of working FDA stock solution to 30 µL of PI stock
solution, which is enough to cover the bottom of one well in the 8-well chamber slides.
Solution was made from stock as needed. Media from the well was removed and FDA/PI
pipetted on top of the cells. Chamber slides were then placed in the refrigerator for about
5 minutes. Cells were counted under dual fluorescent filter (FITC and rhodamine) and
living (green) and dead (red) cells were visualized (Figure 3.5). The FDA/PI live/dead
assays showed that the HUCB cells, in our hands, could be maintained in culture. In
addition, the initial viability and cell seeding density of the cord blood cells influenced
their long-term viability. The cells have better long-term viability when initial viability is
high (75% or greater) and with seeding density of at least 106/cm2 or greater.
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Figure 3.5

FDA/PI Viability of HUCB Cells

Figure 3.5 Fluorescent photomicrographs of HUCB cells immunolabeled with FDA/PI .
However, the photomicrograph has been changed to black and white: * denotes red cells
that are dead; all other cells are alive (stained green). (A, B, & C) Demonstrates that the
initial sample viability and cell number are critical to the long-term cultures of these
cells. (A) Cells at 1 DIV show high viability of sample. (B) Photomicrograph of HUCB
cell at 14 DIV shows low viability. At time of plating, this sample had low cell number
and viability (64%). (C) Photomicrograph of HUCB cells at 14 DIV shows high viability
(all green cells) and at time of plating the cell number and viability (96%) was high. In
this photograph the bottom layer of cells are adherent to the plate and differentiated,
while the top layer of cell are small, floating and have not differentiated. (10x objective)
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3.2.3.5

Proliferation Assay of HUCB Cells

To determine whether HUCB cells proliferate in culture, bromodeoxyuridine
(BrdU), a thymidine analog, that is incorporated during the S (synthetic)-phase of the cell
cycle (Gratzner, 1982) was used. An antibody against BrdU was used to detect the cells
that have incorporated this analog. HUCB contains a heterogeneous population of cells
in which there are approximately 4% stem/progenitor cells that are positive for CD34,
and less than 1% positive CD133 (Cohen, Gluckman, Rubinstein, & Madrigal, 2000).
This is in agreement with our results in Table 3.1. The ability to expand these cells in
culture could be of importance in the cell transplantation field, especially if more cells
from one donor are needed due to its unique properties, such as, its HLA antigens. This
assay will help determine whether there are stem/progenitor cells that can be expanded in
culture.
HUCB cells were prepared as describe above except they were plated in 96-well
plates at a seeding density of either 1 or 2 x 106 per well. Cells were exposed to BrdU (10
µM) in DMEM cell culture media at 6, 24, or 48 hours before fixing the cells to detect
BrdU labeling. Controls used were DMEM and cells plated 1 hour before fixation at the
initial seeding densities but not exposed to BrdU. Figure 3.6 shows the proliferation of
cord blood cells throughout the 48-hour period. Samples and controls were ran in
triplicate. BrdU assay was performed according to the manufacturer’s instruction
(Chemicon, International) and the number of proliferating cells was determine using a
microplate reader (BioTek) set to detect luminescence with wavelength of 450/550 nm.
Results showed that HUCB cell in these culture conditions do proliferate and that higher
concentrations of cells at plating will increase the rate of proliferation.
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Figure 3.6

Proliferation of HUCB Cells in Culture
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Figure 3.6 BrdU labeled HUCB Cells. Cord blood cells were pulsed at 6, 24, and 48
hours. Cells proliferated in culture at both seeding density. The results suggest the cord
blood cells can be grown and expanded in culture and that higher seeding densities result
in an increased rate of proliferation. * Shows significantly more cells in these conditions
compared to either control cells conditions. (Student’s T-test, p < 0.05).

3.2.4

Tool to Measure Migrated HUCB Cells and Control Selection

Several initial steps were taken in order to ensure a reliable and verifiable
migration assay. The primary step was to establish a way to quantify the number of
migrating cells without relying on manual cell counting, as this technique is highly
subjective. Initially the HUCB cells were labeled with calcein AM (Invitrogen), which
fluorescently labels the cell bodies and appears red to orange in color. Figure 3.7 show
the cord blood cell migrating through the membrane. While the calcein AM labeled all
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cells, there was a large amount of fluorescent background, which interfered when cell
plates were read in the automatic plate reader (BioTek). The measurements were not
reliable, which was noticeable in the standard curves. The same was true for cholera
toxin subunit B conjugated to FITC (Alexa Fluor 488, Molecular Probes). While it
labeled the nucleus of cells very well, either the background was high or because the
plate was clear, the fluorescence marker was interfering with neighboring wells. Hoechst
33342, DAPI, fluorescent ester dye labeled the cells nucleus, however, many of the cells,
presumably the stem and progenitor cells, exocytosed the dye very quickly (Figure 3.8).

Figure 3.7

HUCB Cells Migrating through Membrane

Figure 3.7 HUCB cells migrating through the top wel
membrane to neonatal rat brain tissue extract. (A
Photomicrograph taken under bright-field showing pores o
membrane (dark round shapes) and migrating cells * (white
irregular shapes). (B) Fluorescent photomicrograph of same
membrane. HUCB cells were pre-labeled with calcein AM
white * denotes cells (5 µM solution in 1 mL of media). (20x
objective)
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Figure 3.8

HUCB Cells Labeled with DAPI

Figure 3.8 Photomicrographs of HUCB cells in culture at 1DIV. (A) Cells labeled with
DAPI (Hoechst 33342) fluoresced blue under the DAPI filter, but are depicted here in
black and white. (B) Same field taken under bright-field optics. Note not all cells are
labeled with DAPI (10x objective).

Because of the high background in the fluorescent labels, a chemoluminescent
cell viability assay kit (CellTiter-Glo, Promega) was tried. This assay determines the
number of viable cells based on the presence of adenosine 5’ triphosphate (ATP), which
is present in metabolically active cells. The luminescent signal is produced by a
luciferase reaction and the amount of ATP expressed is proportional to the number of
viable cells in the culture. The results from the replication of three standard curves using
HUCB cells are shown in Figure 3.9.
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Figure 3.9 Luminescent Standard Curve of HUCB Cells
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Figure 3.9 HUCB cells were assayed after migration using a luminescent cell viability kit
(Celltiter-Glo, Promega). Standard curves were established for each assay and for determining
sensitivity of the plate reader (BioTech, Inc.). For standard curves, a serial dilution of cells, at a
concentration running from 0 to 80,000 cells/300 µL of media, was performed in quadruplicate,
and pipetted directly into the bottom well of a 96-well plate. RLUs = relative light units. Graph
shows the mean of three standard curves for HUCB cells.

The luminescent signal is proportional to the amount of ATP present, which is
directly proportional to the number of live cells present. The graph contains the mean
data points of three standard curves. The results from the standard curves and from initial
studies proved the CellTiter-Glo cell viability assay to be very reliable and accurate each
time.

78

In addition to finding a reliable tool to measure the cells that had migrated, there
was need for a positive control. The known chemoattractant Stromal Derived Factor –1
(SDF-1) was chosen and both time and dose response curve were determined. SDF-1 is a
strong chemoattractant for CD34+ cells from cord blood and bone marrow. The optimal
dose of SDF-1 to induce migration in HUCB cells was 100 ng/mL and optimal time was
between 4 and 6 hours after which there were no significant increase in the number of
cells migrating (data not shown). Additional controls used in migration assay were the
cell culture media DMEM and PBS. Both served as negative controls.
3.2.5

Protein Assays for Tissue Extracts and Media from HUCB Cells

Bicinchoninic acid (BCA) protein assays (Promega, Madison, WI) were used to
determine the total amount of protein in the tissue extracts for each condition and for both
the positive and negative controls used in the migration assay. Protein assays were
performed twice and each unknown (tissue extracts and controls) or standard were ran in
triplicate (three wells per assay for 6 data points) according to the manufacturer’s
instructions. The standard curves were performed in the same 96 well plate and the assay
had a working range of 20 to 2,000 µg/mL of protein. The plates were read in an
automated plate reader (Synergy, BioTek, Winooske, VT) set to absorbance with
wavelength of 562 nm. After measuring the protein concentration for tissue extracts, the
extracts were standardized to 500 µg/mL for use in migration, cytokine, and ELISA
assays. Figure 3.10 represent the mean of 3 standard protein curves.
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Figure 3.10

Standard Curve for Protein Assays
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Figure 3.10 BCA protein assay standard curve. The standards were performed by serial
dilution, ran in triplicate, and according to manufacturer’s instructions (Promega). The
diluent for the standards was clear DMEM, which was the same dilute for the tissue
extracts used in all migration assays.
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3.3

Migration of HUCB Cells and Animal Models of Disease or Injury
In this section, the migration of HUCB cells to neonatal rat brain, the 6-OHDA rat

model of Parkinson’s Disease (PD), and Sanfilippo mouse model are presented along
with the methods and materials used. The stroke model is presented in Chapter 4. The
disease or injury models that were used in this study were based on the prevalence and
impact they have in the general population of the U.S., and our expertise in performing
these experiments.
3.3.1 Basic Migration Assay Procedure
The following methods were used for all migration assays. HUCB cells were
prepared as described in section 3.2.3.1, except they were plated in low adherence 6-well
culture dishes (Corning, Corning, NY) for 24 hrs in a water jacket incubator set at 370C
and with 5% CO2, which allowed cells to adjust to the environment before beginning the
migration assay. After 24 hrs cells were lifted by gentle pippetting, placed in a 15 mL
tube, centrifuged, resuspended in 1 mL of media, and viability was assessed using the
trypan blue dye exclusion method. Only HUCB cells with 80% or greater viability were
used and cell concentration was adjusted to 62,000 cells/25 µL of media.
The basic procedures for the migration assay in all models are similar. The main
difference in the procedures between models was the selection of brain tissue to use. The
assay uses a 96-well chamber plate consisting of bottom wells that hold the samples or
chemical attractants and a top plate, which is a polycarbonate membrane with 5 µm pore
size and is where the cells are placed. Tissue extracts (300 µL) were pipetted into the
bottom wells of the 96-well plates. The top plate was placed on top of the bottom well
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plate and HUCB cells were directly pipetted into the top well at a concentration of 62,000
cells per 25 µL. The migration chambers were then placed in a water-jacket incubator at
37°C with 5% CO2 for 4 hours. SDF-1 was used for positive control and DMEM used as
negative control. For each assay sample, control and standard were performed in
triplicate. After 4 hours, the top well plates were removed. The bottom plates were then
centrifuged; half the media (150 µL) was removed, and Celltiter-Glo cell viability assay
was performed (according to manufacturer’s instructions). The plates were then read in
an automatic plate reader (BioTek) set to luminescence to determine the number of cells
that migrated into the lower chamber. In all migration studies, the plate reader was set to
a sensitivity of 100.
3.3.2

Preparation of Tissue Extracts

Animals were sacrificed by exposure to CO2. Brains were removed within two
minutes, immediately frozen on dry ice and then stored at –800C until needed. The
frozen brains were semi-thawed, kept cold, and the brain areas of interest were dissected
from both hemispheres. Tissue from each of the conditions were pooled, and kept on ice
in clear DMEM. The preliminary findings showed that fetal bovine serum attracts HUCB
cells, therefore this was not added to the homogenate media (data not shown). Tissue was
homogenized at 150 mg of tissue per 1mL of media. The homogenates were centrifuged
(400g for 20 minutes), the tissue extracts (supernatant) collected, filtered (0.22 µm,
Millipore, Bedford, MA), and stored at -800C until used.
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3.3.3

Animal Models Used for HUCB Cell Migration

The three animal models that follow used the same methods and materials
described above. The unique methods or materials that are relevant to each model is
discussed along with a brief background for each model, which has been incorporated to
provide the reader with the necessary information to comprehend the premise of the
animal models selected.
3.3.3.1

Neonatal Young Rat Model

Cell migration is an essential component of embryonic development as mentioned
in Chapter 2. During embryonic genesis in central nervous system, there is a tremendous
amount of stem cell proliferation, migration, and differentiation. Stem cells reside,
proliferate, and migrate from two germinal matrices. The neuroepithelium (also called
ventricular zone and ependymal layer) is the primary source of neurons and is derived
from the neuroectoderm of the neural plate. The second germinal matrices consist of the
subventricular zone (which is close to the ventricle) and the external germinal/granular
layer (Boulder Committee, 1969). Stem cells in this region give rise to mostly granular
cells. The neuroblast cells (precursors of neurons) migrate away from the matrices in
several manners. They will migrate in both short and long distances in various directions
and go through dense brain tissues and over the surface of the brain. Once the cells reach
their destination, they stop proliferating and differentiate (Altman & Bayer, 1995).
The stem cell proliferation, differentiation, and migration are regulated by a strict
timetable. Neurogenesis is known to continue into the postnatal period, mainly in the
external granular layer with respect to the cerebellar cortex and the dentate gyrus of the
hippocampus (Altman & Bayer, 1995; Peretto, Merighi, Fasolo, & Bonfanti, 1999).
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In the rat, the CNS in not fully developed until at least postnatal day 14 (Clancy,
Darlington, & Finlay, 2001), which enables the study of stem cells’ attraction to the
embryonic and postnatal brain across a developmental period. In addition, cell
transplantation studies in the developing rodent brain have shown that this environment
supports the survival and migration of embryonic human neural stem cells (Flax et al.,
1998), neuronal restricted precursors (Yang et al., 2000), as well as less differentiated
progenitor cells derived from the neonatal subventricular zone (Brustle et al., 1998;
Zigova et al., 1996). Following transplantation into germinal matrices/zones embryonic
stem cells were able to participate in normal development including migration along
established migratory routes and to differentiate into site-specific cell types. Also,
studies have reported that the rodent adult brain can support the transplantation of
subventricular zone derived human embryonic progenitor cells (Fricker et al., 1999; Lois
& Alvarez-Buylla, 1993). These findings suggest that the developing brain is a favorable
environment for studying stem cell proliferation and migration. Therefore, the neonatal
rat brain was used to investigate the migration of HUCB cells to these tissue extracts
(Figure 3.11).
Neonatal Sprague-Dawely rat pups (male and female) were sacrificed
(anesthetized with Equithesin, 3.5 mL/kg and heads decapitated) at postnatal days 2 and 7
(n = 10 per condition). The cerebellum and brain stem were dissected from the brain and
both the cerebellum and whole brain were used for the tissue extracts from the 2 day old
rat pups. The cortex, hippocampus, midbrain and cerebellum were dissected from 7 day
old rats. Tissue was prepared as described above.
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Figure 3.11

Migration of HUCB Cells to Neonatal Rat Brain
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Figure 3.11 The bar graph represents the migration of HUCB cells to neonatal rat brain
tissue extracts. Tissue extracts from 2 and 7 day old rat pups were used. The CellTiterGlo luminescent viability assay kit was used to measure the amount of ATP expressed in
live cells. The luminescent signal is proportional to the amount of ATP present, which is
directly proportional to the number of live cells present. In all brain tissue extract
conditions (*) significantly more cord blood cells migrated to these conditions when
compared to controls (media DMEM). The 2 day brain and 7 day hippocampus
conditions had (**) significantly more HUCB cells that migrated than the other extracts
conditions and more than the positive control SDF-1. [ANOVA One-way between
groups: F = 2.42, df = 7, 31 with p < 0.0001 followed by planned comparisons using
Dunn’s Bonferroni (corrected) test with p < 0.05].
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The results from this experiment showed that the neonatal brain extracts strongly
attracts HUCB cells. Most striking were the 2 day old brain and the 7 day hippocampal
tissue extracts, which had significantly more cord blood cells migrating compare to the
other extract conditions. The results suggest that there are areas within the neonatal brain
that contain signals, chemoattractants, to induce HUCB cells to migrate. Because the
brain is still developing at this time and numerous migration signals are present this
model was chosen to be the first. This allowed the techniques and procedures to be
determined before performing the migration assay on injured or disease models.
3.3.3.2

Parkinson’s Disease – 6-OHDA Rat Model

Parkinson’s Disease is a widespread neurodegenerative disorder first described by
James Parkinson in 1817 (Parkinson, 1817) and is characterized by a gradual
degeneration of the dopamine (DA) nigrostriatal system. Approximately 40,000 people
in the United Stated are diagnosed with PD every day, and over 1 million Americans
have this disease. The daily cost is approximately $66 million that include direct and
indirect costs such as loss of earnings due to inability to work, social security, medical
care, and long term care (PDF, 2005). Symptoms start to appear when at least 50% of the
dopamine (DA) producing neurons in the substantia nigra are lost, which produces a 70 –
80% reduction in the DA content of the caudate and putamen. The most widely used
treatment is L-dopa, a DA precursor that crosses the blood brain barrier. L-dopa
improves symptoms of PD, but this is not a cure and effectiveness is diminished after
long period of administration (C. R. Freed, Breeze, & Fahn, 2000; W. J. Freed, 2000).
The transplantation of human embryonic ventral mesencephalic (VM) tissue has had
encouraging results in patients with PD (Isacson, van Horne, Schumacher, & Brownell,
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2001; Olanow, Kordower, & Freeman, 1996; Piccini et al., 1999). However, there are
some critical limitations with the use of fetal donor tissue. Only a small percentage of
VM cells are dopaminergic (<10%) and of that only 1–5% will survive transplantation,
therefore, up to 15 fetal VM may be required per patient (Isacson, Bjorklund, & Pernaute,
2001). Perhaps concerns that are more critical are the ethical and availability issues of
not only fetal VM tissue but also any other fetal derived cell (stem and progenitor). In
light of this, HUCB cells may be one possible alternative to the use of fetal tissue/cells.
The 6-OHDA experimental model is one of the most commonly used in PD
research. 6-OHDA is a neurotoxin that hydroxylates analogues of the endogenous
neurotransmitter dopamine resulting in nigral degeneration both in vitro and in vivo (for
review see - (Blum et al., 2001; Blum, Torch, Nissou, Benabid, & Verna, 2000). Senoh
and colleagues (1959) were the first to report its isolation (Senoh, Creveling, Udenfriend,
& Witkop, 1959; Senoh, Witkop, Creveling, & Udenfriend, 1959), and then later Porter
and colleagues (1963) showed that 6-OHDA depleted noradrenaline in the heart (Porter,
Totaro, & Stone, 1963). The presence of this neurotoxin has been reported in the human
and rat brain, suggesting it may be an endogenous substance (Curtis & Johnston, 1974).
6-OHDA is typically injected unilaterally into the striatum, substantia nigra or the
ascending medial forebrain bundle, because it cannot cross the blood brain barrier. This
induces asymmetric degeneration of the substantia nigra pars compacta and quantifiable
motor behavior after administration of DA receptor agonists.
Several populations of cells have been experimentally transplanted into the PD
animal model, with some success. One of the more interesting was the use embryonic
stem cells, which were reported to proliferate and differentiate into DA neurons within
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the striatum (Bjorklund et al., 2002). Another study using the 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) mouse model of PD demonstrated that the intrastriatal
transplantation of bone marrow stromal cells did improve behavioral deficits seen in mice
(Y. Li et al., 2001). Both pre-clinical and clinical studies have shown that certain stem
cells migrate to the degenerative PD brain. Therefore, it seemed probable that HUCB
cells would migrate toward 6-OHDA lesion brain extracts. However, it was also
probable that 6-OHDA toxin would inhibit cell migration. The results are presented in
Figure 3.12. Additionally, the migration of HUCB cells to 6-OHDA lesioned brain
extracts are presented in Figure 3.13.
In this experiment adult male Sprague-Dawley rats were lesioned with 6-OHDA.
The rats (n = 10) were anesthetized with Equithesin (3.5 mL/kg) and unilateral injections
of 6-OHDA (Sigma; 2.5 µL, 3.6 µg/µL in 2% ascorbic acid in saline) was made at 4.4
mm posterior to bregma, -1.2 mm laterally and –7.8 mm ventral to dura with the toothbar
set at –2.4 mm and delivered at a rate of 1 µL/min. Five minutes after each injection the
needle was slowly withdrawn and incision sutured. Other rats (n = 10) received sham
injection (2% ascorbic acid in saline). Animals were sacrificed 3 weeks after 6-OHDA
lesion or sham surgery. Tissue extract preparation was performed as describe above,
except that the left and right substantia nigra and the striatum were dissected. The
preparation of the cord blood cells and migration assay methods were identical to those
described above.
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Figure 3.12

Migration of HUCB Cells to 6-OHDA Toxin and SDF-1
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Figure 3.12 Migration of HUCB cells to the toxin 6-OHDA and to the chemoattractant
SDF-1. 6-OHDA had an inhibitory effect of the migration of these cells in a dose
dependent manner. The opposite was seen with SDF-1 in which cord blood cells
significantly migrated to this chemoattractant in a dose dependent manner. All
conditions of SDF-1 induced (*) significantly more cells to migrate compared to all other
conditions. 6-OHDA was not different from controls. The CellTiter-Glo luminescent
viability assay kit was used to measure the amount of ATP expressed in live cells. The
luminescent signal is proportional to the amount of ATP present, which is directly
proportional to the number of live cells present. [ANOVA One-way between groups: F =
2.30, df = 8, 35 with p < 0.0001 followed by planned comparisons using Dunn’s
Bonferroni (corrected) test with p < 0.05]
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ATP Expressed by Migrated HUCB Cell (in RLUs)

Figure 3.13

Migration of HUCB Cells to 6-OHDA Animal Model of PD
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Figure 3.13 Migration of HUCB cells to tissue extracts from rat 6-OHDA model of PD.
Sham is equal to sham surgery and injected with vehicle instead of 6-OHDA and 6OHDA PD equal lesion animals that have been injected with 6-OHDA. Tissue extracts
from the substantia nigra and the striatum of unilateral 6-OHDA lesion brains showed
significantly more migration of HUCB cells compared to the controls and their respective
sham surgery conditions. * Significantly different from sham surgery and from plain
media and PBS controls. [ANOVA One-way between groups: F = 2.38, df = 5, 59 with p
< 0.0001 followed by planned comparisons using Dunn’s Bonferroni (corrected) test with
p < 0.05]
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These results showing migratory behavior of the HUCB cells in this PD model
suggest that there are endogenous signals generated by pathology that are capable of
attracting these cells to the area of injury. The toxin 6-OHDA actually inhibited the cord
blood cells from migrating (Figure 3.12). The typical amount of 6-OHDA used in rat
models of PD ranges between 3 to 10 µg, which is usually dependent on the injection
site. In this experiment, the rats received at total of 9 µg. However, the brains of these
animals were not taken until 3 weeks after administration of toxin, which should be
enough time to reduce the amount of 6-OHDA level directly at the site of the lesion. The
sham surgery tissue extracts (Figure 3.13) were significantly different from the toxin 6OHDA. This suggests that in addition to the 6-OHDA in the tissue extracts some other
factor(s) may be inducing the migration of these cells, such as, chemokines or
neurotrophic factors. It also seems likely that the trafficking of these mononuclear cells
to the site of injury in an in vivo animal model of PD would be a function of several
factors, including blood brain barrier breakdown, chemokines, and inflammatory
response.
3.3.3.3

Sanfilippo Mouse Model

Sanfilippo syndrome type B or mucopolysaccharidosis type III (MPS III) is a
group of hereditary lysosomal storage disorders resulting from a failure to break down
glycosaminoglycan, heparan sulfate, within lysosomes. Sanfilippo syndrome or each of
the four subtypes (A, B, C, and D) is an autosomal recessive disorder caused by the
deficiency of a different enzyme in the degradative pathway of heparan sulfate: A)
heparan-N-sulfatase, B) α-N-acetylglucosaminidase (Naglu), C) acetyl-CoA N91

acetyltransferase, and D) N-acetylglucosamine-6-sulfatase. The absence of any one of
these enzymes leads to undegraded heparan sulfate accumulation in lysosomes and then it
is excreted in urine. MPS III is caused by a deficiency of enzyme alpha-Nacetylglucosaminidas (Naglu), as a result of a mutation on chromosome 17q21 in the
gene encoding Naglu. Premature death occurs one hundred percent of the time (usually
occurs between 11-20 years of age) with devastating clinical abnormalities, severe central
nervous system involvement and somatic disease. Sanfilippo syndrome has no cure and
affects approximately 1 in 25,000 births in the United States (MPS, 2003)
A knockout mouse model of MPS III B, demonstrating biochemical abnormalities
similar to the human disease, has been created by disrupting the Naglu gene responsible
for heparan sulfate degradation (H. H. Li et al., 1999). In this mouse model, biochemical
abnormalities have been report to be similar to those in human patients (no Naglu activity
and accumulation of heparan sulfate in many organs). As the mouse age’s, pathological
changes are observed and become more prominent, which include brain disruptions in the
neurons. Visible symptoms start to occur at 6 months; these symptoms include
abdominal distention, weight loss, and distended urinary bladder. Behaviorally the mice
are hypoactive when tested in open field (Gografe et al., 2003).
All animals used in the study were obtained (a gift) from Dr. Svitlana GarbuzovaDavis’ established colony of Naglu mice, at the University of South Florida, which was
developed from three heterozygous breeding pairs resulting is strain B6.129S6Naglutm1Efn mouse (The Jackson Laboratory, Bar Harbor, Maine). This was the only
disease model that was used in the migration studies and there was preliminary data from
our laboratory (Dr. Garbuzova-Davis) suggesting the HUCB cells (when injected into the
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Naglu mice at one month of age) may increase the life span of these animals. Therefore,
the migration study would determine whether HUCB cells would migrate to brain areas
in this animal model.
Mice [10 Wild Type (WT) and 10 mutant (MT)] were sacrifice near end of life
(between 1 to 3 days before death, between 11 to 12 months old), which was determined
by physical examination of known signs that are exhibited by this mouse population.
Tissue extracts were prepared as describe above and cerebellum and brain stem were
dissected from brain this area was labeled “whole brain” (WB).
The graph (Figure 3.14) represents one of three migration assays that were
performed for this disease model. As a result of the nature of these findings, we felt there
may have been interference with either the protein or some other factor in the tissue
extracts. The protein concentration for mutant and wild type mouse extracts ranged from
1900 to 2100 µg/mL, which is in the high range of the protein assay (working range of 20
to 2,000 µg/mL). Therefore, two more assays were performed, with further diluted
extracts, 100 µL or 10 µL of extract diluted with 200 µL or 290 µL of media,
respectively. These assays did not show a pattern of migration and were not similar to
the initial migration assay using extracts that were standardized for protein concentration
(protein 500 µg/mL) for each condition. Although the statistical analysis showed
significantly more cells migrating to the WT cerebellum extract this finding did not
match with diluted assays findings. In fact, in the other assays more cells were found
migrating to the all tissue extract conditions. Overall, the data for this model is not
conclusive.
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Figure 3.14 Migration of HUCB Cells to Sanfilippo Tissue Extracts
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Figure 3.14 Migration of HUCB cells to Sanfilippo tissue extracts. The WT stem
cerebellum extract was the only condition that showed a significant difference from
media control. Each unknown (the tissue extracts), standards, and controls were
performed in triplicate and the migration assay was performed twice for a total of 6 data
points per condition. Significance was set at p<0.05. (Student’s T-test). WB = whole
brain, CB = cerebellum and Stem = brain stem.
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3.4

Summary
The results from the preliminary data have shown that HUCB cells (in vitro) will

survive for an extended period and that they are capable of proliferating. After testing
several labeling methods, to determine the number of migrated cells, the CellTiter-Glo
luminescent assay was determined to be the most reliable method. HUCB cells were
shown to be attracted to the neonatal brain extracts from rats. A significant number of
HUCB cells were shown to migrate to the 2 and 7 day old whole brain tissue extracts and
to hippocampal extract of 7 day old rats. This suggests that the developing brain does
contain chemoattractants that are signals to HUCB cells to migrate. It may also be that as
the brain develops the chemoattractant signaling may become more restricted to certain
brain regions as indicated by the 7th day.
The 6-OHDA rat model of PD, showed the migration of HUCB cells to the
substantia nigra and striatum extracts of lesioned rats. In addition, HUCB cells, in vitro,
were shown to be inhibited from migrating to the toxin 6-OHDA at doses from 1 to 10
µL, which suggest that there are endogenous signals generated by pathology of this
model that are capable of attracting these cells to the area of injury. This is an intriguing
possibility and other models of PD should be investigated for a chemoattractant property
and compared to the 6-OHDA model
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The data from the Sanfilippo mouse model was unclear and we could not confirm
that HUCB cells migrate to tissue extracts from this disease model.
The next two chapters present the data on stroke animals, the cytokines produce in
the ischemic tissue extracts, and the cytokines or chemokines present in condition media
from HUCB cells in various culturing conditions.
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Chapter 4

4.0

Stroke Induced Migration of Human Umbilical Cord Blood (HUCB) Cells:
Time Course and Cytokines

4.1

Abstract
There is often a significant delay from the onset of ischemia to the time when

therapy is initiated in stroke patients.

Thus, there is a critical need to extend the

therapeutic window regardless of the treatment regime. Previously, we have shown
significant improvements in the behavioral defects of rats that received HUCB cells
twenty four-hours after a middle cerebral arterial occlusion (MCAO). While the delivery
of HUCB cells at 24 hours was effective, the optimal time to administer these cells has
not been established. Thus, this study investigated the migration of HUCB cells to
ischemic tissue extracts over several time points with an in vitro model. A forty eighthour “window of opportunity” was established for the delivery of HUCB cells to
ischemic brain.
extracts,

The migrated HUCB cells formed cell aggregates in the ischemic

suggesting

cell-to-cell

signaling

occurs

and

the

expression

of

cytokines/chemokines in the ischemic extracts suggests their participation in HUCB cell
migration.

The results from this study are promising in that the current 3-hour

therapeutic window for the treatment of stroke victims, using approved anticoagulant
treatment, may be extended with the use of cord blood cell therapy with the peak at 48
hours.
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4.2

Introduction

Stroke is a leading cause of disability worldwide and in the United States affects
approximately 700,000 (~500,000 first and 200,000 recurrent stroke) people annually
(AHA 2005). Although, in recent years there has been an increase in stroke survivors,
there is still a need to develop more effective treatments and rehabilitative therapies that
will allow fuller recovery than what is presently seen.

The only Food and Drug

Administration (FDA) approved drug treatment for acute ischemic stroke is the
thrombolytic tissue-Plasminogen Activator (t-PA), which acts by breaking down the
blood clot in the vessel, thus allowing the blood to flow through. However, t-PA must be
administered within the first three hours after the onset of acute ischemia and the
effectiveness of t-PA decreases with time (NINDS, 1995). Unfortunately, approximately
40% of stroke patients do not reach a medical establishment within the 3-hour treatment
window, and the possibility of intracranial hemorrhage must be ruled out by CT thus
furthering the delay in treatment.

Effective treatments with a longer window of

opportunity that increases survival rate and improves subsequent recovery are desirable.
This could also lower the cost of on-going and long-term care.
Our research group, demonstrated that transplanted HUCB cells significantly
improve behavioral defects in animal models of stroke (J. Chen et al., 2001; Vendrame et
al., 2004; Willing, Lixian et al., 2003; Willing, Vendrame et al., 2003), spinal cord injury
(Saporta et al., 2003), and traumatic brain injury (TBI) (Lu et al., 2002). Further, HUCB
cells lengthen life span in mouse model of amyotrophic lateral sclerosis (ALS) (Chen &
Ende, 2000; Garbuzova-Davis et al., 2003). In addition, others have shown functional
101

recovery in a mouse stroke model after delivery of CD34+ HUCB cells; this functional
recovery was accompanied with

neovascularization and neuroangiogenesis at the

infarcted site (Taguchi et al., 2004). Thus, the improved behavioral defects in damaged
CNS animals utilizing HUCB cells is well recognized and has been extensively reviewed
(Newman, Davis, Borlongan, Emerich, & Sanberg, 2004; Newman, Davis, KuzminNichols, & Sanberg, 2003; Newman, Emerich, Borlongan, Davis Sanberg, & Sanberg,
2004). However, several factors pertaining to the HUCB cell treatment model of induced
MCAO in animals require additional investigation. Some of the most critical factors that
require further analysis are the dose of HUCB cells required, location site(s) of infusion,
delivery time of the cells after induction of MCAO and possible cytokine/chemokines
that may attract cells to the infarct area or produce the improvements seen in behavioral
deficits.
Vendrame et al., (2004), studied the number of HUCB cells required in MCAO
rats, and showed that the HUCB cells dose dependently reduced the infarct volume of
ischemic rats.

The optimal dose was 107 cells; at this dose, infarct volume was

11.46+4.13% of the total hemisphere while control rats (media injected) had an infarct
volume of 33.15+4.29%. Particularly important to these findings was the observation
that the number of cells that migrated to the site of injury was far less than the number of
cells that were administered. Similar results were also obtained in spinal cord injury
(Saporta et al., 2003), and TBI models (Lu et al., 2002). The location in which to
delivery these cells was addressed in a study by Willing et al., (2003). They showed that
intravenous delivery of HUCB cells to stroke rats resulted in significantly enhanced
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behavioral improvements compared to intrastriatal injection. However, the time at which
to administer these cells has not been addressed until now.
Typically, HUCB cells have been administered 24 hours after inducing MCAO in
the rats, and the evolving damage and death of cells, from the ischemic insult have been
reported to continue up to 21 days post-ischemia (Butler, Kassed, Sanberg, Willing, &
Pennypacker, 2002). The loss of blood flow induces an ischemic cascade of events that
begins within seconds with the accumulation of Na+ in neurons leading to the shortage of
ATP and general loss of ionic homeostasis. The immediate and long-term tissue damage
depends on the total reduction in cerebral blood flow (CBF), the amount of time the
tissue is ischemic, the presence of residual flow and the amount of CBF that returns
(Maxwell, 1999). In addition to the primary insult, an inflammatory response starts
within hours and can last for days, which can lead to further damage from proinflammatory cytokines (i.e. tumor necrosis factor-alpha (TNF-α), IL-1β and IL-6, (see Vila et al., 1999), free oxygen radicals, and nitric oxide (Liu et al., 2001). Therefore, in
the treatment of stroke there may be on optimal therapeutic window in which to deliver
HUCB cells that will assist in preventing or reducing the inflammatory insult. Thus, this
study systematically addressed the optimal period to administer HUCB cells, by
determining when enhanced migration of HUCB cells to ischemic tissue extracts is
observed in vitro. In addition, the second part of this study addressed the cytokines
contained within ischemic tissue extracts. The results will help determine whether a
critical window of opportunity exists to administer these cells and provide insight into the
possible chemokines/cytokines involved in ischemia and the migration of HUCB cells to
the infarct site.
103

4.3

Material and Methods

4.3.1

Animal Care and Handling

Adult male Sprague-Dawley rats (Harlan) weighing 200 to 300g were used for
this study (n = 6 per condition for a total of 54 rats). Animals were housed in pairs in a
temperature-controlled room (22 + 30 C) with free access to food and water, and kept on a
12 hour light /dark cycle. The rats were handled and monitored daily for two weeks
before MCAO surgery and afterward until they were sacrificed. All experimental
procedures were approved by the USF’s Institutional Animal Care and Use Committee
and comply with the National Institute of Health, Guide for the Care and Use of
Laboratory Animals.
4.3.2

Middle Cerebral Artery Occlusion Surgery

Animals were anesthetized with 5% Isoflurane in 1L O2/min and maintained in
1.0 to 2.0% Isoflurane in 1L O2/min throughout surgery. Anesthetized rats were placed
in a supine position and a neck incision was made to expose the junction between the
right external and internal carotid arteries. The right common carotid, external carotid,
internal carotid, and pterygopalatine arteries were isolated using blunt dissection
techniques. The common carotid was dissected free of the vagus nerve. The external
carotid artery was permanently tied in two positions rostrally and a cut was made
between the two sutures. After clamping the common and internal carotid arteries, a 26gauge needle was inserted into the lumen of the external carotid artery and an embolus (a
nylon filament 40 mm in length) was inserted through the lumen of the internal carotid
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artery to the origin of the middle cerebral artery (approximately 25 mm from point of
entry). The filament was tied to produce a permanent stroke and the neck incision was
closed. Body temperature was kept within normal limits by use of heating pads until the
rat recovered. All animals received Baytril 0.5 ml/kg s.c. and Ketofen 5 mg/kg i.m. for 3
days after surgery and were monitored continuously until sacrificed.
4.3.2.1

MCAO Behavior Test

To insure MCAO surgery induced ischemia the Postural Tail-Hang test (also
known as The Forelimb Akinesia test) was performed on rats anywhere between 3 to 24
hours after surgical recovery. Briefly, the rats were held by the base of the tail and the
positions of the forelimbs were recorded. Rats in which stroke was induced demonstrated
a characteristic posture with the left forelimb flexed to their chest and with the right
forelimb stretched out. Only the rats that met criteria with complete flexure of the
forelimb were included in the study.
4.3.3

Preparation of Brain Tissue Extracts

Animals were sacrificed by exposure to CO2 at 4, 6, 12, 24, 48, 72 hours or 1
week after MCAO. Brains were removed within two minutes, immediately flash-frozen
and then stored at –800C until needed. The frozen brains were semi-thawed, kept cold,
and the striatum, hippocampus, and the cortex were dissected from both the ipsilateral
and contralateral sides to the occlusion. The same dissections were performed for sham
surgery and normal rats. Tissue from each of the conditions were pooled, and kept on ice
in clear Dulbecco’s modified Eagle’s medium (DMEM, Invitorgen, Carlsbad). Tissue
was homogenized at 150 mg of tissue per 1mL of media. The homogenates were
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centrifuged (4000g for 20 minutes), the tissue extracts (supernatant) collected, filtered
(0.22 µm, Millipore, Bedford, MA), and stored at -800C until used.

4.3.4 Protein Assay
Bicinchoninic acid (BCA) protein assays (Promega, Madison, WI) were used to
determine the total amount of protein in the tissue extracts for each condition and for both
the positive and negative controls used in the migration assay. Protein assays were
performed twice and each unknown (tissue extracts and controls) or standard were ran in
triplicate (three wells per assay for 6 data points) according to the manufacturer’s
instructions. Briefly, 25 µL of tissue extracts or controls were pipetted directly into the
wells of a 96-well plate, 200 µL of working reagent was added, and the plate was placed
on a shaker for 30 seconds, covered, and incubated at 370C for 30 minutes. The standard
curves were performed in the same 96 well plate and the assay had a working range of 20
to 2,000 µg/mL of protein. The plates were read in an automated plate reader (Synergy,
BioTek, Winooske, VT) set to absorbance with wavelength of 562 nm. After measuring
the protein concentration for rat ischemic tissue extracts they were standardized to 500
µg/mL for use in migration, cytokine, and ELISA assays.
4.3.5

Preparation of HUCB Cells

Cryopreserved mononuclear fraction of HUCB cells were obtained from Saneron
CCEL Therapeutics, Inc. Cells were thawed and pipetted into 9 mL of media [clear
DMEM with 5% FBS and 1 µL/1mL of Gentamicin (Sigma, St. Louis)]. Cells were then
centrifuged at 400 g for 15 minutes, the supernatant was removed, and the cells
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resuspended in 1 mL of media. Cord blood cells were then plated in low adherence 6
well culture dishes (Corning, Corning, NY) for 24 hrs in a water jacket incubator set at
370C and with 5% CO2... After 24 hrs cells were lifted by gentle pippetting, placed in a 15
mL tube, centrifuged, resuspended in 1 mL of media without FBS, and viability assessed
using the trypan blue dye exclusion method. Only HUCB cells with 80% or greater
viability were used and cell concentration was adjusted to 62,000 cells/25 µL of media.
4.3.6

Migration Assay

The tissue extracts (supernatant) of each brain area (striatum, hippocampus, and
cortex) from both the ipsilateral and contralateral sides and for each time period (4, 6, 12,
24, 48, 72 hours, or 1 week after stroke) were pooled together per condition. The 96Chemotx® Chambers (Neuro Probe, Gaithersburg) were used for these migration assays.
The chamber is a 96-well plate consisting of bottom wells that hold the unknowns or
chemoattractant and a top plate, which has a polycarbonate membrane with 5 µm pore
size. Either 300 µL of the tissue extracts (unknowns), standards, or controls were
pipetted into the bottom wells, in triplicate, after which the top plate was securely
attached to the bottom plate. The HUCB cells were pipetted directly into the top well at a
concentration of 62,000 cells per 25 µL. The migration chambers were then placed in a
water-jacket incubator at 37°C with 5% CO2 for 4 hours. The top plates were removed
and the bottom plates were then centrifuged (300g for 10 minutes) so that all migrating
cells would be forced to the bottom. Half the media (150 µL) was then removed and a
cell viability assay (CellTiter-Glo Kit, Promega), which is based on the incorporation of
adenosine 5’ triphosphate (ATP) into live cells, was used to determine the number of
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cells that had migrated. The migration plate was read in an automated plate reader
(BioTek) set to luminescence.
4.3.6.1

Controls

Stromal cell-derived factor – 1 (SDF-1, 100 ng/mL, Serologicals, Norcross), a
chemoattractant known to induce the migration of HUCB CD34+ cells, was used in this
study as a positive control. Clear DMEM, which was used as the diluent in the tissue
extracts and the media used to culture HUCB cells, was used as a negative control in the
migration and protein assays.
4.3.6.2

Standard Curves

Standard curves were established for the migration assays and for determining
sensitivity of the plate reader. A serial dilution of cells, at a concentration running from 0
to 80,000 cells/300 µL of media, was performed in triplicate, and pipetted directly into
the bottom wells of a 96-well plate. The CellTiter-Glo cell viability assay was performed
according to the manufacturer’s instructions. The amount of ATP expressed was directly
proportional to the number of cells present in each well.
4.3.7

Rat Cytokine Array

The rat cytokine antibody array kit (RayBiotech, Inc) simultaneously profiles’ 19
cytokines from rat brain tissue extracts. Array membranes were placed in the tray
provided 2 mL of blocking buffer was added and incubated for 30 minutes at room
temperature. After washing [3 times with 2 mL of Wash Buffer I (provided), then 2
times with Wash Buffer II (provided) on shaker for 5 minutes], 1 mL of standardized
striatal tissue extracts (12, 48 hours, 1-week MCAO and non-MCAO extract) was added
and incubated for 2 hours with the membrane to allow cytokine binding to immobilized
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antibodies on the arrays. Membranes were washed again as described above and 1 mL of
diluted biotin-conjugated antibodies (4 µL in 996 µL of blocking buffer) was added,
incubated for 2 hours, and washes were repeated. After which 2 mL of diluted HRPconjugated streptavidin (2 µL in 1998 µL of blocking buffer) were incubated on
membranes for 60 minutes and washes were repeated and decanted. Detection buffer
(500 µL) was placed on the membranes for 5 minutes, membranes were lifted with
forceps to drain excess buffer, placed on Whatman paper, covered with Saran, exposed to
x-ray film (1 to 5 minutes) and developed.
4.3.8 ELISA for Rat GRO/CINC-1 and MCP-1 in Ischemic Tissue Extracts
Ischemic tissue extracts were prepared as described above. The striatum,
hippocampus, and cortex areas in ischemic rats taken at 4, 6, 12, 24, 48, 72 hours and 1
week after MCAO from the ipsilateral and contralateral sides to the occlusion were used
in both rat ELISAs. In the rat GRO/CINC-1 ELISA, 100 µL of ischemic and control
tissue extracts for each condition were incubated in 96 well micro-plate (unknown and
standards were performed in triplicate) for 1 hour with immobilized polyclonal antibody
to rat GRO/CINC-1. The bound cytokine was incubated with appropriate labeled
antibody, substrate solutions, and standard curve performed according to manufacturer’s
instructions (TiterZyme EIA, Assay Designs, Inc.) with a range of 0 - 300 pg/mL. In the
rat Monocyte Chemoattractant Protein-1 (MCP-1) ELISA, 50 µL of ischemic and
controls tissue extracts were incubated in a 96-well plate (each unknown and standards
were performed in triplicate) for 1 hour with immobilized antibody to rat MCP-1. Bound
cytokines were incubated with appropriate labeled antibody, substrate solutions, and
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standard curve performed all in accordance to manufacturer’s instructions (Rat MCP-1
ELISA Kit, Pierce Endogen). The assay had a range of 0 - 1500 pg/mL. The amount of
bound GRO/CINC-1 and MCP-1 were measured in a chemoluminescence reader
(Synergy, BioTek, Winooske, VT ) set to absorbance at 450nm and 550nm, respectively.
4.3.9

Statistical Analysis

Migration assay unknowns (the tissue extracts), standards, and controls were
performed in triplicate and the migration assay was performed twice for a total of 6 data
points per condition. A two-way analysis of variance was used to analyze data for the
migration assay and significance was set at p<0.05.

Further analyses of planned

comparisons were performed using Dunn’s Bonferroni (corrected) test.

The same

analysis was used for the ELISAs, and Student’s t-Tests were used for the rat cytokine
arrays after using Image Pro Plus software (Media Cybernetics, Inc Silver Spring, MD) to
determine optical density.

4.4

Results

4.4.1

Migration of HUCB Cell to Ischemic Tissue Extracts

When we examined the HUCB cells after migration to the ischemic tissue extracts
from striatal and hippocampal conditions at 24, 48, and 72 hours, we observed the
formation of cell aggregates which were progressively larger in the later times after
stroke (Figure 4.1). This migration of the HUCB cells to the stroked tissue extract is
typical of true chemotaxis (the attraction of cells in a positive gradient). Aggregates did
not form in the non-stroke brain areas (contralateral sides). The positive control, SDF-1,
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showed migration of these cells in a random fashion with no cell aggregation or cluster
formation upon reaching the bottom well, indicative of chemokinesis (migration in a
random direction).
Figure 4.1 Migrated HUCB Cells in Striatal Ischemic Tissue Extracts

Figure 4.1 Bright-field photomicrographs of HUCB cells that have migrated to MCAO tissues extracts and
controls. Pictures were taken of the bottom well in the 96-well plate on an inverted microscope at 10x.
(A,C,E) Shows the numerous HUCB cells that migrated to striatal and hippocampal extracts at both 24 hr
and 72 hr after MCAO. Upon reaching the bottom plate, the cells began to form cell-clusters in these
conditions. (B, D, F, H) Very few cells migrated to the control conditions and this was typical for all
samples tested. (G) Cells also migrated to this chemoattractant SDF-1, however, the pattern of migration
was more random with no defined cell clusters. Bar = 100 µm applies to all photomicrographs
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This is the first study to report a time-dependent factor in which the mononuclear
fraction of HUCB cells migrate to ischemic tissue extracts; the time at which the brains
of stroked rats are harvested after MCAO directly effects the number of HUCB cells that
migrate toward brain areas damaged by ischemia (Table 4.1). Significantly more HUCB
cells migrated to the ipsilateral striatal extract at 24, 48 and 72 hours after MCAO
compared to the same area on the contralateral side (p <0.0001) and to media control
(Figure 4.2.A). Significantly fewer cells migrated to striatal ipsilateral tissue extracts at
4, 6, and 12 hours compared to their contralateral control side (p <0.05). However, by 1
week there were no significant differences between the tissue extracts of either side. The
tissue extracts for the hippocampal area showed similar results as the striatum, at both 48
and 72 hours (Figure 4.2.B); significantly more HUCB cells migrated to the stroke side
than to the non-stroke side, media control, and when compared to the stroke side at 4, 6,
12 hours and 1 week (p <0.0001). A trend similar to that seen with striatal extracts were
observed in the earlier time points with fewer HUCB cell migration at 4 and 6 hours to
the hippocampal ipsilateral tissue extracts when compared to their contralateral side
(p<0.005). When we examined the cortex, there were significant main effects for the side
of the brain and time factors (p <0.0001, Table 4.1) and a side by time interaction
(p<0.0001). Upon further analysis, there were only significant differences between the
stroke and non-stroke cortex extracts at 24 hours and 1 week (Figure 4.2.C). Fewer cells
migrated to the cortex stroke brain tissue extract at 24 hours compared to the non-stroke
side. Lastly, at 1 week more HUCB cells migrated to the cortex stroke brain tissue
extract than the non-stroke side.
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Table 4.1.
Analysis of Variance for HUCB Cells Migration to Striatum
Source

df

F-Ratio

Prob

Striatum (A)
Time (B)
AXB
Within Cell
Total

1
6
6
70
83

0.35482
467.3022
137.6980

0.5333
<0.0001
<0.0001

Analysis of Variance for HUCB Cells Migration to Hippocampus
Source

df

F-Ratio

Prob

Hippocampus (A)
Time (B)
AXB
Within Cell
Total

1
6
6
70
83

14.9061
559.209
178.2521

<0.0002
<0.0001
<0.0001

Analysis of Variance for HUCB Cells Migration to Cortex
Source

df

F-Ratio

Prob

Cortex (A)
Time (B)
AXB
Within Cell
Total

1
6
6
70
83

32.4057
99.1623
71.2945

<0.0001
<0.0001
<0.0001
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Figure 4.2 Migration of HUCB Cells to Stroke Tissue Extracts
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Figures 4.2 The relative number of HUCB
cells that migrated to MCAO brain tissue
extracts at 4, 6, 12, 24, 48, 72 hrs and 1 week
after ischemia and to controls.
(A) There was a significant number of HUCB
cells that migrated to the stroked striatal tissue
extracts at 24 hours (*) and to the stroked
striatal and (B) hippocampal tissue extracts at
48 and 72 hour conditions (*) when compared
to tissue extracts from non-stroke side or plain
media. (A) Interestingly, at 4, 6, and 12 hours
significantly fewer cells (#) migrated to the
striatal stroke tissue extracts compared to nonstroked control.
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Figure 4.2 (continued) (B) And at 4 and 6 hours after stroke fewer cells (#) migrated to
hippocampal stroke tissue extracts compared to non-stroke hippocampal extracts. (C) At 1
week (#) more cells migrated to cortex stroke extracts than from cortex non-stroke extracts
while at 24 hr fewer cells migrated to the stroke side when compared to non-stroke side. (D)
Significantly more HUCB cells (**) migrated to SDF-1 chemoattractant and fewer cell
migrated to the media control (#) compared to all other conditions.
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4.4.2

Rat Cytokine Array

The rat cytokine array showed that the cytokine with the most intensity was
Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) for striatal tissue extracts at 12, 48
hours and 1 week when compared to non-stroke tissue extracts and control media (Figure
4.3).

Figure 4.3 Rat Ischemic Extracts Cytokine Array

Figure 4.3
Photomicrographs of the rat cytokine
membrane film. (A,B) Shows cytokines expressed at 12
hours after ischemia in striatal extracts. TIMP-1 was more
intense at 12 and 48 hours and 1 week in striatal ipsilateral
sides (B, D, and F). (C and D) At 48 hours MCP-1 and
CINC-1 were also, elevated compared to control sides. (E
and F) By 1 week CINC-1 and β-NGF were more
intensely labeled on the stroked side than the non-stroked
side. (G) DMEM (the media) used for tissue processing,
shows no cytokine expression. (H) Normal striatal rat
brain extract had no measurable cytokine expression.
Student’s T-test was used to test significance (p < 0.05).
Optical density of stroke conditions (B,D,F) were
compared to non-stroke conditions (A,C,E).

In addition, the other cytokines visualized and found significant in order of
intensity were MCP-1 and Cytokine-induced Neutrophil Chemoattractant-1 (CINC-1) at
both 48 hours and 1 week, CINC-3 and Nerve Growth Factor-beta (β-NGF) at 1 week
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compared to non-stroke tissue extracts and media controls. Based on these data we chose
to investigate further Growth-Regulated Oncogene/CINC-1 (GRO-CINC-1) and MCP-1
using ELISA to determine expression over time after MCAO in rats. GRO-CINC-1 has
been reported to be the rat equivalent to human Interleukin 8 (IL-8) (Ramos, Heluy-Neto,
Ribeiro, Ferreira, & Cunha, 2003). Even though rats do not produce IL-8 they do
respond to it. Mast cells in the HUCB cell population have also been reported to produce
IL-8.

4.4.3

Rat ELISAs

Unexpectedly, both GRO/CINC-1 and MCP-1 showed a time-dependent pattern
that was similar to the time course of cell migration (Figure 4.4 and 4.5). The striatal
ischemic tissue extracts had significantly more GRO/CINC-1 at 4, 6, 24, and 48 hours
compared to non-ischemic striatal extracts at the same time points (Figure 4.4.A).
Similar results were seen with hippocampal tissue extracts where GRO/CINC-1
concentrations significantly increased at 4, 12, 48 and 72 hours, while the cortex extracts
had elevated levels at all time points compared to non-ischemic extracts (Figure 4.4.B).
By 1 week for striatal and hippocampal ischemic extracts levels of GRO/CINC-1 had
returned to normal, however the level remain elevated in the cortex extracts. In sham
surgery and normal rat brain extracts GRO/CINC-1 were significantly lower than the
ischemic striatal, hippocampal, and cortex concentrations at all times (Figure 4.4.C and
D).
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Figure 4.4 Levels of GRO/CINC-1 in Ischemic Extracts
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Figure 4.4 Continued
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Figure 4.4 ELISA graph of GRO/CINC-1 in rat ischemic and non-ischemic tissue
extracts. (A, B, C) GRO/CINC-1 concentration in ischemic (stroke) rat tissue extracts
from 4 hours to 1 week. (*) shows significant difference from controls (non-stroke) at
corresponding time points. (D) GRO/CINC-1 concentration in striatal extracts from
sham surgery and normal brain controls. Presented controls represents the most
elevated levels from sham and normal brain.
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The MCP-1 in ischemic tissue extracts was expressed later then GRO/CINC-1. In
striatal ischemic extracts, significant elevations of MCP-1 were shown at 6, 12, 48 and 72
hours (Figure 4.5.A), while hippocampal ischemic extracts showed increased levels at 12,
24, 48, and 72 hours (Figure 4.5.B) and the cortex only showed increases in MCP-1 at 6,
12 hours and 1 week (Figure 4.5.C) compared to non-ischemic tissues. MCP-1 for sham
surgery and normal rat brains was extremely lower compared to concentrations observed
in ischemic conditions (Figure 4.5.D).
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Figure 4.4 Levels of MCP-1 in Ischemic Extracts
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Figure 4.5 Continued
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Figure 4.5 ELISA graph of MCP-1 in rat ischemic and non-ischemic tissue extracts. (A, B, C)
MCP-1 concentration in ischemic rat tissue extracts from 4 hours to 1 week. (*) shows
significant difference from control at corresponding time points. (D) MCP-1 concentration from
sham surgery and normal brain controls. The controls present here represent the most elevated
levels in all control conditions.
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4.5

Discussion

In utilizing an in vitro model of migration, we were able to emulate the actions of
HUCB cells in the microenvironment of stroke. The present findings are the first to show
the aggregation and migration of HUCB cells to ischemic tissues extracts with a timedependent factor. In addition, this is the first report of the levels of GRO/CINC-1 and
MCP-1 in ischemic extracts at several periods after stroke has occurred.
Once the HUCB cells migrated to the tissue extracts, cell clusters formed on the
bottom well with smaller aggregates of cells in the striatal and hippocampal tissue
extracts at 24 hours, and larger aggregates at 48 and 72 hours. Although some cells
migrated to extracts of the contralateral sides, these cells upon reaching the bottom well
did not form clusters (Figure 4.1) suggesting a random migration. Even with the SDF-1
chemoattractant, in which a large number of HUCB cells migrated, no clustered
formations were observed which is consistent with our previous observation of this
chemoattractant in vitro. The aggregation of these cells in the stroke tissue extracts
suggest that in this microenvironment there is cell-to-cell interaction and signaling, which
could be mimicking what occurs upon transplantation of these cells in this model of brain
injury.
We used the MCAO animal model of stroke in rats to establish the optimal time
for delivery of these cells for use in transplantation. This model produces localized CNS
infarction in which intervention strategies such as neural transplantation can easily be
evaluated. The middle cerebral artery receives approximately 80% of the blood passing
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through the internal carotid artery. The MCAO model has been shown to produce
marked cell damage and neurobehavioral deficits that parallel the ischemic strokes
observed in humans. The occlusion of the MCA results in cell damage and/or loss of
cells in the striatum, hippocampus, and cortex ipsilateral to the occlusion.
Typically, our laboratory and others have transplanted HUCB cells 24 hours after
induction of ischemia. The findings from this study suggest that a later time (48 hours)
may be a more optimal time to deliver these cells, with more cells migrating to the
ischemic extract (Figure 4.2) resulting in greater therapeutic benefits. This is especially
important when cells are administered intravenously, after which the cells must migrate a
rather far distance to the site of injury. However, research by this laboratory and others
have established the “proof of principle” that intravenous administration of HUCB cells
results in vast improvement in behavioral deficits in animal models of stroke (Chen et al.,
2001; Taguchi et al., 2004, Willing et al., (2003); Vendrame et al., 2004; Willing,
Vendrame et al., 2003). Also, the same has been shown in spinal cord injury (Saporta et
al., 2003), TBI (Lu et al., 2002), and ALS (Chen & Ende, 2000; Garbuzova-Davis et al.,
2003).
The observed migration of HUCB cells to extracts from the injured brain is
consistent with earlier reports (J. Chen et al., 2001; Lu et al., 2002). Previously, HUCB
cells have been shown to migrate toward ischemic cerebral tissue extract taken at 24
hours after stroke while bone marrow cells migrated to cerebral extracts at 6, 24, and 48
hours after stroke compared to controls (Chen et al., 2001; Chen et al., 2001). However,
this is the first study to examine systematically the migration of HUCB cells to selected
areas affected by MCAO over time in rats.
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Together these studies suggest that

endogenous signals generated by the pathology are capable of attracting HUCB cells to
the area of insult, and migration is dependent on the area of the brain and the time the
cells are administered after stroke. The results also suggest that at earlier time points the
injured tissue may be sending out inhibitory cues that inform the cells of a hostile
environment. After the initial insult, both cytokines and chemokines are expressed in a
complex temporal cascade of events.

The pro-inflammatory cytokines have been

reported to be released early in response to the loss of blood flow followed by
excitotoxicity of the cells within the core of the infarct (for review see - (Leker &
Shohami, 2002). There is an increase in IL-1β, IL-6, TNF-α, interferon- γ (IFN-γ), and
transforming growth factor - β (TGF-β 1 & 2) mRNA expression as early as 1 hour after
stroke (Leker & Shohami, 2002). Expression of these cytokines peaks between 12 and 24
hours in permanent focal ischemia as determined by mRNA (Hill et al., 1999). Resident
reactive microglia are believed to be one of the sources of these cytokines (Kostulas,
Pelidou, Kivisakk, Kostulas, & Link, 1999; Leker & Shohami, 2002).

These pro-

inflammatory cytokines may exacerbate neuronal damage (Barone et al., 1997;
Tarkowski et al., 1995; Yang, Zhao, Davidson, & Betz, 1997) and are known to induce
neutrophil infiltration possibly by the stimulation of CINC.
Both IL-8 and CINC belong to CXC family of chemokines and are present in
ischemic brain. In the cytokine array and ELISAs we showed that CINCs were present in
ischemic tissue extracts (Figure 4.3 & 4.4). In the cytokine array, CINC-1 was observed
at 48 hours and 1 week, while CINC-3 was weakly observed at 1 week. In the ELISAs
although there were peaks at certain time points, GRO/CINC-1 was shown to decrease
gradually from 4 hours to 1 week in all brain tissue extracts. CINC-1, GRO/CINC-1 and
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IL-8 all serve as proinflammatory agents, attract neutrophils, and serve as the first line of
defense in inflammation, which may be why GRO/CINC-1 is highly elevated early in the
ischemic striatal extracts (4hrs.).

This is especially true if the progression of

degenerating tissue is considered (from the core outwards), which may indicate that
neutrophils within the HUCB cells are migrating to the core in a progressive manner and
aid in reducing the infarct size. Indirect evidence of this has been reported in Vendrame
et al. (2004) who showed that HUCB cell infusion reduced the volume of the infarct in
MCAO rats.
stimulating

In humans, IL-8 indirectly regulates the migration of neutrophils by
CINC-1

in

mast

cells

(Ramos

et

al.,

2003),

directly

attracts

polymorphonuclear neutrophils (Kostulas et al., 1999), and participates in mediating the
inflammatory response and the trafficking of leukocytes into the ischemic area. The
infiltration of leukocytes to the ischemic area are believed to be aided by intercellular
adhesion molecule (ICAM), endothelial leukocyte adhesion molecule (Pantoni, Sarti, &
Inzitari, 1998) and tissue metalloproteinases (MMPs) which are zinc-dependent
proteolytic enzymes that are known to weaken the blood brain barrier (Crocker,
Pagenstecher, & Campbell, 2004).
TIMP-1 was present on cytokine arrays for all ischemic extracts (12hrs, 48hrs,
and 1wk) and has also been shown in ischemic rats using other methods (Hedrick, Cohen,
Nielsen, & Davis, 1984; Romanic et al., 2002). This cytokine is believed to inhibit
MMPs in diverse conditions such as wound healing, angiogenesis, cancer metastasis, and
stroke (Crocker et al., 2004).

One role of TIMP-1 is to rebuild or remodel the

extracellular matrix by the inhibition of MMPs.

We suggest here that TIMP-1 is

performing a similar function in rebuilding the extracellular matrix that has been
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destroyed by MCAO and at a future point may serve as an adjunct therapy, especially
because TIMP-1 is seen at 1 week, on both the ipsilateral and contralateral side to the
occlusion (even though the intensity is weaker on the contralateral side of the brain).
However, the exact function of TIMP-1 in the ischemic brain requires further
investigation.
In addition, to GRO/CINC-1 an elevation in MCP-1 was also observed in both the
rat cytokine array and ELISA.

MCP-1 has previously been shown to increase the

migration of bone marrow stromal cells to rat cerebral ischemic tissue extracts (Wang, Li,
Chen, Gautam et al., 2002; Wang, Li, Chen, Chen et al., 2002).

Here MCP-1

concentration peaked at 48-hours in striatal extract on cytokine arrays, and in striatal and
hippocampal tissue extracts at 48 and 72-hours in the ELISAs. This is similar to other
reported findings for MCP-1 in ischemic tissue (Wang, Li, Chen, Chen et al., 2002). This
chemokine strongly attracts monocytes and serves as a potent immunoregulator, which
would explain why we see more HUCB cells migrating at the 48-hour period than at
earlier or later times.
IL-1β, IL-6, and TNF-α participate in mediating the inflammatory response and
are chemoattractants for leukocytes as well.

Although the exact actions of these

individual cytokines remains unknown; both TNF-α and IL-1 have been shown to
increase the infarct size (Barone et al., 1997; Yamasaki et al., 1995), while IL-6 may act
as both a pro and anti – inflammatory agent (for review see - Benveniste, 1998).
Furthering our understanding of initial cytokines expression will aid in establishing
whether they are responsible for inhibiting the migration of HUCB cells at the earlier
times to ischemic tissue extracts observed in this study.
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SDF-1 was used for a positive control in this study as it has been shown to be a
strong chemoattractant for hematopoietic progenitor cells (CD34+) from HUCB (Kim &
Broxmeyer, 1998) and for monocytes and lymphocytes. In addition, CD34+ HUCB cells
express a higher level of the CXCR4 (SDF-1 receptor) which is believed to aid in their
ability to home to bone marrow when transplanted (Yong et al., 1999). In a mouse model
of MCAO, SDF-1 was reportedly associated with reactive astrocytes, mostly localized
within the penumbra, and transplanted green fluorescent protein expressing bone marrow
cells were found in areas highly immunoreactive for SDF-1 thus suggesting a
chemoattractant role for SDF-1 (Hill et al., 2004). There is evidence that SDF-1 has a
broader role by stimulating release of other chemokines, regulating leukocyte trafficking,
stimulating the renewal of stem cell, and the release of maturing cells from bone marrow
for continued hematopoiesis (Broxmeyer et al., 1999; Lee et al., 2002; Onai et al., 2000).
Two studies have reported that SDF-1 selectively induces the chemokine IL-8
from cord blood-derived human mast cells (Lin, Issekutz, & Marshall, 2000, 2001).
Therefore, evidence suggests that multiple chemokines are involved in the migration of
HUCB cells to ischemic tissue extracts and furthermore, it is likely that several factors,
including blood brain barrier breakdown, inflammatory response, and trophic factor
production may be involved in the trafficking of these mononuclear cells to the site of
injury.
The results from this study showed that 48-hours is the optimal time for the
migration of HUCB cells to ischemic tissue and suggest that these cells are induced to
migrate perhaps by MCP-1, IL-8 (GRO/CINC-1) or other chemokines, and once there the
chemokine(s), or other factors, induce these cells to aggregate. Further studies of the
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intrinsic and extrinsic mechanisms are required to understand the signals involved in the
migration of cells to the site of injury. Our research group is currently investigating the
optimal time of 48-hours to deliver HUCB cells in our in vivo model of MCAO in rats, as
well as examining the cytokines and chemokines produced by cord blood cells.

In conclusion, these new results suggest that a wider therapeutic window (from 48
to 72 hours after stroke) may exist for the treatment of stroke victims using cord blood
cells, compared to the existing 3-hour post stroke t-PA. This may also decrease mortality
rate and improve long-term outcomes for patients.
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Chapter 5

5.0

Cytokines Produced by Cultured Human Umbilical Cord Blood Cells

5.1

Abstract
The potential therapeutic benefits from Human Umbilical Cord Blood (HUCB) cells

for the treatment of certain injuries, diseases, and neurodegeneration is becoming
increasingly recognized. The utilization of cord blood cells in various animal models, such
as ischemia/stroke, traumatic brain injury, myocardial infarction, Parkinson’s Disease, and
Amyotropic Lateral Scelerosis, has resulted in improvements of behavioral deficits and for
some diseases, prolonged lifespan. Previously, we reported the migration of HUCB cells to
ischemic brain tissue extracts is time-dependent, and that expression of certain
cytokines/chemokines within the ischemic extracts corresponds to this migration pattern.
However, the mechanism(s) responsible for the functional improvements in the animal
models and for the migration of these cells to site of injury or tissue extracts are unknown.
Here we investigated the expression of cytokines/chemokines produced by HUCB cells
under various experimental conditions in vitro. Certain cytokines were consistently
expressed in the majority of experimental conditions, such as interleukin-8, monocyte
chemoattractant protein-1, and interleukin-1α. This research provides insight as to the
possible cytokines from cord blood cells involved in the functional improvements seen in the
animal models of injury/disease.
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5.2

Introduction

The field of cell replacement/repair for the treatment of diseases and injuries,
especially those of the central nervous system (CNS), is a crucial area of research that
could eventually benefit millions of people. In the last 20 years, although tremendous
progress has been achieved in the cell transplantation field, negative outcomes reported
from clinical trials along with ethical concerns involving the use of fetal cells or tissue
and embryonic stem cells have delayed progress in the cell replacement/repair field. Our
group, along with others, has turned to other potential cell sources in order to continue
the progression of this field. We have been utilizing cells of hematopoietic origin. The
most promising has been those from human umbilical cord blood (HUCB). Theses cells
have been used extensively in the treatment of various nonmalignant and malignant
hematopoietic diseases, especially in children, for the last 15 years (for reviews see - (Lu,
Shen, & Broxmeyer, 1996) (Cohen, Gluckman, Rubinstein, & Madrigal, 2000).
Functional improvements in behavioral deficits have been confirmed in rats that
were administered HUCB cells following middle cerebral artery occlusion (MCAO)
(Chen et al., 2001; Vendrame et al., 2004; Willing, Lixian et al., 2003; Willing,
Vendrame et al., 2003). Despite reports that HUCB cells express neural phenotypes both
in vitro and in vivo (Garbuzova-Davis et al., 2003; Ha et al., 2001; J. R. Sanchez-Ramos,
2002; J R Sanchez-Ramos et al., 2001; Zigova et al., 2002), few cord blood cells are
present in the ischemic region when compared to the number of cells injected (Vendrame
et al., 2004), suggesting that cell replacement is not the responsible mechanism for the
functional improvements seen.
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Previously, we have demonstrated a temporal pattern in the migration of HUCB
cells to ischemic tissue extracts (Newman et al., In press; Newman et al., 2003). The
time at which the rats’ brains were harvested after MCAO proved to be a critical factor in
the migration of HUCB cells to ischemic brain tissue extracts. The optimal time after
stroke proved to be 48 hours. In addition, the striatal ischemic tissue expressed cytokines
and the chemoattractants, cytokine-induced neutrophil chemoattractant-1 (CINC-1) and
monocyte chemoattractant protein-1 (MCP-1), at 48 hours after MCAO. Further analysis
showed that both growth-regulated oncogene/CINC-1 [GRO/CINC-1, the rat equivalent
of human interleukin-8 (IL-8)] and MCP-1 from ischemic tissue had time-dependent
pattern similar to that observed in the migration assays.
The mechanism by which HUCB cells induce functional improvements in
behavioral deficits of MCAO rats remains unknown. We have suggested previously that
HUCB cells, once at the infarct, are releasing certain cytokines, chemokines or trophic
factors that are aiding in the repair and are involved in the functional recovery seen in the
stroke animal. Also, the HUCB cells could be releasing signals that attract endogenous
stem cells to the site of injury, which may further aid in the recovery of the injured
animals. In this study we sought to identify properties of HUCB cells that may be
responsible for the therapeutic benefit seen in the rat model of MCAO. Specifically, we
have investigated cytokines and chemokines produced by HUCB cells under various
culture conditions.
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5.3

Materials and Methods

5.3.1

Preparation of HUCB Cells

Cryopreserved mononuclear fractions of HUCB were obtained from Saneron
CCEL Therapeutics, Inc. (Tampa, FL.). Frozen samples were thawed either in 10 mL of
clear DMEM with 5% FBS and Gentamicin (50 µg/mL, Sigma) or with Ex Vivo 10
media (Cambrex) with Gentamicin (50 µg/mL). Cells were centrifuged at 400 g for 15
minutes, the supernatant was removed, and the cells re-suspended in 1 mL of the same
media. The viability of all samples ranged from 73 to 95 percent as determined by the
trypan blue exclusion method. Cord blood cells were cultured in 5 mL of media in low
adherence 6 well plates (Costa, Corning) in an incubator set at 370C and with 5% CO2...
Cells were treated in accordance with the protocols for each experiment as described
below, after which Conditioned Media (CM) (supernatant) was transferred to sterile
conical tubes by gentle pipetting, and centrifuged at 400 g for 15 minutes to remove any
remaining cells and stored at -800C.
5.3.2

Human Cytokine Array Protocol

Human cytokine antibody array kits (RayBiotech, Inc) simultaneously profiled
either 23 (Array 1.0) or 43 (Array 3.0) active cytokine/chemokine proteins in CM. Array
membranes were placed in the provided 6-well tray with 2 mL of blocking buffer and
incubated for 30 minutes at room temperature. After washing [3 times with 2 mL of
Wash Buffer I (provided), then 2 times with Wash Buffer II (provided) while on a shaker
for 5 minutes] 1 mL of CM and control media were added to separate wells and incubated
for 2 hours with the membrane to allow cytokine binding to immobilized antibodies on
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the arrays. Membranes were washed again as described above and 1 mL of diluted
biotin-conjugated antibodies (4 µL in 996 µL of blocking buffer) was added, incubated
for 2 hours, and washes were repeated. Diluted HRP-conjugated streptavidin (2 µL in
1998 µL of blocking buffer) was incubated on membranes for 60 minutes, washes were
repeated and the supernatant decanted. Detection buffer (500 µL) was placed on the
membranes for 5 minutes, membranes were carefully lifted with forceps to drain excess
buffer, placed on Whatman paper, covered with Saranwrap, exposed to x-ray film (1 to 5
minutes) and the film was developed. In addition to the positive and negative controls on
each array, we employed cultured media that had not been used to culture the cells as a
control array, which was used to compare with CM arrays.
5.3.2.1

Human Cytokine Array Time Response

Cells from the mononuclear fraction of HUCB (10 million/5mL) were cultured in
DMEM with 5% FBS and Gentamicin (50 µg/mL) for 4 days. Media was removed and
fresh DMEM with no FBS was incubated with the cells for an additional 6 days for a
total of 10 days or for additional 18 days for a total of 28 days, with media changes
occurring every 3 days. The CM and control media were then processed as described
above and 1 mL of each used in the human cytokine array (Ver. 1.0).
5.3.2.2

Human Cytokine Array Seeding Density

Cells from the mononuclear fraction of HUCB were cultured in serum free
DMEM with Gentamicin (50 µg/mL) for 3 days at concentrations of 5, 10, or 30 million
cells/5mL of media. The CM and control media were then processed as described above
and 1 mL of each used in the human cytokine array (Ver. 1.0).
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5.3.2.3

Human Cytokine Array Hematopoietic Media and Stimulants

HUCB cells (10 million/5mL) were cultured for 1, 5, or 12 days in serum free Ex
Vivo 10 media with Gentamicin (50 µg/mL). In addition, cord blood cells (10
million/5mL) were cultured for 4 days in serum free Ex Vivo-10 media with Gentamicin
and then media was changed and supplemented with either human Interleukin-3 [5
ng/mL, (IL-3); BioSource International, Camarillo, CA], thrombopoietin [25 ng/mL,
(TPO); Chemicon International, Temecula, CA] or no supplementation for an additional
5 days after which media was changed to plain Ex Vivo-10 for additional 3 days for a
total of 12 days in culture. The CM and control media were then processed as described
above and 1 mL of each used in the human cytokine array (Ver. 3.0).
5.3.3 ELISA for Human IL-8 and MCP-1 in Culture HUCB Cells
HUCB cells were cultured for 3 and 7 days in serum free DMEM or Ex Vivo-10
with Gentamicin (50 µg/mL). CM was obtained according to the protocol described
above. ELISA kits (Endogen, Pierce) were used to measure the amount of human IL-8
and MCP-1 in CM produced by HUCB cells according to the manufacture instructions.
Briefly, 50 µL of CM for each condition and controls were pipetted, in triplicate, along
with serial diluted standards, into a 96-strip well plate, incubated for 1 hour with
immobilized antibody at room temperature and wells were washed 3 times. Then
biotinylated antibody (50 µL) was added, incubated for 1 hour at room temperature, and
washed 3 times. Next 100 µL of streptavidin-HRP solution was added to wells incubated
for 30 minutes and wells washed 3 times. To allow enzymatic color reaction TMB
Substrate Solution was added to each well (100 µL) incubated for 30 minutes in the dark,
stop solution (100 µL) was added incubated for 30 minutes, and ELISA’s plates were
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measured in a chemoluminescence reader (Synergy, BioTek, Winooske, VT ) set to
absorbance at 450nm and 550nm.
5.3.4

Migration Assays

HUCB cells were prepared as described above and cultured for 24 hours before
use. The 96-Chemotx® Chambers (Neuro Probe, Gaithersburg) were used for the
migration assays. The chamber is a 96-well plate consisting of bottom wells that hold the
unknowns or chemoattractant and a top plate, which is a polycarbonate membrane with 5
µm pore size. The chemoattractants used were human recombinants MCP-1 (5, 10, 20,
and 30 ng/mL; Endogen, Woburn, MA), IL-3 (1, 5, and 10 ng/mL) TPO (10, 25, and 40
ng/mL), and Stromal cell-derived factor – 1 [100 ng/mL, positive control (SDF-1);
Serologicals, Norcross, GA], along with the serum free DMEM and Ex Vivo-10 (300
µL/well) were pipetted directly into the bottom wells, in triplicate, after which the top
plate was securely attached. The HUCB cells were pipetted directly into the top well at a
concentration of 62,000 cells per 25 µL. The migration chambers were then placed in a
cell culture incubator at 37°C with 5% CO2 for 4 hours. The top plates were removed and
the bottom plates were then centrifuged (300 g for 10 minutes) so that all migrating cells
would be forced to the bottom. Half the media (150 µL) was then removed and a cell
viability assay (CellTiter-Glo Kit, Promega) based on the incorporation of adenosine 5’
triphosphate (ATP) into live cells was used to determine the number of cell that had
migrated. The migration plate was read in an automated plate reader (BioTek) set to
luminescence.
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5.3.5

Statistical Analysis

The membranes used in the cytokines arrays were developed onto x-ray film. The x-ray
film was then scanned and the image analysis program, ImagePro-Plus (Version 5.0,
Media Cybernetics, San Diego, CA) was used to measure optical density. Higher
concentrations of cytokines were denser (darker) on the membrane and had a lower
numeric value, which equated to the optical density. The measurements were performed
three times by individual investigators blind to the treatment conditions and interrelator
reliability was between 85 and 98%. The three measurements were used in the statistical
analysis, which was performed using Student’s t-Test with significant set at p<0.05 and
compare to the control array(s), which was cultured media (no cells). ELISA’s also
employed Student’s t-Test to determine significance (p<0.05), and each condition was
compared to control (DMEM or Ex Vivo-10 media).

5.4

Results

This is the first study to report that the mononuclear fractions of HUCB cells
produce various cytokines and chemokines in response to culture conditions.
Interestingly UCB cells in all culture conditions, except for TPO, consistently produced
two chemokines, IL-8 and MCP-1. These results support our working hypothesis that
transplanted HUCB cells release factors that contribute to the recovery of behavioral
deficits in stroke rats and other injury/disease models, and produce chemokines that may
be attracting endogenous cells to the area of insult, which are thought to aid in repair and
recovery. The most important factors that contributed to the chemokine production were
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the amount of time the HUCB cells were in culture and the media and stimulants used.
The concentration of cells did not contribute to additional cytokine production. The
stronger concentration of a cytokine the denser (darker) it appears on the membrane,
which equates to smaller numeric values on the graphs.
5.4.1

Human Cytokine Array Time Response:

Cord blood cells were cultured for a total of either 10 or 28 days in DMEM. The
CM from cells that were cultured for the 28 days showed more cytokines compared to the
10 days condition (Figure 5.1). All cytokines/chemokines presented in Figure 5.1 were
significantly different from control. IL-8 and MCP-1 were at both times and showed an
increase in intensity by 28 days. At 10 days in vitro (DIV) the CM from HUCB cells
contained epithelial cell-derived neutrophil activating protein (ENA-78), macrophage
derived chemokine (MDC), onocostation (OSM), and vascular endothelial growth factor
(VEGF) all of which were not present by 28 days in culture.

However, by day 28 several additional cytokines and chemokines were present:
IL-6, tumor necrosis factor-α (TNF-α), IL-1α, IL-10, TNF-β, granulocytes-macrophage
colony stimulating factor (GM-CSF), interferon-γ (IFN-γ), MCP-2, and MCP-3.
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Figure 5.1 Cytokines Produced by HUCB Cells 10 and 28 DIV
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Figure 5.1. Human cytokines produced by HUCB cells at 10 and 28 days in vitro
(DIV). Graphs represent the optical density of cytokines in the conditioned media (CM)
from cultured HUCB cells that were bound to the membrane array. The higher the
concentration of bound cytokines to the membrane the denser (darker) it appears, which
when electronically measured for optical density equates to: the smaller the numeric
value the greater the concentration of the cytokine. (A) Cytokines in CM from HUCB
cells that were culture in DMEM for total of 10 days. (B) Cytokines in CM from HUCB
cells that were culture in DMEM for total of 28 days. (A,B) All cytokines present were
significantly different from control array (DMEM) and from negative control. The
background, negative control and control array were between 90 to 100% identical for
optical density measures. All cytokines presented in the graph were significantly
different from control array (Student’s T-test, p < 0.05).

5.4.2

Human Cytokine Array Seeding Density

To determine whether the number of cells influenced cytokine production, cord
blood cells were cultured at increasing concentrations (5, 10, and 30 million cells).
HUCB cells were cultured for 3 days and the CM from all concentrations expressed the
same 5 cytokines; IL-8, MCP-1, IL-1α, IL-3, and RANTES, which were all significantly
denser than control (Figure 5.2.). There was a significant increase in intensity of these
cytokine that corresponded to the increase in HUCB cell concentration.
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Figure 5.2 Effect of Seeding Density on Cytokine Secretion
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Figure 5.2 Human cytokines produced by HUCB cells at increasing concentration. Graph
represents the effect of seeding density on cytokine production in cultured HUCB cells.
Cells were plated at seeding densities of 5, 10, and 30 million cells/5mL of media
(DMEM) for 3 days in vitro (DIV). Cytokines showed a progressive increase in optical
density that corresponded to the concentration of HUCB cells plated. All cytokines
present were significantly different from control array (DMEM) and from negative
control. The background, negative control and control array were between 98 to 100%
identical for optical density measures. All cytokines presented in the graph were
significantly different from control array (Student’s T-test, p < 0.05).
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5.4.3

Human Cytokine Array Hematopoietic Media and Stimulants

To determine whether a serum free media designed to support hematopoietic cells
or the addition of proliferative agents would induce or inhibit the release of chemokines
in cord blood cells, they were cultured in hematopoietic media with or without the
addition of IL-3 or TPO (Figure 5.3 & 5.4). In Ex Vivo-10 (a serum free media designed
to support long-term cultures of hematopoietic cells), cord blood cells were induced to
release the chemoattractant SDF-1, which was not seen in the DMEM conditions. Again
IL-8 was the most prominent chemokine released in all Ex Vivo-10 conditions.
Macrophage colony-stimulating factor (MCSF) was present in the 5 and 12 DIV
conditions; it was not previously seen in the CM from cells cultured in DMEM (Figure
5.3 B & C). In addition, only in the 5 DIV condition was the cytokine Leptin present in
the CM (Figure 5.3 B).
Figure 5.3 Effects Hematopoietic Media has on Cytokine Secretion
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Figure 5.3 Effects that HUCB cells cultured with hematopoietic media has on cytokine
production. Cord blood cells were cultured with serum free Ex Vivo-10 media at a
seeding density of 10 million cells/5 mL for either, (A) 1 DIV, (B) 5 DIV, or (C) 12 DIV.
(A) Most cytokines in CM from HUCB cells at 1 DIV were not as intense compared to
same cytokines at 5 DIV (B) or 12 DIV (C). (B,C) At 5 and 12 DIV is first time SDF-1
was shown to be present in CM from HUCB cells. All cytokines presented in the graph
were significantly different from control array (Student’s T-test, p < 0.05).
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When IL-3 was added to the Ex Vivo-10 media a down regulation of several
cytokines occurred (Figure 5.4 A). While TPO inhibited MCP-1, it induced the HUCB
cells to produce transforming growth factor-β (TGF-β) and macrophage inflammatory
protein-1δ (MIP-1δ), which were not seen in any of the other conditions (Figure 5.4 B).

Figure 5.4 Effects on Cytokines Secretion by IL-3 and TPO
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Figure 5.4 Cytokine release after IL-3 and TPO added to hematopoietic media. HUCB
cells were cultured for 4 day in serum free Ex Vivo-10, after which cells were cultured
with fresh media and either (A) IL-3 (5 ng/mL) or (B) TPO (25 ng/mL) for 5 days (with
media refreshed at 2.5 days). Cells were then cultured in Ex Vivo-10 for additional 3
days for a total of 12 DIV. (A,B) Overall fewer cytokines were present in CM from
these conditions. However, the most prevalent cytokine remained IL-8 and surprisingly
followed by SDF-1 in both conditions. (B) Although the additions of TPO down
regulated MCP-1, this condition was the only one to show TGF-β and MIP-1δ in the
CM.
All cytokines presented in the graph were significantly different from control
array * (Student’s T-test, p < 0.05).

5.4.4

ELISA results for Human IL-8 and MCP-1 in CM from HUCB Cells

To investigate further IL-8 and MCP-1 enzyme link immunoassays were
performed (Figure 5.5 A & B). In agreement with the cytokine arrays, IL-8 was present
in CM from both Ex Vivo-10 and DMEM conditions at significantly higher levels than
controls, however, there were no significant differences seen between 3 and 7 DIV
conditions or between media conditions (Figure 5.5 A).
Consistent with the cytokine arrays, there was significantly more MCP-1 in the
CM from cord blood cells cultured for 3 days with Ex Vivo-10 than in CM from day 7 Ex
Vivo-10 and day 3 DMEM conditions (Figure 5.5 B).
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Figure 5.5 ELISA of IL-8 and MCP-1 from CM of HUCB Cells
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Figure 5.5 ELISA confirmation of human IL-8 and MCP-1 in CM from HUCB cells.HUCB
cells at 10 million cells/5 mL were culture in serum free Ex Vivo-10 or DMEM for 3 or 7 DIV.
(A) IL-8 (pg/mL) was found in all conditions, except controls (media and PBS), and there were
no significant differences. (B) MCP-1 (pg/mL) was also shown in all conditions, except controls
(media and PBS), and the CM from 3 DIV Ex Vivo-10 condition contained significantly more
MPC-1 then at 7 DIV or in the DMEM 3 DIV condition. * (Student’s T-test, p < 0.05).

5.4.5

Migration Assays

To examine whether MCP-1, IL-3 or TPO were chemoattractants for HUCB cells,
migration assays were performed. Previously we have shown that striatal ischemic tissue
extracts from rats contain MCP-1 and here we show that HUCB cells strongly migrate to
this extract (Figure 5.). IL-3 and TPO are often used to maintain long-term cultures and
for progenitor proliferation. Therefore, we wanted to determine whether either had
chemoattractant properties, as well. Significantly more HUCB cells migrate to MCP-1,
IL-3 and TPO compared to controls (DMEM and PBS). However, there were no
significant differences between the doses used for each protein, which was likely due to
the closeness in range of the doses employed.
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Figure 5.6 Migration Assay
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Figure 5.6 Migration of HUCB cells to MCP-1, IL-3 and
TPO. HUCB cells show a strong chemoattraction to all three
cytokines/chemokines MCP-1, IL-3 and TPO. Although a
dose range for each chemokine was performed there were no
significant differences between the doses. A standard curve
was also performed with the HUCB cells from 0 to 80,000
cell which corresponded to ATP expression in relative light
units (RLUs) 0 to 2,500. * (Student’s T-test, p < 0.05). C1 =
DMEM, C2 = PBS
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5.5

Discussion
Cytokine arrays, in which multiple cytokines are simultaneously identified (23 to

43 per membrane), allowed us to obtain “cytokine profiles” of what HUCB cells are
producing in various culture conditions and at various times. This study demonstrates the
significant signal interaction that must be occurring between HUCB cells in order to
produce this variety cytokines and chemokines and whose profiles change as the culture
conditions change.
IL-8 and MCP-1 are more extensively produced than any other chemokines in the
human body and have been implicated as the first line of defense in the inflammatory
reaction. In this study, both IL-8 and MCP-1 were significantly elevated in the CM of
HUCB cells under varying culture conditions. IL-8 was detected in the CM from HUCB
cells in all culture condition. Additionally, the intensity of IL-8 was the highest in every
condition. IL-8 belongs to the super family of cytokines, under the category of
chemokines, and more specifically is considered an α-chemokine (or chemotactic
cytokine). This chemokine is a strong chemoattractant for neutrophils and lymphocytes
(T-cells), and induces a full pattern of response from these cells, with activation of the
motile apparatus and directional migration, increase in surface adhesion molecules,
lysosomal enzyme release, and reactive oxygen intermediates production (Wang, Xu,
Murphy, Taub, & Chertov, 1996). We have previously shown an elevated presence of
IL-8 (Growth-Regulated Oncogene/ Cytokine-induced Neutrophil Chemoattractant-1
GRO/CINC-1 – rat equivalent of human IL-8) in striatal, hippocampal, and frontal cortex
of ischemic rat tissue extracts, which was elevated from 24 hours to 72 hours after stroke
when compare to non-stroked tissues (Newman et al., 2003; Newman, Willing, Manresa,
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Davis Sanberg, & Sanberg, 2004). IL-8 is also elevated in the sera from patients in a
number of human injuries and diseases, such as, Multiple Sclerosis (Lund et al., 2004),
coronary heart disease (Qi et al., 2003), traumatic brain injury (Kushi, Saito, Makino, &
Hayashi, 2003), and ischemic stroke patients {Kostulas, 1999 #6608;Kostulas, 1999
#6611}. In addition, IL-8 from cord blood alone or together with other cytokines is being
used as a determinant for neonatal sepsis (Berner, Tuxen, Clad, Forster, & Brandis, 2000;
Dollner et al., 2001; Krueger et al., 2001).
TNF-α and IL-1 have been implicated as the cytokines responsible for stimulating
the release of IL-8 and MCP-1 (Kasahara, 1991; Kim, 1996; Yang, Hu, Chang, Tai, &
Leu, 2004) . However, recently neutrophil chemoattraction to IL-8 was shown to be
dependent on CINC-1 produced from mast cells (Ramos, Heluy-Neto, Ribeiro, Ferreira,
& Cunha, 2003). This discovery may be of importance in the migration of HUCB cells to
ischemic tissue. Both neutrophils and mast cells are within the heterogeneous population
of HUCB cells and depending on the culturing conditions may be maintained for long
periods (Dvorak, Estrella, Mitsui, & Ishizaka, 1993; Dvorak, Mitsui, & Ishizaka, 1993).
In addition, ischemic tissue extracts were previously shown to contain significant levels
of CINC-1 and CINC-3 (Newman et al., In press) and this study has shown the presence
of IL-8 in every HUCB cell culture condition. We believe that these converging lines of
evidence suggest that HUCB cells are partially attracted to ischemic tissue as a result of
its content of CINC-1, the variety of and interaction of cells within the cord blood
(including neutrophils and mast cells), and the production of IL-8 from these cells.
MCP-1 a β-chemokine, was the second most prevalent cytokine present in every
condition except TPO. As the name implies MCP-1 is a strong chemoattractant for
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monocytes and has a role in the accumulation of monocytes over a 48 hour period after
interaction of antigen and sensitized lymphocytes (Yoshimura & Ueda, 1996). However,
in the Ex Vivo-10 conditions for 1 and 12 DIV, there was a higher level of IL-6 than
MCP-1, and in IL-3 stimulated condition, both SDF-1 and TNF-α levels were higher than
MCP-1. In the brain, MCP-1 is well documented as a major chemoattractant for
monocytes especially after disease state onset or after injury as part of the inflammatory
response. IL-1, TNF-α, IFNγ, and several other stimuli are known to induce the
expression of MCP-1 from many cell types (for review see - Yoshimura & Ueda, 1996).
More recently, MCP-1 has been reported to induce the migration of rat-derived neural
stem cells in vitro (Widera et al., 2004). Previously, we have shown that the peak
expression of MCP-1 in ischemic rat brain corresponds to the time when the greatest
number of HUCB cells migrate to ischemic striatal and hippocampal extracts. The down
regulation of MCP-1 seen in the IL-3 condition and more so in the TPO condition may be
a function of the time at which the CM was taken, which was 12 DIV. It is possible that
MCP-1 was expressed at an earlier time in these conditions. Although IL-1α was present
in the TPO condition the level of expression was not very strong and TNF-α was not
present at all in this CM, which suggest cells were not stimulated enough to induce MCP1 secretion. In addition, both IL-3 and TPO are used as a culturing tool to stimulate cell
proliferation and maturation, and the exposed HUCB cells may have been reacting to
these cytokines and their microenvironment by down-regulating unnecessary proteins to
conserve energy for proliferation.
Interestingly, when HUCB cells were cultured in the hematopoietic media (Ex
Vivo-10) at 5 and 12 DIV and with IL-3 or TPO, SDF-1 was secreted from the cells,
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which was not seen in any conditions using DMEM. SDF-1 has been shown to induce
the homing and mobilization of hematopoietic stem cells (HSC), especially to bone
marrow (Broxmeyer et al., 1999). Enhanced cell survival (Lee et al., 2002) and the
potentiation of angiogenesis (Mirshahi et al., 2000; Salvucci, Basik, Yao, Bianchi, &
Tosato, 2004) has also been shown to be induced by SDF-1. The chemoattraction of cord
blood HSC to SDF-1 has been reported as well (Yong et al., 1999). This chemoattractant
has been shown to induce IL-8 production in cord blood-derived human mast cells (Lin,
Issekutz, & Marshall, 2000, 2001). However, in this study, HUCB cells in cultured
conditions without SDF-1 also induced IL-8 secretion, which indicates that the presence
of SDF-1 is not necessary for IL-8 production in cord blood cells.
Another unique finding was the presence of Leptin, which was induced when
HUCB cells were cultured in hematopoietic media at 5 DIV. Leptin is a protein
predominantly produced by adipocytes and has a role in regulating long-term body
weight. Although Leptin has been found in the serum of cord blood and in cells of the
placenta (Senaris et al., 1997), its function or importance in cultured HUCB cells is
unknown.
The amount of time in culture and the media plus the supplements used in culture
were the major influences in the production of cytokines by the HUCB cells. The
cytokine profiles demonstrate the direct reaction of the cord blood cells to their culture
environment, with cytokines being produced or inhibited in concert with changes in their
environment. While these findings give us insight into the ability of HUCB cells to
produce both cytokines and chemokines, there are remaining questions that need to be
addressed. Are selected cells producing only certain cytokines? If cells are selected
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based on a phenotype of interest, will they work independently or is the heterogeneous
population needed for the correct cell-to-cell interaction? Lastly, could it be that this
heterogeneous microenvironment of cells is necessary for the benefits seen in the
previous transplant studies?
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Chapter 6

6.0

Relevance of the Dissertation Studies, Conclusions, Limitations, and Future

Directions

The main objective of this study was to determine whether HUCB cells had the
ability to migrate to the injured brain. The previous transplantation studies in the
ischemic rat model, which have used these cells, all reported significant functional
improvements in behavioral deficits (see – Chapter 1). However, these studies did not
report a larger number of transplanted cells at the site of injury. Therefore, we needed to
determine whether the cord blood cells were attracted to or inhibited from the area of
injury. The secondary objectives were to determine, whether there was an optimal time,
after stroke, in which more cells migrated to ischemic extracts and to identify factors that
were involved with their migration. An in vitro model of cell migration and tissue
extracts from MCAO rat model of stroke were used in this study.
The results from our preliminary data, which was used to characterize the
properties of the HUCB cells (in vitro), showed that these cells will survive for an
extended period and proliferate in culture. Additionally, these data showed five distinct
cell types based on morphological visualization, and that the mononuclear fraction of
cord blood cells are heterogeneous and contains both stem and progenitor cells, which
was shown by immunophenotyping analysis and their exocytosis of certain nuclear dyes.
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These results are important especially if the cells are approved to be used in human
transplantation to repair the injured brain. The expansion of cord blood cells might be
necessary if a certain fraction contains unique properties particular for an individual(s)
(such as their HLA antigens) or if a subpopulation of cells, within the cord blood, are
determined to have properties exclusive for the repair of a certain brain injury. Although
these cells have been used to treat nonmalignant and malignant hematopoietic diseases
(see – Chapter 1) and more recently cord blood cells have been successfully transplanted
into infants with Krabbe’s disease (Escolar et al., 2005) and in children with Hurler’s
syndrome (Staba et al., 2004), they have not been approved for other treatments or for use
in brain repair.
In the migration experiments, the HUCB cells were shown to migrate to the
chemoattractant SDF-1, in a dose dependent manner, 100 ng/mL was the optimal dose
and 4 hours was the optimal time for migration of the cells. In the neonatal brain assays,
HUCB cells migrated to the 2 and 7 day brain extracts and the hippocampal extracts in
the 7 day condition. The PD animal model that was studied used the toxin 6-OHDA to
create a lesion in the rat brain. The toxin is not the cause of human PD, but does result in
pathology and symptoms similar to those seen in PD patients. In the migration assay,
HUCB cells significantly migrated to tissue extracts from the 6-OHDA lesioned
substantia nigra and striatum. In addition, this toxin had an inhibitory effect on the cord
blood cells, in that the cells did not migrate to the toxin when in solution with media
only. The 6-OHDA rat brains were harvested 3 weeks post-lesion, which corresponds to
the time when lesioned rats have the symptoms and pathology (significant decrease of
DA neurons and levels) of PD seen in humans. In addition, 3 weeks post-lesion should
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be sufficient time for the toxin to clear or at least appreciably decrease so that it would
not interfere, to a great extent, with the cell migration.
More importantly and the primary focus of this study was the MCAO rat model of
stroke. HUCB cells were attracted to ischemic tissue extracts in a time dependent
manner. More cells migrated to the ischemic extracts that were taken and processed
between 24 and 72 hours after induction of MCAO in the rat, with the peak migration
occurring at 48 hours after inducing the stroke. These results suggested a window of
opportunity in which to deliver the cells. A typical protocol for transplantation studies in
the MCAO model is to administer the cells 24 hours after inducing the stroke. These
results showed that 48 hours after stroke might be more optimal for cell transplantation
studies; we are now examining this in vivo. Dr. Willing’s group, from our laboratory, has
been investigating this phenomenon. Adult male rats received either HUCB cells 48
hours after MACO or no cells. The results showed almost full amelioration of behavioral
and neurophysiological deficits produced by the stroke, and a reduction of the infarct
volume in MCAO rats. The results also suggested that the neurons in the core of the
infarct may not die immediately, and that it is more probable that these cells die slowly
through apoptotic cell death (Newcomb et al., 2005). Together the results suggest that
additional therapeutic strategies, such as anti-inflammatory agents in addition to the
administration of HUCB cells would increase survival rate and overall recovery. Most
importantly, these studies provide strong evidence that the therapeutic window could be
extended from the current 3 hour treatment and thus allow more stroke victims to be
treated.
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The results from the MCAO study also showed an inhibitory effect in the
migration of HUCB cells to the earlier time points in the ischemic tissues. Both the 4 and
6 hours ischemic striatal and hippocampal extracts attracted fewer cells than the
corresponding contralateral sides, signifying an inhibitory effect. This effect is possibly
the result of an increased invasion of pro-inflammatory cytokines (e.g. TNF-α, IL-1β),
which are known to be released soon after ischemia occurs and peak about 12 hours poststroke.
In studying this model, we also determined some of the cytokine and chemokines
present in the striatal ischemic tissue extract (see – Chapter 4). TIMP-1 was the strongest
expressed cytokine and present in all striatal ischemic extracts assayed and in the
contralateral side extracts as well. The TIMPs family has a significant role in rebuilding
the extracellular matrix that has been damaged during an insult to the brain (Crocker,
Pagenstecher, & Campbell, 2004). The strong presence of TIMP-1, in the tissue extracts,
suggest that in the ischemic brain this protein is performing a similar function probably
by inhibiting the tissue metalloproteinases (MMPs), which are known to participate in the
breakdown of extracellular matrix and in weakening the blood brain barrier. Therefore, it
is reasonable to assume that TIMP-1 is produced and released by surviving cells around
the infarct in a response to protect the break down of the BBB extracellular matrix.
Two known chemoattractants were also strongly present in the ischemic extracts.
Both MCP-1 and CINC-1 were expressed on the cytokine arrays from the striatal
ischemic extracts at 48 hours and 1 week. To help determine whether they had a role in
the migration of HUCB cells we further investigated their expression in ischemic and
non-ischemic tissue extracts overtime, by ELISA. Interestingly, the presence of
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GRO/CINC-1 (IL-8) and MCP-1 in the ischemic extracts, over the same time periods as
the migration studies, showed a pattern that was similar to the results of the migration of
HUCB cells to the ischemic extracts. In that both IL-8 and MCP-1, levels were lower in
the earlier time periods and peaked between 24 to 72 hours, which is when cell migration
to ischemic extracts was at its peak.
Our findings are in agreement with the findings of other researchers. The
expression of MCP-1 in ischemic brain peaks 2 to 3 days after stroke (Yamagami et al.,
1999); (Che, Ye, Panga, Wu, & Yang, 2001). MCP-1 may be stimulated by several
factors, such as, TNF-α, IL-1, IFNγ, LPS, and platelet derived growth factor (PDGF).
TNF-α, IL-1 and IFNγ are present in ischemic tissues as early as 3 to 6 hours after stroke
(Kim, 1996) and are key responders to inflammation (Sharma & Kumar, 1998). In vitro
studies have shown that TNF-α and IL-1 may induce the production of IL-8 and MCP-1
from astrocytes (Kim, 1996). This suggests that these two pro-inflammatory cytokines
may have a role in chemotaxis. Both IL-8 and MCP-1 are chemoattractants for
monocytes, and both were present in the ischemic tissue and in the conditioned media
from the cord blood cells in culture without any inflammatory agents present. Although,
the exact chemokines that induce the cells to migrate remain to be identified, we now
have insight as to which chemokine families are involved and we believe that more than
one chemokine is responsible for the attraction of HUCB cells to ischemic tissue.
A second primary objective of this study was to identify the cytokines and
chemokines that may be produced by HUCB cells in culture (see – Chapter 5). The
amount of time the cells were cultured and the culturing conditions are the two principal
factors that influenced the cord blood cells secretion of cytokines and chemokines. The
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most prevalent chemokine was IL-8, which was present in every culture condition. This
was followed by the presence of MCP-1. Several other cytokines and chemokines were
also produced from the cultured HUCB cells. We postulate that significant cell-to-cell
signaling (interactions) occurred with the cultured HUCB cells in order for the production
of such diversity in the cytokines and chemokines. Further evidence of cell to cell
signaling is observed in the cytokine profiles, which change as the culturing conditions
change. However, within the population of cord blood cells the cells that are producing
and secreting certain cytokines or chemokines remain to be determined.
In conclusion, the results suggest that a wider therapeutic window (from 48 to 72
hours after stroke) may exist for the treatment of stroke victims using cord blood cells,
when compared to the existing 3-hour post-stroke use of t-PA. The chemokines that may
be partially responsible for the migration of HUCB cells were identified (IL-8 and MCP1). The cytokine profiles demonstrated the direct reaction of the cells to their culturing
environment, with cytokines being produced or inhibited in concert with changes to their
environment. This suggests that when cells are administered in the ischemic rat they
would have the ability to produce cytokines or chemokines that may aid in the repair of
the injured brain. An intriguing possibility is that the two most prevalent chemokines
produces by HUCB cells (IL-8 and MCP-1) may induce the attraction of endogenous
cells (stem cells) to the site of injury, thus further aiding in the repair of the damaged
tissue. Converging lines of evidence, from the transplanted post-stroke animals, the
migration assays showing an extended therapeutic window (from 3 hours to now 48
hours), and the production of cytokines and chemokines by HUCB cells, suggest their use
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as a treatment for stroke, which may improve the mortality rate and long-term outcomes
for patients.

6.1 Limitations

In these studies, as with any study, there are the existences of intrinsic limitations.
Using in vitro cultures and assays is the major limitation in this set of studies. One major
problem with in vitro model systems is that they do not necessarily reflect the activity
that takes places in vivo. This is especially true with the migration assays that employ a
chamber, which is an artificial condition that does not contain all the components of the
in situ environment. Although this type of design affords the opportunity to examine the
migration functions in an isolated environment, which has its advantages, it does not
allow for the complex interactions that undoubtedly occur during the endogenous
migration of HUCB cells with the surrounding cells, matrix, and the numerous cytokines,
chemokines or trophic factors that are produced in reaction to ischemia. The in vitro
assays allows for isolating the experiment from extraneous variables and may lead to
significant findings, it is also possible, and must be considered, that false leads could be
generated. This problem can be circumvented, to a certain extent, by verifying the in
vitro results with animal studies, which is currently underway in our laboratory.
Nonetheless, it must still be appreciated that both the migration assays and the
cytokines/chemokines produced by cultured HUCB cell systems are an artificial construct
that can only suggest possible mechanisms that must be explored and the results
compared to intact animal experiments.
168

6.2 Future Directions

Cell transplantation for CNS diseases has always held tremendous medical
potential. Chapter 1 discussed the problems associated with fetal or embryonic cells and
the selection of HUCB cells as an alternative source for cell therapy. HUCB cells have
been found to exert pronounced effects when administered systemically in the treatment
of animals with CNS diseases and injuries as reviewed.
If the functional benefits of HUCB cells endure scientific scrutiny and with
appropriate standard pre-clinical safety and toxicological, testing initial Phase I clinical
evaluation is conceivable in the short term. The FDA has already approved clinical trials
using HUCB cells for hematologic malignancies, aplastic anemia, immunodeficiency
diseases, and metabolic disorders (Thomson et al., 2000; Wagner, Kernan, Steinbuch,
Broxmeyer, & Gluckman, 1995). While these clinical trials are not for neurological
disorders, the level of comfort that regulatory agencies already have with this general
approach together with the data collected from ongoing trials (related to dosage, GVHD,
cell survival, safety of the HUCB cells, and their efficacy) will facilitate entry into
clinical trials for cellular transplantation therapies. With over 1500 cord blood
transplants performed worldwide, a strong safety and efficacy database is being compiled
(Gluckman, 2001; Laughlin et al., 2001)(Gluckman et al., 2001; Laughlin et al., 2001).
Before HUCB cells, are ready for the clinic, fundamental issues need to be
addressed. One of the most obvious issues is the cell type(s) underlying the behavioral
effects of HUCB injections, which needs to be identified. HUCB cells are a
heterogeneous population of cells and have been shown to differentiate into neural cells
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both in vitro and in vivo. While it is tempting to speculate that neural cells are one of the
essential ingredients for the improved deficits in behavior, this remains an open question.
The animal transplant studies utilizing cord blood cells thus far are not indicating cell
replacement as the mechanism for the improvements in the behavioral deficits. The
possibility exist that these cells, upon migrating to the injured tissue, are releasing
cytokines and chemokines that are either directly or indirectly responsible for these
effects. Alternative factors, such as these, are being addressed by our laboratory and
others. Future studies should systematically isolate the various cell components in
HUCB and evaluate their therapeutic role in animal models. These studies should also
identify effective and non-effective clonal stem cell lines as well as identify methods of
expanding those lines prior to transplantation. Serious attention should be paid to
identifying culturing conditions, media, serum, and other factors to enhance or maintain
expansion as well as the stage of differentiation of the cells for specific disease
indications.
Another issue is the role of the recipient’s immune system after the
transplantation of HUCB cells. Grafted HUCB cells (which are considered foreign to the
host) were shown to have a low rejection rate (see – Chapter 1), but they may also induce
a low level of chronic inflammatory response that contributes to or minimizes their
therapeutic potential. Transplant studies across discordant hosts would provide insight
into this issue. Perhaps the observed effect in animals (where a xenograft is being used)
underestimates the potential in humans. This is an important point when considering the
optimization of this or any transplant approach that borrows heavily from pre-clinical
animal data. In addition to the host immune response, the role of the host stem cells
170

should be evaluated. It is possible that HUCB cells are providing benefits through these
host cells. Studies should begin to determine whether grafted HUCB cells stimulate or
augment the proliferation, migration, and differentiation of endogenous stem cells.
Refinements in cell labeling coupled with cross-species grafts should be used to
determine the proportion of host versus donor stem cells within the region of interest.
Lastly, long-term safety studies along with duration of the behavioral effects and
survival of the grafted cells should be addressed. The current studies are relatively short
term and do not permit determination of any continued improvements, diminishments in
efficacy over time or overall safety. These studies should incorporate detailed anatomical
analysis of cell types within the injured region with particular emphasis on the
appearance of specific cell types prior to the onset of behavioral improvements and from
any anatomical abnormalities.
Certainly, this is only a partial list and we are in the process of fully evaluating
the effectiveness of HUCB cells in a number of different injury and disease models.
Despite the need to evaluate further, the issues discussed above, the pre-clinical
transplantation studies utilizing cord blood cells and the results of theses studies, it is
reasonable to propose that HUCB cells are a formidable cell source for cellular therapies
in CNS disorders.
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